Psychiatry Bullets
Thein_FM.indd i
11/4/2010 7:25:36 PM
Thein_FM.indd ii
11/4/2010 7:25:37 PM
Psychiatry Bullets...
141 downloads
2581 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Psychiatry Bullets
Thein_FM.indd i
11/4/2010 7:25:36 PM
Thein_FM.indd ii
11/4/2010 7:25:37 PM
Psychiatry Bullets
Mimi W.Thein, M.D.
Instructor, Harvard Medical School Assistant Medical Director, Berkshire On-Call Associates Staff Psychiatrist, Children’s Hospital Boston Boston, Massachusetts
Thein_FM.indd iii
11/4/2010 7:25:37 PM
Acquisitions Editor: Charley Mitchell Product Manager: Tom Gibbons Vendor Manager: Bridgett Dougherty Senior Manufacturing Manager: Benjamin Rivera Marketing Manager: Brian Freiland Design Coordinator: Doug Smock Production Service: SPi Global © 2011 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business Two Commerce Square 2001 Market Street Philadelphia, PA 19103 USA LWW.com All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. Printed in China Library of Congress Cataloging-in-Publication Data Thein, Mimi W. Psychiatry bullets / Mimi W. Thein. p. ; cm. Includes bibliographical references and index. ISBN-13: 978-1-60913-450-1 ISBN-10: 1-60913-450-8 1. Psychiatry—Outlines, syllabi, etc. 2. Psychiatry—Examinations, questions, etc. I. Title. [DNLM: 1. Mental Disorders—Outlines. WM 18.2] RC457.2.T44 2011 616.89—dc22 2010028404 Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of the information in a particular situation remains the professional responsibility of the practitioner. The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug. Some drugs and medical devices presented in the publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice. To purchase additional copies of this book, call our customer service department at (800) 638-3030 or fax orders to (301) 223-2320. International customers should call (301) 223-2300. Visit Lippincott Williams & Wilkins on the Internet: at LWW.com. Lippincott Williams & Wilkins customer service representatives are available from 8:30 am to 6 pm, EST. 10 9 8 7 6 5 4 3 2 1
Thein_FM.indd iv
11/4/2010 7:25:46 PM
For my parents, San andWendy Thein Thank you for teaching me Love,Wisdom, Humor, and The Main Point
Thein_FM.indd v
11/4/2010 7:25:46 PM
Thein_FM.indd vi
11/4/2010 7:25:46 PM
Preface
This manuscript represents a synopsis of countless conferences and publications presented by some of the world’s thought leaders in the field of psychiatry. The purpose of this manuscript is to provide a succinct yet comprehensive overview of psychiatry. The ideal reader would be one preparing for board certification or simply wishing to reference the most current information. My intent is to provide a thorough, detailed presentation of the vast compendium of the most up-to-date, cutting-edge thinking in psychiatry in the most efficient, succinct form possible. This manuscript is not intended to replace the details found in the current comprehensive literature.
vii
Thein_FM.indd vii
11/4/2010 7:25:47 PM
Thein_FM.indd viii
11/4/2010 7:25:48 PM
Acknowledgements
Thank you to Richard Lampert of Lampert Consulting Agency for his invaluable advice and counsel in the preparation of this manuscript. Thank you to the many superb colleagues with whom I have worked over the past years and my mentors through residency, fellowship, and in my clinical practice. Special thanks are due to those clinicians and scientists whose tireless research in psychiatry has provided the foundation for this work. Thank you to my siblings, May-Win and Minn, for their patience and support. For the memory of my older brother, Moe, who always inspires me to laugh through absurd and intolerant moments. Thank you to my husband, Marc, for his unbelievable love and strength.
ix
Thein_FM.indd ix
11/4/2010 7:25:49 PM
Thein_FM.indd x
11/4/2010 7:25:50 PM
Contents
Unit I: Brain 1 2
Anatomy Related to Psychiatric Conditions Physiology
1 5
Unit II: Specific Diseases 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Schizophrenia Depression Bipolar Disorder Anxiety Substance Use Disorders Personality Disorders Somatoform Disorders Dissociative Disorders Factitious Disorders and Malingering Eating Disorders Sleep Gender Identity Disorders and Sexual Disorders PMDD, Pregnancy, Postpartum State, and Breast Feeding Impulse Control Disorders Pain Geriatric Psychiatry Mental Disorders Due to a General Medical Condition Child and Adolescent Psychiatry
9 31 51 65 87 125 129 131 133 135 143 159 163 171 175 183 205 215
Unit III: General Diagnostic Approaches 21 Laboratory and Diagnostic Testing 22 Psychological Assessments 23 Biometrics
259 263 267
Unit IV: Therapeutic Methods 24 25 26 27 28 29 30
Hypnosis Cognitive Behavioral Therapy Family Therapy Adult Psychodynamic Therapy Group Therapy Milieu Therapy Couples Therapy
271 273 275 281 285 287 289
xi
Thein_FM.indd xi
11/4/2010 7:25:50 PM
xii
Contents
Unit V: Law and Ethics and Economics 31 32
Law and Ethics Economic Issues
291 297
References
299
Index
309
Thein_FM.indd xii
11/4/2010 7:25:51 PM
Unit
I Brain Chapter
1
Anatomy Related to Psychiatric Conditions Arousal and attention CNS areas Prefrontal cortex Limbic regions Reticular activating system (RAS) Memory Types Immediate seconds Recent minutes Remote months-years (working memory incorporates immediate and recent memory) Categories Episodic Recollection of events and details of events Located in medial temporal lobe anterior thalamic nuclei mammillary body fornix prefrontal cortex Semantic Knowledge of specific facts Located in inferolateral temporal lobes Procedural Knowing how to perform tasks Located in basal ganglia cerebellum supplementary motor area Motor and motoric behaviors CNS areas Frontal lobe Spinal tracts Rubrospinal tracts Vestibulospinal tracts Basal Ganglia Globus pallidus Caudate nucleus Putamen Substantia nigra Cerebellum 1
Thein_Chap01.indd 1
11/3/2010 2:38:50 PM
2
Psychiatry Bullets
Autonomic motor system Sympathetic Parasympathetic Emotion (depression and anxiety) CNS areas Frontal lobe Orbital frontal cortex (OFC) Prefrontal cortex (PFC) Ventromedial (VMPFC) Lateral orbital (LOPFC) Dorsal lateral (DLPFC) Limbic system Hippocampus Fornix Cingulate gyrus Amygdala Septal nuclei Thalamus Nucleus accumbens Neuroendocrine HPA axis Perception Somatosensory Functions Light touch Pressure Pain Temperature Vibration Proprioception CNS areas Afferents/efferents to/from parasympathetic nervous system (PNS) Thalamus Homunculus (Brodmann areas 1, 2, and 3) Visual Functions Contextualizes visual stimuli CNS areas Afferents/efferents to/from PNS Occipital lobe Thalamus Temporal lobe Inferior temporal cortex Function—“the what” Shape Form Color Left sided (complex shapes) Posterior parietal cortex Function—“the where” Location Motion Destination Development of association fibers occurs early (postnatally)
Thein_Chap01.indd 2
11/3/2010 2:38:57 PM
Chapter 1 Anatomy Related to Psychiatric Conditions
3
Auditory CNS areas Afferent/efferent to/from PNS Thalamus Temporal lobes Gustatory Function Taste CNS areas Afferent/efferent to/from PNS Brainstem (nucleus solitarius) Thalamus Olfactory Function Smell CNS areas Afferent/efferent to/from PNS Autonomic nervous system “unconscious” Addiction CNS areas Frontal lobe Nucleus accumbens Ventral tegmental area Obsessions and compulsions CNS areas Cingulate cortex Basal ganglia Thalamus
Thein_Chap01.indd 3
11/3/2010 2:38:57 PM
Thein_Chap01.indd 4
11/3/2010 2:38:57 PM
Chapter
2
Physiology
BASIC INFORMATION 1011 neuronal cells 1012 glial cells, which comprise Astrocytes Actions Nutrition Deactivates neurotransmitters Integrates with the blood-brain barrier Types Oligodendrocytes found in the central nervous system Schwann cells found in the peripheral nervous system Microglia/macrophages—remove neurons after death Neural formations Neural tube results in the formation of the central nervous system Ectoderm gives rise to the neural crest, which results in the formation of the peripheral nervous system Peak of proliferation of cells occurs during the middle of the second trimester (250,000 born/ minute) Neurotransmitters Types Biogenic amines Serotonin (5-HT) Histamine Dopamine (DA) Acetylcholine (ACh) Amino acids Peptides Nucleotides Neurotrophic factors Brain-derived neurotrophic factor (BDNF) Neuronal growth factor (nGF) Neurotrophin 3, 4 Glial-derived neurotrophic factor Insulin Cytokines Eicosanoids Metabolite of arachidonic acid Prostaglandins Prostacyclins Thromboxane Leukotrienes
Thein_Chap02.indd 5
5
11/3/2010 2:43:42 PM
6
Psychiatry Bullets
Anandamides Endogenous cannabinoid CB1 receptor found in the central nervous system CB2 receptor found in the peripheral nervous system Sigma receptors Membrane proteins distributed throughout the brain Role in binding to antipsychotic agents such as haloperidol Biogenic neurotransmitters DA Tracts Nigrostriatal Substantia nigra → striatum (movement) (associated disease: Parkinson’s) Mesolimbic Ventral tegmental area (VTA) → nucleus accumbens Tuberoinfundibular Mesocortical Hypothalumus → pituitary → release of prolactin Critical formations (NB: DA refers to dopamine NE refers to norepinephrine E refers to epinephrine DOPA refers to dihydroxyphenylalanine) Tyrosine → DOPA (the rate-limiting step) via tyrosine hydroxylase DOPA → DA → NE → E DA metabolism Reuptake via DAT (Dopamine transporter) in the striatum and basal ganglia then via monoamine oxidase A and B (MOA A, MOA B) → 3,4 dihydroxyphenylacetic acid (3,4 DPA) → via catechol-O-methyltransferase (COMT) → homovanillic acid (HVA) Reuptake via NET (Norepinephrine transporter) in the PFC (prefrontal cortex) Then via COMT → 3 methoxy tyramine → via MOA → HVA Receptors D1 involves stimulatory G-proteins which increases cAMP D2 found in the striatum involves inhibitory G-proteins which decreases cAMP (associated with attachment) D3 found in the nucleus accumbens (NA) involves inhibitory G-proteins which decreases cAMP D4 found in the frontal lobe involves inhibitory G-proteins which decreases cAMP D5 involves stimulatory G-proteins which increases cAMP Norepinephrine (NE) and Epinephrine (E) Formation DA → (via B-hydroxylase) → NE → (via PNMT) → E PNMT refers to phenylethanolamine N-methyltransferase Receptors Alpha-adrenergic Alpha 1A Alpha 1B Alpha 1D Blockade leads to sedation, lowered blood pressure Agonist leads to lowered blood pressure (via presynaptic down-regulation and release of NE––mechanism of action of clonidine) Alpha-2 antagonist (an area responsible for sexual dysfunction)
Thein_Chap02.indd 6
11/3/2010 2:43:43 PM
Chapter 2 Physiology
7
Beta-adrenergic B1 B2 B3 Blockade postsynaptically involving Gi decreases cAMP 5-HT Rate-limiting step is availability of tryptophan (dietary source) Receptors (site of action of LSD) 5-HT1 agonist examples: buspirone, trazodone, nefazodone 5-HT1A activity involved in treatment of depression 5-HT2 5-HT3 Histamine Receptors H1 Antagonists at this site increase IP3 (inositol triphosphate) and DAG (diacylglycerol), both second messenger molecules used in signal transduction Postsynaptic receptor Antagonists block allergic response Via decreased vascular permeability Reduction of pruritus Relaxation of the smooth muscle Respiratory Gastrointestinal tract Common side effects of antagonism Nausea Vomiting Weight increase Sedation H2 Antagonists at this site increase cAMP Postsynaptic receptor Found primarily on gastric mucosa H3 Vasculature Presynaptic receptor Possible roles in Wakefulness Hunger Cognition H4 Recent identification Hematopoietic lines
Thein_Chap02.indd 7
11/3/2010 2:43:43 PM
Thein_Chap02.indd 8
11/3/2010 2:43:43 PM
Unit
II Specific Diseases Chapter
3
Schizophrenia
EPIDEMIOLOGY Prevalence 0.3% to 0.4% or 15 to 20 per 100,000 per year 0.6% to 1% lifetime risk Pockets of low and high prevalence do exist Low socioeconomic status in United States Urban dwellers (1.5 to 2 times in the urban areas) Possibly due to migration to the city Population density and schizophrenia—possible connection Morbidity WHO—eighth leading cause of world medical disability Morbidity is greater in developed countries Less than 15% are employed 10% die of suicide High comorbidity (diabetes mellitus or cardiovascular disease) Higher homeless and incarceration rates Mortality Average lifespan decreased by 25% Average lifespan decreased by 15 to 20 years Age-standardized mortality doubled in schizophrenia Causes Suicide
10× greater risk than general population
Diabetes mellitus
2×
Cardiovascular disease
2× (general population’s no. 1 killer)
No increased risk with cancer, rheumatoid arthritis Metabolic syndrome present in 30% to 40% of individuals with nonmedicated schizophrenia Cancers females (breast, ovarian, endometrial, cervical) males (colorectal, prostate) Respiratory 3.2× Infectious disease 2.1×
9
Thein_Chap03.indd 9
11/3/2010 2:45:40 PM
10
Psychiatry Bullets
Age of onset Very rarely presents prior to age 9 Childhood prevalence is rare—50 times less than adult (1/50,000 vs. 1/1,000) Sex ratio—over time, the ratio equalizes, but males may manifest earlier Type of onset—insidious rather than acute onset associated with poorer prognosis Deterioration in functioning Often severe at presentation and with significant deterioration Poor prognosis Early age of onset Family history Poor premorbid functioning Poor long-term functioning Disorganized type of schizophrenia
ETIOLOGY Historical Perspectives Kraepelin
“Dementia praecox” (cognitive changes over time)
Bleuler
“Four A’s”––Autism, Associations, Ambivalence, Affect and coined schizophrenia
Kretschmer
“Body type”—asthenia
Schneider
“First rank symptoms” Audible thought commenting, voices commenting, Thought withdrawal, insertion, and broadcasting “Second rank symptoms” Delusions, perplexity, emotional impoverishment
Jaspers
Psychotic meaning to delusions and auditory hallucinations
Meyer
Schizophrenia secondary to stress
DSMII schizophrenia in childhood intended for a wide spectrum of patients DSMIII resembled that of adult schizophrenia Historical Theories Frontal cortex—Bleuler, 1978 Frontal function abnormalities (hypofrontality)—Ingvar and Franzen, 1974 Frontal function affecting dopaminergic dynamics in the striatum—Meyer-Lindenberg, 2002 Symptomatic Cellular Neurochemical Dendritic Expression differences Hippocampus—Benes, 1991; Gao, 2001; Heckers, 1998 Thalamus—Andreasen, 1994 Cerebellum—Andreasen, 1994 Abnormal dopamine transmission—Laruell, 1996 Excitatory function abnormalities—Gao, 2000 GABA-mediated inhibition abnormality—Benes, 1996 Brain Regions Neurodevelopmental abnormality Premorbid evidence of “deviant” childhood development Characteristics of brain abnormalities Nonprogression of certain MRI findings over time possibility Aberrant neurodevelopment
Thein_Chap03.indd 10
11/3/2010 2:45:43 PM
Chapter 3 Schizophrenia
11
Obstetric complications Trimester II insults Rubella Flu Complications during pregnancy Abnormal fetal growth and development Complications during delivery Anoxia Neurologic soft signs Minor physical abnormalities Neurodegenerative disorder Diagnose and treat aggressively immediately—due to the toxicity of psychosis itself Progression of symptoms and deficits early in the illness Decline in cognitive function early in the illness Rapid decline in social functioning early in the illness Progression of some brain abnormalities Increased ventricular size Decreased dominant superior temporal lobe The longer the untreated illness progresses, the more severe the negative symptoms and dysfunction Suggested neuroanatomic abnormalities Brain structure Volume 3% reduction Gray matter reduction Ventricular size increase (lateral and third) Ventricle/brain ratio increased (most consistent neuroanatomic finding) Smaller hippocampus Limbic cortex—major part of the “psychosis circuit” Size Axial orientation Neuronal and nonneuronal cells Transmission and development changes Structural changes Hippocampus Pyramidal cell apical dendrite orientation (anterior/middle CA2 border) Reduced volume Regional abnormalities (particularly the head region) Entorhinal cortex Cytoarchitectural abnormality of entorhinal cortex (Nicotinamide adenosine dinucleotide phosphate neurons) Reduction in volume Reversal of normal cerebral asymmetry Reduced prefrontal cortex (PFC) structure volumes (the orbitofrontal cortex is the most inferior aspect of the prefrontal cortical area and is thought to be involved in emotional expressivity hypofrontality) and enlarged basal ganglia (BG) Various imaging studies examining neuroanatomical factors CT Enlarged lateral/third ventricles (most consistent) MRI Asymmetry of basal ganglia Reduced sizes of frontal and temporal lobes Greater ventricular volumes Cerebellum Smaller areas Smaller hemispheric sizes
Thein_Chap03.indd 11
11/3/2010 2:45:44 PM
12
Psychiatry Bullets Temporal lobes Larger superior temporal gyrus Right smaller than left Associated with negative symptoms Thalamus—smaller midsagittal; subnuclei Corpus callosum—conflicting studies Cavum septum pellucidum enlarged in adolescence SPECT—MRI Abnormal frontal lobes with lower N-acetylamide (NAA)/creatine activity PET—decreased right parietal metabolism Brain Microstructure Disarray of pyramidal cells (hippocampal and entorhinal) Decreased density of small interneurons in anterior cingulate cortex, which are GABAergic Decreased neuropil in neocortex Absence of gliosis (thus, no inflammation seen in schizophrenia) Abnormal levels of phospholipids Abnormal G proteins Brain Physiology Blood flow and metabolism: hypofrontality Smooth pursuit eye tracking abnormalities Prepulse inhibition deficiencies (thus, unable to filter out unnecessary information) Reduced auditory P-300 amplitude of event-related potentials during visual recognition tasks Sleep physiology Abnormal sleep continuity and maintenance Decreased total sleep time Increased sleep latency Increased awakening after sleep onset Reduced slow-wave sleep Shortening REM latency Cognition Impaired verbal memory Impaired attention Impaired general intellectual ability Impaired working memory SPECT and PET findings Decreased prefrontal blood flow during Wisconsin card sorting task Electrophysiology Increased sensitivity to activation (as seen in sleep deprivation) Decreased alpha activity Increased theta and delta activity Epileptiform activity Greater left-sided abnormalities Evoked potentials Increased early component Decreased late component Spikes found in limbic areas Increased frontal slow-wave activity Increased parietal fast-wave activity Neurotransmitters Dopamine Pathways Mesolimbic pathway Responsible for positive symptoms Mesocortical pathway Responsible for negative symptoms
Thein_Chap03.indd 12
11/3/2010 2:45:44 PM
Chapter 3 Schizophrenia
13
Nigrostriatal pathway Responsible for tardive dyskinesia and other extrapyramidal symptoms Tuberoinfundibular pathway Pathway involving prolactin Neural connectivity abnormality “Too much dopamine”—overly simplistic? Limbic dopamine hyperfunctioning (MESOLIMBIC) Positive symptoms Cortical dopamine hypofunctioning (MESOCORTICAL) Negative symptoms Tonic dopamine hypofunctioning and phasic dopamine hyperfunctioning Decreased D1 receptors in the prefrontal cortex (cognitive symptoms) Medication principals Blocking DA-mediated transmission—Antipsychotic activity Partial DA agonist action—antipsychotic activity DA synthesis blockade—antipsychotic activity Hyperactive DA system—propsychotic activity Receptors—there are no consistent abnormalities Glutamate (metabotropic and NMDA ionotropic receptors) NMDA-sensitive glutamate antagonism can be propsychotic (ketamine effects) Areas of limbic cortex changes Anterior cingulate Hippocampus Ventral striatum Glutamate is found in Frontal cortex Hippocampus Limbic system Striatum Thalamus Cholinergic deficiency (muscarinic and nicotinic) Serotonin 5-HT6 and 7 receptors 5-HT2A involved in cognition GABAergic deficiency? Changes in GABA density, release—particularly in the hippocampus. Others are pending Peptides Neurotensin Somatostatin Dynorphin Substance P Neuropeptides Y Studies of the CSF metabolites––(nothing consistent)
Thein_Chap03.indd 13
Dopamine overactivity
+ Symptoms
Serotonin
Atypical antipsychotic medications effectiveness for positive and negative symptoms
Norepinephrine
Responsible for anhedonia?
GABA
Regulates dopamine “the brakes”
Glutamate
PCP usage leads to psychosis
Neuropeptides
Substance P; neurotensin
Acetylcholine
Cognition
Nicotine
Cognition
11/3/2010 2:45:44 PM
14
Psychiatry Bullets
Other Etiologies Genetic General population lifetime risk of 0.6% to 1% Gene and risk Monozygotic twins
100% genes shared
50% chance of transmission
Dizygotic twins
50% genes shared
10% chance of transmission
First-degree relatives
50% genes shared
10% chance of transmission
Second-degree relatives
25% genes shared
2% to 4% chance of transmission
Related genes (there is no major gene—all have <2% chance of transmission) COMT, DA, Glutamate, Nicotinic receptor COMT val/met polymorphism COMT val allele associated with increased DA breakdown Individuals with schizophrenia with greater COMT val allele occurrences Cytogenetic abnormalities Familial patterns Family history twin studies Paternal age greater than 60 years Genomics Suggested genetic testing via standard microarray 22q11 (and its association with VCFS) 1q21.1 15q13.3 15q11.2 DrD2 promoter region variation first episode DrD2-141C insertion/deletion response to atypical antipsychotics DrD2 A-241G response to atypical antipsychotics (agranulocytosis to clozapine) Neuropsychological factors Fine motor skills, attention, or short-term memory IQ functioning may be affected in childhood (possible baseline verbal and visual learning deficits) Neurolinguistic factors Pragmatics, prosody, auditory processing, abstract language Psychological and social factors—none found Risk factors Obstetric complications inconclusive Born January to April (July to September in southern hemispheres) Maternal flu during the second trimester Gender
Equal below the age of 15 years
Pubertal development
No clear findings
Medical conditions
Complex partial seizures like temporal lobe epilepsy
Neurological signs
Movement disorders Poor sensory integration
Infectious disease and immunological factors Infectious disease Prenatal rubella Prenatal influenza (as noted above) Elevated IgG and IgM to HSV2 Autoimmune
Thein_Chap03.indd 14
11/3/2010 2:45:44 PM
Chapter 3 Schizophrenia
15
Neurophysiological factors Event-related potential studies—dysfunction in the frontal lobes P300 Eye tracking studies—impairments of smooth pursuit eye movements Autonomic function studies—high levels of resting activity impaired response to new stimuli failure to stop responding to familiar stimuli
DIAGNOSIS Signs and Symptoms Characteristic symptoms Current DSM-IV TR diagnostic criteria for schizophrenia At least two symptoms for at least 1 month Delusions Hallucinations Disorganized speech Grossly disorganized or catatonic behavior Negative symptoms (affect, alogia, avolition) Deterioration in functioning (social, occupational, or appropriate functioning) Duration greater than 6 months (ICD 10 is actually 1 month) Not Mood with psychotic symptoms Substance intoxication/metabolic/neurologic Pervasive developmental disorder Typical clinical symptoms Hallucinations Mostly all had auditory or visual hallucinations (1/3 of patients), rarely tactile hallucinations Delusions Frequency varies, but persecutory/somatic much more frequent than thought disorders Cenesthetic hallucinations “brain is burning” Simulation of one sensory path leads to sensation of another sensory path Relatives of those with full condition Affective disturbances Thought disorder
Flattened affects, negative symptoms Illogical thinking and loose associations (poverty of speech) Symptoms of ADHD (inattention)
Cognitive functioning Subaverage IQ (average IQ is 80 to 84) Distractibility Memory deficits Short term (typically verbal—possible hippocampal role) Nonverbal Abstract thinking impairment Language, communication, and information processing frequently affected Neurobiological deficits Progressive increase in ventricular size Decrease in cortical gray matter in adolescents (frontal and temporal lobes) Smaller volumes with negative symptoms Comorbidity—obesity, diabetes mellitus, cardiovascular, HIV, COPD
Thein_Chap03.indd 15
11/3/2010 2:45:44 PM
16
Psychiatry Bullets
Subtypes Paranoid Disorganized Catatonic Undifferentiated Other Bouffee delirante Latent Oneiroid Paraphrenia Pseudoneurotic Simple deteriorative disorder
lasting <3 months
Dreamlike Increased paranoia in presence of a known delusion Anxiety worsening to psychosis “Simple schizophrenia” Gradual decrease in ambition Postpsychotic depressive disorder of schizophrenia Early (< 18 years of age) versus late (> 45 years of age) Deficit Enduring idiopathic negative symptoms
Scales PANSS 30-item scale
(Positive and Negative Symptom Scale)
16 general psychopathology symptom questions 7 positive symptom questions 7 negative symptom questions 7-point severity scale Potential score of 30 to 210 Most commonly used Scores 60
Minimally ill
100
Moderately ill
Improvement is considered with 20% reduction of scores (Critics believe an improvement in symptoms should be a 50% reduction of scores) BPRS (Brief Psychiatric Rating Scale) Positive symptoms, general psychopathology, and affective symptoms 18-item scale 7-point severity scale Differential Diagnosis Mood disorder: Bipolar (consider proportion and duration of mood) Substance use/abuse/dependence (look for temporal relation between use and symptoms) Psychotic disorders Delusional, schizophreniform disorder (consider duration and extent of psychotic symptoms) Physiological causes Other psychiatric disorders Brief reactive psychosis Schizophreniform Schizoaffective disorder Delusional disorder Brief psychotic disorder Shared psychotic disorder Psychotic disorder due to a general medical condition Psychotic disorder NOS Autism Personality disorders Anxiety disorders
Thein_Chap03.indd 16
<1 month <6 months Mood symptoms
11/3/2010 2:45:44 PM
Chapter 3 Schizophrenia
17
COURSE Premorbid personality Abnormal in 1/3 of patients Characteristics Shy Poor grades/academic functioning Difficulties in language acquisition especially speech development Poor peer relationships Bizarre preoccupations Dysphoria Polysubstance abuse Steeper decline leading to a first psychotic break Late adolescence or early adulthood (especially males) Females approximately 25 years (but after menopause, course is just as severe) suggesting estrogen as an attenuating factor Insidious onset is more common Earlier onset if substance abuse, head injuries are present If considering a neurodevelopmental etiology An earlier onset would be more prevalent But the condition often manifests during adolescence coinciding with pruning and myelinization Importance of early diagnosis and effective treatment Most deterioration occurs early—“toxicity of psychosis” There is an average of 1 to 1½ years delay between onset of the illness and treatment Lifelong prognosis Adolescent/early adult onset 90% lifelong 33% with mild impairment 33% with moderate impairment 33% with significant impairment High rates of medication nonadherence High rates of medical comorbidities Working with collateral systems is imperative Primary care providers School/employment systems Avocation Family
AFFECTIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA Depression Lifetime risk of general population is 7% to 25% and with schizophrenia is 50% to 80% 50% of individuals with schizophrenia have co-occurring depression Risk factor for poor prognosis of schizophrenia Important to treat both conditions to optimize patient outcome Suicide 10× higher risk for patients with schizophrenia than the general public 50% of patients with schizophrenia attempt suicide Lifetime suicide risk 10% Major risk factor: Substance abuse and depression Substance abuse 80% of individuals with schizophrenia utilize tobacco
Thein_Chap03.indd 17
11/3/2010 2:45:44 PM
18
Psychiatry Bullets
Consequences of substance abuse comorbidity Worsens mental illness Increased risk Suicide Violence Risky behavior Poorer health Increase in health service utilization Decreased service capacity and coordination Individual outcome optimization Treatment Treatment Medications Cognitive behavioral therapy Rehabilitation Enhance vocational skills Enhance social skills Supports Housing Supportive Costs and unintended side effects Side effects Costs Discrimination Related health risks Reduce disease burden and treatment burden Vocational or educational functioning Independent living Physical health Adherence Social integration Quality of life
TREATMENT Considerations of medication choices Choice of drug First episode Maintenance Multiple episodes Poor or partial responder History of nonadherence Comorbidities Dosage Minimum effective dose Maximum tolerated Increase dose if inadequate response noted (as tolerated) Potential helpfulness of blood levels Duration How long Wait 2 to 5 weeks for the initial response 2-week response predicts 3-month response What is most appropriate response measure?—PANSS Possible early predictors of response Therapeutic effects Adverse effects
Thein_Chap03.indd 18
11/3/2010 2:45:44 PM
Chapter 3 Schizophrenia
19
Alternative strategies Dose increase Augmentation Switching Clozapine Important factors in applying evidenced-based trial conclusions Physician skill (therapeutic alliance) Patient/family requests Existing systems of care Reimbursement Clinical decisions How much improvement is enough? When to change treatments? When to change again? When do side effects determine changes in treatment? Can locus of care be changed? First-generation antipsychotics (FGA) Based upon DA receptor antagonism (ranging from high to low potency) Second-generation antipsychotics (SGA) Based upon DA and 5-HT receptor activity Specific agent’s side effects Clozapine Myocarditis Interstitial nephritis Agranulocytosis More commonly associated during initial usage Check CBC weekly for first 6 months, then biweekly Seizures associated with doses >500 mg/d Olanzapine Pancreatitis Somnambulism Periodic leg movements and restless legs Weight gain Risperidone—Hyperprolactinemia Serum prolactin >30 ng/mL Mechanism of action Dopamine 2 receptor blockade increases prolactin and Risperidone’s 9-OH metabolite has a high affinity for D2 (Marketed as Invega) Greater risk when combined with clozapine Sex differences Males Ejaculatory dysfunction Gynecomastia Decreased libido Doses 4 to 10 mg correlates to side effects Females Amenorrhea Galactorrhea Decreased libido Osteoporosis Doses not correlated to side effects General categories of side effects QTc prolongation
Thein_Chap03.indd 19
11/3/2010 2:45:44 PM
20
Psychiatry Bullets Specific agents Thioridizine associated with the longest (Black box warning) Ziprasidone 20.6 ms Quetiapine 14.5 ms Risperidone 10.0 ms Olanzapine 6.4 ms Haloperidol 4.7 ms Factors Advancing age Drug and alcohol abuse Polypharmacy Recommended interventions Screen Individual intervention If tachycardia, light-headedness, dizziness, or palpitations are reported, collaborate with primary care provider to determine course of action Avoid excessive alcohol intake Notify medication provider if over-the-counter agents or dietary supplements are used Holter monitoring Metabolic syndrome Defined by Waist circumference Males >40″ Females >35″ Triglyceride levels >150 mg/dL HDL—C levels Males <40 mg/dL Females <50 mg/dL Blood pressure >130/85 mm Hg Fasting glucose ≥110 mg/dL Time of occurrence Most often during the first 12 weeks Weight stabilizes after 6 to 12 months Consider that individuals may have preexisting symptoms prior to medication initiation CATIE: 4/10 pts already had metabolic syndrome Consideration of cardiovascular disease risk factors Modifiable and nonmodifiable risk factors Modifiable risk factors Obesity Dyslipidemia Glucose intolerance Hypertension Smoking Nonmodifiable risk factors Gender Family history Personal history Age The lipid profile “The Framingham Heart Study” Classic 1980 study examining the risk factors for coronary artery disease Although both HDL and LDL are important, low HDL more critical (<45 mg/dL)
Thein_Chap03.indd 20
11/3/2010 2:45:44 PM
Chapter 3 Schizophrenia
21
All statin agents show robust reduction of mortality Niacin may be helpful in raising HDL levels Triglyceride levels >200 mg/dL and HDL levels <45 mg/dL are poor prognostic signs Exercise decreases LDL levels Lowering high LDL levels is easier than increasing HDL levels Treatment of dyslipidemia Medications Statins Function—inhibits cholesterol synthesis All lowers LDL-C Rosuvastatin (Crestor) lowers LDL and triglycerides more robustly Mechanism of action Inhibition of HMG CoA reductase (rate limiting step of cholesterol synthesis) Clinical advisory—Hepatotoxicity is rare Fatal rhabdomyolysis is rare Nonstatins Types Niacin-immediate release (Nicotinic acid, vitamin B3) Side effects Flushing (long-acting forms cause less flushing but are more associated with hepatic side effects) Increased serum glucose (check HgA1c) Hyperuricemia (check uric acid—especially if gout is present) Fibrates Fenofibrate Careful if given along with stain Like niacin, increases HDL and lowers LDL and triglyceride levels Gemfibrozil (Lopid) Metformin Ezetimibe (Zetia) prevents absorption of cholesterol in the intestines (Vytorin) Diabetes mellitus Associations Body mass index (BMI) Especially if >30 Risk for Diabetic ketoacidosis (DKA) Nonketotic hyperosmolar coma Prevalence Ethnic Asians>Blacks>Latin>Caucasian Overall rates are increasing (10% of entire US predicted in 2010) Monitor regularly for worsening glucose control Check fasting plasma glucose prior to initiation Monitor regularly during treatment Screening questions Increased thirst Urinary frequency Unexpected lethargy Free fatty acids exit from adipose into plasma which then Decrease glucose utilization Decrease lipolysis Increase glucose output Plasma glucose ideally always should be <126 mg/dL Especially problematic in Asian individuals Individuals with type II diabetes and prior myocardial infarctions are at risk for fatal future myocardial infarction
Thein_Chap03.indd 21
11/3/2010 2:45:44 PM
22
Psychiatry Bullets Possible mechanisms of action Weight gain D2 receptor antagonism (bromocriptine as an antidiabetic agent) 5-HT2c receptor is involved in food intake/appetite H1 receptor Muscarinic acetylcholine receptors Inhibition of glucose transport Insulin resistance Leptin resistance Insulin resistance Risk factors Hypertension Increased C-reactive protein levels High triglyceride levels Low HDL levels High plasma insulin levels Albuminema High plasma glucose Presence of insulin resistance seen 7 years prior to the diagnosis of diabetes Treatment Consultation on diet and exercise Specific agents Consider cessation of the SGA Consider switching to a different SGA Suggestion that risperidone is less diabetogenic Bromocriptine Dopamine agonist FDA-approved for diabetic treatment Metformin Weight neutral Side effects (diarrhea nausea) DPP-4 inhibitors Examples Sitagliptin (Januvia) Saxagliptin (Origlyza) Weight neutral Side effects—well tolerated hypoglycemia Sulfonyureas Examples Glipizide Glyburide Glimepiride Not weight neutral (weight gain) Side effects—hypoglycemia Thiazolidinediones Examples Rosiglitazone (Avandia) Pioglitazone (Actos) Not weight neutral (weight gain) Side effects edema contraindicated in CHF GLP-1 receptor agonists Examples Exenatide (Byetta) Liraglutide (Victoza) Weight loss Side effects, nausea, pancreatitis Insulin therapy
Thein_Chap03.indd 22
11/3/2010 2:45:44 PM
23
Chapter 3 Schizophrenia
Role of blood pressure Systolic blood pressure appears to be more critical (>160) than diastolic However, if the person is younger than 50 years, diastolic levels (>95) are more critical With every 20/10 mm Hg increase, the risk for cardiovascular disease doubles 115/75 relative risk multiplied by 1 135/85 relative risk multiplied by 2 155/95 relative risk multiplied by 3 175/105 relative risk multiplied by 4 African Americans are at much greater risk for hypertension—thus, aim for blood pressure <120/80 mm Hg Treatment of hypertension algorithm PreHTN No medication Lifestyle modification Stage I Hydrochlorothiazide Beta-blockers Angiotensin, ACE inhibitors* Alpha blockade, Calcium channel blockers *6% risk for cough (50% risk in Asians) Stage II two medication combination (like HCTZ + ACE inhibitor) Early and aggressive treatment with a goal of 120/70 mm Hg Monitor for risk factors: Diabetes mellitus >2 other risk factors for heart disease African American ethnicity History of heart disease (especially past myocardial infarction) Chronic renal insufficiency or failure Classification of blood pressure readings Normal <120 mm Hg Prehypertension 120 to 139 mm Hg HTN Stage I 140 to 159 mm Hg Stage II >160 mm Hg
Encompassing Major Side Effects
Lithium Valproate Carbemazepine ± Lamotrigine Clozapine Olanzapine Risperidone Ziprasidone Quetiapine Aripiprazole
Thein_Chap03.indd 23
Wt gain
CNS
EPS
Derm
GI
++ ++ +++ ± ++++ +++ ++ ± ++ ±
+++ ++ 0 − +++ ++ + + ++ +
0 0 +++ 0 0 + ++ + 0 +
++ + + +++ + + + + + +
++ ++ + + + + + + ++
11/3/2010 2:45:44 PM
24
Psychiatry Bullets
Goal
Lower cardiovascular disease
Cholesterol
10% drop results in 30% drop in cardiovascular disease
Hypertension
4 to 6 mm Hg drop results in 16% to 42% drop in CVD/stroke
Smoking
Stopping drops 50% to 70% drop in cardiovascular disease
BMI < 25
Drops 35% to 55% chance of cardiovascular disease
Exercise
Drops 35% to 55% chance of cardiovascular disease (20 minutes daily)
STUDIES EXAMINING SGA’S CATIE: Schizophrenia trial design Phase I 1,460 patients randomized to Olanzapine Quetiapine Risperidone Ziprasidone Perphenazine Dosing of agents is controversial Olanzapine
High
Quetiapine
Low
Risperidone
Low
Ziprasidone
low (and without the emphasis of better absorption with food)
Patients with tardive dyskinesia were not randomized to take perphenazine Phase II Those who failed Phase I due to inefficacy were randomized to clozapine or other SGAs (as noted) or if they failed Phase I due to intolerability, were randomized to other SGAs (not clozapine) Phase III Those who failed Phase I and II were given options of above antipsychotics plus fluphenazine decanoate or any combination of two Phase I Double blinded and randomized Demographics and clinical characteristics (BROAD but no first break patients) Conclusions Discontinuation All agents were associated with discontinuation 75% discontinued before 18 months Causes of discontinuation Weight gain/metabolic symptoms Extrapyramidal side effects Overall, olanzapine associated with the least discontinuation (but caused the most weight gain) Overall, risperidone was the most tolerated Olanzapine Most effective Associated with greatest risk for metabolic syndrome Risperidone Lower efficacy than olanzapine, but comparable to others Highest prolactin serum levels Lowest discontinuation due to side effects
Thein_Chap03.indd 24
11/3/2010 2:45:44 PM
25
Chapter 3 Schizophrenia Quetiapine Lower efficacy than olanzapine, but comparable to others Good extrapyramidal and prolactin profiles Ziprasidone Lower efficacy than olanzapine, but comparable to others Excellent safety profile Perphenazine Lower efficacy than olanzapine, but comparable to others Well tolerated Higher discontinuation due to extrapyramidal side effects Metabolic findings Mean plasma glucose and HgA1C levels Olanzapine>Quetiapine>Risperidone>Perphenazine>Ziprasidone Total cholesterol and triglycerides As above but ziprasidone may have reversed raised cholesterol levels
ADA Consensus on Antipsychotic Drugs and Obesity and Diabetes Drug
Weight Gain
Diabetes Mellitus Risk
Dyslipidemia
Clozapine
+++
+
+
Olanzapine
+++
+
+
Risperidone
++
discrepant
Quetiapine
++
discrepant
Ariprazole
±
−
−
Ziprasidone
±
−
−
Some other interesting findings Switching antipsychotics lowers weight Stronger H1 receptor affinity associated with stronger weight gain Clozapine>Olanzapine>Quetiapine>Risperidone >>Aripiprazole>Ziprasidone equal to Perphenazine The SGAs are independent risk factors for diabetes Clozapine>Olanzapine>Quetiapine=Risperidone Clozapine‘s effectiveness in schizophrenia—a meta-analysis Clozapine is underutilized Helpful for Poor or partial responders to other antipsychotic agents Suicidal individuals Aggressive individuals Individuals with substance use/abuse/dependence Comparing relapse rates between FGA and SGA Risperidone has smaller relapse rate compared to Haloperidol Olanzapine has smaller relapse rate compared to Haloperidol FGAs have relapse rate of 58%, whereas the SGAs have a relapse rate of 23% Adding SGA to FGA reduces relapse rate by 35% Possible explanations for above observations Adherence Mechanism of action not limited to dopamine Incidence of tardive dyskinesia with SGA Meta-analysis 2004 suggests substantially less incidence with SGA Monitoring for extrapyramidal side effects even with SGA critical Adding valproate—meta-analysis reveals a negative impact
Thein_Chap03.indd 25
11/3/2010 2:45:44 PM
26
Psychiatry Bullets
CUtLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study [2006]) Design 14 clinics Randomized controlled trials FGA and SGA (except clozapine) Evaluation at week 12, 26, and 56 227 individuals aged 18 to 65 years Measure Quality of Life Scale Conclusions FGA and SGA are equally therapeutic Davis, J Arch Gen Psych, 2003—Effect sizes Clozapine
0.6
Risperidone
0.5
Olanzapine
0.5
Others “didn’t do as well” Kane, J Clin Psych, 2007: Perphenazine equivalent to aripiprazole Lindemeyer, 2007: Olanzapine superior to Haloperidol for negative symptoms SGAs more effective with negative symptoms Neither FGAs nor SGAs effective for neurocognitive Find improvement in quality of life Emphasis that neurocognitive improvement is critical for Social rehabilitation Cognitive rehabilitation Jones, Arch Gen Psych, 2006: FGA>SGA for quality of life Geddes MJG 2000: lower discontinuation rate for SGA (unless you look at comparable haloperidol doses) Multiple studies point out to similar therapeutic effects amongst SGAs, but clozapine had greater efficacy Differences in response—genetic polymorphisms? Cytochrome P-450 variants 2D6 7% of the Caucasian population are poor metabolizers leading to higher serum plasma levels due to slower metabolism 1% other ethnic groups 2D6 poor metabolizers Safe for Clozapine Olanzapine Quetiapine Ziprasidone Care required for FGA (especially thioridazine) SGA (possibly for aripiprazole)
PRACTICE RECOMMENDATIONS (FDA ISSUED A WARNING IN 2003 REGARDING SGA AND METABOLIC PROFILE; AND, IN 2008, ADDED FGA) Before initiating treatment History and physical exam
Thein_Chap03.indd 26
11/3/2010 2:45:45 PM
Chapter 3 Schizophrenia
27
Document personal/family history Diabetes Obesity Hyperlipidemia Cardiovascular disease Weight and height (to determine BMI) Waist circumference Blood pressure Laboratory tests Fasting glucose Fasting lipids Prolactin levels TSH Monitoring Weight At month 1, 2, 3 If >5% (especially in first month), consider switch/cessation Monitor Glucose Consultation if glucose > 300 mg/dL Lipids Blood pressure Others as applicable
PHARMACOLOGICAL STRATEGIES FOR TREATMENT-RESISTANT SCHIZOPHRENIA Rapid treatment for extreme agitation Haloperidol and lorazepam Fast acting per oral forms Quetiapine 200 to 800 over 4 days Olanzapine 40 mg over 4 days Intramuscular atypical antipsychotic agents Ziprasidone 10 to 20 mg/d; max 40 mg daily Olanzapine 10 mg/d Aripiprazole 9.75 mg Clozapine for antihostility Mood stabilizers—modest results Beta-blockers/SSRIs—modest results Benzodiazepines—watch for exacerbation or disinhibition Combination Polypharmacy strategy Benefits Symptom targeted treatment Address unremitted symptoms Lower the dose of a more toxic agent Risks Cumulative toxicity/adverse events Adherence issues Enables suboptimal monotherapy Lack of evidenced-based strategies Compensates for Weak D2 blockade Strong 5-HT2a blockade Rapid D2 dissociation—haldol can block for days to weeks
Thein_Chap03.indd 27
11/3/2010 2:45:45 PM
28
Psychiatry Bullets
Possible synergistic effects Controversial Greater likelihood of side effects Even efficacy shows mixed results Examples Adding clozapine Adding lamotrigine No significant differences in five studies Possible reduction of alcohol craving for individuals with schizophrenia Adding antidepressants for negative symptoms Adding cognitive enhancers—no positive findings Adding FGAs—may negate benefit of SGAs Pharmacokinetics Lithium increases ziprasidone levels Valproate decreases ziprasidone levels Fluvoxamine increases clozapine and olanzapine levels by as much as four times Lamotrigine increases risperidone and olanzapine levels slightly Importance of p-glycoprotein Found in vessels of blood-brain barrier Prevention of harmful agents entering into brain Altering them has advantages and disadvantages Risperidone and its metabolite are potent inhibitors of p-glycoproteins Thus, other drugs will flow through more easily Long-acting forms Haloperidol decanoate Paliperidone ER Metabolite of risperidone Daily dose 3 to 12 mg Osmotic control-released oral delivery system, OROS General approaches Clozapine trial Switching technique Decrease first dose Gradually add second drug Use non–weight gaining SGA Add FGA Adding other medication classes ECT for behavioral disruption or augment for clozapine-resistant individuals Future medications COMT polymorphism D3 receptor polymorphisms may predict TD and EPS 5-HT2c predicts weight gain Glutamate NMDA receptor enhancers D-cycloserine Glycine agonists Amphokines Nicotinic-cholinergic agonists Alpha 7 ACh receptor agonists for glutamate hypofunction—thus improving cognition Stimulants—improving attention Intensive treatment of comorbid PSA Homocysteine excess in pregnancy Inhibiting cannabis-1 receptor Specific agents Asenapine (currently available) 5-HT and NE also Clozaril-like
Thein_Chap03.indd 28
11/3/2010 2:45:45 PM
Chapter 3 Schizophrenia
29
Iloperidone D1 and 5-HT2A receptors Low weight gain, diabetes mellitus, EPS, no prolactin Prolongs QTc
SUBSTANCE ABUSE IN INDIVIDUALS WITH SCHIZOPHRENIA High in patients with schizophrenia Possibly self-medicating frontal lobe dysfunction (nicotine) Possibly medicating deficits discussed CB1 receptors in the frontal lobe Family history of schizophrenia or DA pathway polymorphism May be more sensitive to THC psychosis Agents which may exacerbate psychotic symptoms Stimulants Cocaine Cannabis PCP Prevalence Nicotine—81% to 88% of individuals with schizophrenia smoke cigarettes Other agents—40% to 60% Risk factors Young age Male Less educated Less peer support Poorer treatment outcome Treatment Long-term strategies should be implemented Medication and therapy Initial goal is to stabilize psychosis and then focus on substance use Medical considerations Hepatic Cardiac Drug interactions Side effects of drugs Specific agents Alcohol
Naltrexone
Opioids
Methadone
Nicotine
Nicotine patch Bupropion
Collaborative team approach
NONPHARMACOLOGIC TREATMENT Approaches Psychoeducation 10 studies Decrease in relapse or readmission rates (NNT 9) Compliance significantly improved in one study Positive effect on the patient’s well-being
Thein_Chap03.indd 29
11/3/2010 2:45:45 PM
30
Psychiatry Bullets No impact on insight/med adherence Assertive community treatment 17 trials More likely to remain in contact with services Less readmission (NNT 10.3) and shorter hospitalization stay More likely to live independently, less unemployment, more happy Better than hospital-based rehabilitation Cognitive behavioral therapy 13 trials CBT+standard care increased discharge rates NNT 3 No improvement in relapse or readmission More medication adherence Family intervention 13 trials Decrease rate of relapse NNT 6.5 Tend to be medication adherent Enhance family communication Enhance family problem solving skills Cognitive rehabilitation Three trials Improved self-esteem No difference in mental state, social, or occupational functioning
Thein_Chap03.indd 30
11/3/2010 2:45:45 PM
Chapter
4
Depression
OVERVIEW OF EMOTIONS (Understanding emotions spotlights the complexity of how treatment interventions theoretically work) The three components of emotion Physiologic arousal Changes in heart rate, blood pressure, respiratory rate Changes in muscle tension Changes in perspiration (skin conductance response) Changes in perceived body temperature Changes in sensory sensitivity (pain) Behavioral expression—social interactions and “hard wired” Facial expression Tone of voice Posture Conscious experience—subjective feeling of an emotion “Types” of emotions—“How many emotions do humans have?” Plutchik (researcher in the mid-1900s) Anger Fear Sadness Joy Disgust Surprise Curiosity Acceptance Ekman (researcher in the late 1900s) observed populations in the tropics Anger Fear Sadness Happiness Disgust Neurobiologically based components of emotions Perception/evaluation—based upon past experience “hard wiring” Subjective experience—conscious experience that is positive or negative Conditioning/learning—situation/experience linked to emotional reaction Expression—somatic and autonomic activity elicited Role of emotions Safety Social Decisions/guiding behaviors 31
Thein_Chap04.indd 31
11/3/2010 2:52:00 PM
32
Psychiatry Bullets
Words on fear and anxiety Hard wired and species-typical response (not learned or conditioned) Involvement of Identification of fear-inducing agent “hard wired” Defensive behaviors Autonomic arousal Hypoalgesia Potentiation of somatic reflexes Hypothalamic-pituitary-adrenal (HPA) axis activation Response triggers can be learned or conditioned Amygdala and HPA axis play critical roles
ETIOLOGY OF DEPRESSION Neurotransmitter construct monoamine (and receptor) hypothesis Explanation Depression is due to a deficiency of monoamines (NE/5HT) in neuronal synapses Evidence Certain drugs that deplete monoamines cause depression Certain drugs that increase monoamines improve depression Problems Levels of monoamines increase immediately, but response is delayed An increase in the monoamines and a physiological change in the postsynaptic neuron receptors are involved in this hypothesis Specific pathways NA—noradrenergic pathway Locus coeruleus → prefrontal cortex and limbic Depletion affects Mood Concentration Interest Energy Causes psychomotor retardation Functions Frontal projections Mood Arousal/attention Limbic projections Energy Agitation/anxiety Emotions (motivation/pleasure) Cerebellar projections—tremor Brain stem projections—blood pressure, appetite 5HT—serotonin pathway Raphe nucleus→ PFC and limbic areas Depletion affects Anxiety Mood Functions Frontal cortex projections Mood Basal ganglia projections Akathisia/agitation/anxiety Obsessive compulsive activity Limbic projections Anxiety
Thein_Chap04.indd 32
11/3/2010 2:52:01 PM
Chapter 4 Depression
33
Hypothalamic projections Appetite Brain stem projections Insomnia Nausea/vomiting Temperature regulation DA—dopamine pathways Functions Nigrostriatal (basal ganglia) Movement Mesolimbic (midbrain—nucleus accumbens) Pleasure Perception integration (delusions/hall) Tuberoinfundibular (hypothalamus and anterior pituitary gland) Prolactin Mesocortical (midbrain to frontal cortex) Positive and negative symptoms Cognition Support of the neurotransmitter construct Antidepressants will eventually lead to down-regulation of receptors which the monoamines bind The time course of this down-regulation corresponds to the delayed onset of the antidepressant action The time course also corresponds to the time it takes patients to become tolerant to side effects Anatomical construct Areas of interest Limbic System Cingulate gyrus Fornix Septal nucleus Mammillary body Amygdala Hippocampus Insular cortex Frontal lobe systems OFC (orbitofrontal cortex) VMPFC (ventral medial prefrontal cortex) Pain, aggression, social, and sex behavior Autonomic and neuroendocrine DLPFC (dorsal lateral prefrontal cortex) Cognitive control, solving complex tasks, memory manipulation Low activity associated in depression High activity in this area suggests low activity in VMPFC (via cingulate and hippocampus via glutamate and GABA but 5HT and NE possibly control direction of activity) LOPFC (lateral orbital prefrontal cortex) Depression, OCD, panic, PTSD Corrects and inhibits maladaptive, preservative, and emotional Spotlight on the limbic system Amygdala Importance Coordinating center for the emotional expression of fear Afferent and efferent pathways active Unconscious emotional memory Fear conditioning
Thein_Chap04.indd 33
11/3/2010 2:52:01 PM
34
Psychiatry Bullets
Stimulation causes fear/withdrawal/rage Kluver-Bucy syndrome Afferents and effects Lateral hypothalamus → sympathetic activation Dorsal motor nucleus of vagus nerve → Parasympathetic activation Parabrachial nerve→ dyspnea/hyperventilation Ventral tegmental area Locus coeruleus Dorsal lateral tegmental area → behavioral arousal/EEG arousal (hypervigilance) Nucleus reticularis pontis caudalis → increased startle Midbrain central gray → freezing, fear of dying Trigeminal/facial motor nerve → facial expression of fear Paraventricular nucleus → HPA activation Hippocampus—and its role in depression If the amygdala is the activating force, then the hippocampus associates emotional valence to the memory Roles Cognitive functioning Emotions Neuroendocrine functioning Learning Communication with hypothalamus and pituitary Smaller volume can be an obstacle to future treatment Neuroendocrinological Construct Monoamines Serotonin and norepinephrine influence GABAergic activity as well as glutamatergic activity in the prefrontal and limbic cortices. Excessive glutamatergic activity results in decreased locus coeruleus and raphe nucleus activity, which then reduce serotonin and norepinephrine activity. Excessive glutamate leads to production of glucocorticoids, which have been known to have toxic effects on the hippocampus Dysfunction of the hippocampus contributes to cognitive impairment and emotional and neuroendocrine dysregulation Cortisol and depression Early trauma (parental loss or abuse) can lead to permanent changes HPA axis Increased HPA axis activity Increased hypothalamic production of cortisol releasing factor (CRF) Increased pituitary secretion of Adrenocorticotropic Hormone (ACTH) leading to Increased adrenal secretion of cortisol Increased number of CRF neurons Hypersensitive and increased CRF and cortisol responsiveness Thus, even mild stress can lead to an exaggerated CRF and cortisol response Chronic exposure to above normal cortisol leads to Hippocampal damage Hippocampal damage correlated to MDD HPA axis and fear General adaptation syndrome Nonspecific stimuli Hypothalamus → cortisol releasing hormone (CRH) → pituitary → Adrenocorticotropic hormone (ACTH) → Adrenal cortex → cortisol (which (increases energy) → B endorphin (which promotes analgesia) → Sympathetic NS → NE and E Fight-or-flight response NE (norepinephrine) Increased heart rate and blood pressure
Thein_Chap04.indd 34
11/3/2010 2:52:01 PM
Chapter 4 Depression
35
Increased lipid breakdown (lipolysis) Peripheral vasoconstriction E (epinephrine) Increased heart rate and blood pressure Increased lipid breakdown (lipolysis) Peripheral vasoconstriction Coronary dilation/bronchial dilation Muscle’s glycogen broken down to glucose Antidepressants’ association with reparation and growth construct (Antidepressants enhance the connectivity of impaired networks) The amygdala is the “activating” force and the hippocampus is the “modulator” of emotional response The hippocampus Appears to be a center for making and storing emotional memories Toxicity due to excessive input from VM PFC and glucocorticoids (physically changes the hippocampus) Dysfunction may contribute to cognitive impairment, emotional dysregulation, neuroendocrine dysregulation Hippocampal volumes tend to be smaller (?brain plasticity) In individuals with childhood PTSD In individuals with longer duration of untreated depression Neurons under stress are less arborized (cortisol toxicity) Role of Mediators—BDNF (brain-derived neurotrophic factor) Functions Assists in survival of existing neurons Encourages growth and differentiation of new neurons and synapses Adult neurogenesis occurs normally in olfactory bulb and hippocampus Do antidepressants increase hippocampal neurogenesis/neuroplasticity (since depression causes decreased hippocampal volume)? Role in depression Stress and glucocorticoids suppress BDNF expression in the hippocampus at the mRNA and protein level Antidepressants enhance BDNF expression and its receptor Trk3 in the hippocampus Antidepressant-treated patients have enhanced BDN Infusing BDNF into animals’ hippocampus has an antidepressant effect Increases in BDNF promote synaptic plasticity and new spine formation in the hippocampus Neurogenesis continues to occur in key brain areas (hippocampus) BDNF associated with production of new neurons and their growth and development Neurotrophins modify synaptic transmission in an activity developmental manner Downregulated in MDD and increased in antidepressant treatment Has a hypothetical neurotrophic effect that influences mood and perception of pain Increased levels increase the “3 N’s” Neuroplasticity—cells can communicate effectively Neurogenesis—proliferation of new cells Neuroprotection—increases cellular resistance Stress/glucocorticoids/glutamate → decreases BNDF, decreases synapse and neuronal size Animal models—stress and pain lower BDNF gene expression Antidepressants and neurogenesis Chronic antidepressant treatment in adults increases hippocampus neurogenesis Disrupting antidepressant-induced neurogenesis blocks behavioral response to antidepressants
Thein_Chap04.indd 35
11/3/2010 2:52:01 PM
36
Psychiatry Bullets
Genetics Construct The 5-HT transporter (5-HTT) promoter gene polymorphism (5-HTTLPR) ss represents the short allele promoter region ll represents the long allele promoter region Having the ss allele/variant Associated with Increased amygdala reactivity response ( f MRI demonstration) Decreased anterior cingulate filtering response Higher vulnerability for adult major depression (especially in context of environmental stressors) Associated with poor antidepressant efficacy to Fluvoxamine Paroxetine Associated with greater adverse effects from Fluoxetine Paroxetine Associated with better efficacy in Asians from Fluvoxamine Paroxetine Having the ll allele/variant Associated (in STAR *D) with longer duration on citalopram 5-HT 2A receptor and 102 T/C SNP Having C/C variant Associated with poor clozapine response Associated with paroxetine adverse effects In patients with MDD there are state-dependent increases in activation of the amygdala and increased amygdala activation influences perception of perception and cognition (?worry/rumination) An increase in the monoamines and a physiological change in the postsynaptic neuron receptors are involved in this hypothesis Other Etiologies Impaired regulation of hormonal release Decreased growth hormone (GH) Thyroid-stimulating hormone (TSH) Substance P neurokinin 1 (Subs P preferring receptor), therefore, neurokinin receptor antagonist Found in stress-response brain areas Converges with NA, DA, 5-HT pathways associated espec 5-HT Therapy changes our limbic responses “top down” and medications are “bottom up” Depression as a “Metabolic Syndrome” Construct Medical illness and relationship with depression Some facts HTN if also depressed associated with 3× morbidity risk CAD “ 40% increased cardiac risk Post-MI “ 33% at 3 months—mortality 4 – 6× Poststroke “ 20% – 25% Diabetes mellitus “ 15% – 20% poor glycemic control Arthritis “ 40% – 60% increased mortality Other connections Post MI patients with depression more likely not to exercise Smokers with depression 40% less likely to quit over 9 years CAD with depression less likely to adhere to low dose Aspirin patients with depression 3× more compliant Systemic consequences of depression Hypothalamus stimulates the pituitary gland to release excessive ACTH
Thein_Chap04.indd 36
11/3/2010 2:52:01 PM
Chapter 4 Depression
37
Adrenal gland releases excessive catecholamines and cortisol catecholamine increases lead to myocardial events, decreased heart rate variability, and possibly ventricular arrhythmias Platelet activation increase which leads to cytokines and interleukins release, which may lead to atherosclerosis and hypertension Cortisol antagonizes insulin leading to dyslipidemia, diabetes, and obesity Suppresses the immune system Recovery decreases with the duration of major depressive episodes 54% recovery rate after 6 months; 16% after 1 year Progression of depression—“kindling” and stress After six to seven episodes of depression, stress has little impact on relapse Thus, the number of depressive episodes increases the risk of relapse
RISK FACTORS FOR DEPRESSION Suggested risk factors Dysthymia is associated with 70% – 80% chance of MDD Loss of a parent before the age of 11 years Childhood onset of depression Medical illness (pancreatic cancer, multiple sclerosis, brain tumors) Stress/learned helplessness Screening for risk factors Screening options Two question screening (Either positive response is a positive screen): Over the past 2 weeks have you felt down or hopeless? Over the past 2 weeks have you felt little interest in doing things? PHQ-9 Nine-item questionnaire Self-administered or by a clinician
SUICIDE Risk factors Increases with age (especially after the age of 85 years) Psychiatric Illness (depression, bipolar, dysthymia, OCD, panic disorder, schizophrenia, alcoholism) Bipolar disorder associated with higher risk factor Young males with schizophrenia with depression not actively hallucinating associated with higher risk factor Acute risk factors (within 1 year of assessment) Severe anxiety Panic attacks Global insomnia Recent alcohol abuse Severe anhedonia Chronic risk factors (within 2 – 10 years of assessment) Suicidal ideation (assess risk of method also) Prior suicide attempts (assess severity also) Hopelessness * predictor of strong MDD Other risks The individual believed that the risk was high Male—especially if Caucasian and older than 45 years
Thein_Chap04.indd 37
11/3/2010 2:52:01 PM
38
Psychiatry Bullets Ethnicity (Caucasian>Native Americans>Hispanics>Blacks) Access to firearms Lack of intact family, living alone Mother with mood disorder Poor communication with family Father crime history Family history of suicidal behavior Failing/disciplinary/suspension/dropping out Lack of college education Occupation (chemistry, farming, law enforcement, women in medicine) Hopelessness External locus of control Parental death (loss of mother more so than father) Family history of psychiatric illness Family history of suicide Poor physical health NOT socioeconomic status Differential diagnoses: Self-injurious behaviors High-risk behaviors Polysubstance use Comorbidity Major depression Alcohol abuse/dependence Illicit drug use Conduct disorder Treatment Containment Health insurance Quality of care in the emergency department If family dysfunction—family therapy Treat psychiatric conditions
SUBTYPES Severe depression What is severe depression? Clinical setting Psychotic Suicidal Melancholic Receiving inpatient care Comorbidity exists Functional impairment Treatment resistance Research setting—defined by research measures Discipline-specific Relevance of severity Less likely to remit Longer treatment periods Marker for comorbidity High rate of suicidality Few spontaneous remissions. DSM-IV-TR Measuring severity
Thein_Chap04.indd 38
11/3/2010 2:52:01 PM
Chapter 4 Depression
39
QIDS PHQ-9 Treating severe depression Antidepressants Combination of medication and therapy Electroconvulsive therapy (ECT) Vagal nerve stimulation (VNS) Repetitive transcranial magnetic stimulation (rTMS) Deep brain stimulation therapy (DBS) Severity as a predictor of antidepressant medications Depressed inpatients had a more robust response to TCAs (compared to placebo) Desipramine response better in those with higher HAMD scores Amitriptyline better than placebo with HAMD>12 Mild depression placebo responses are better than with severe depression Studies Escitalopram and paroxetine SADHART CREATE STAR*D ECT and rTMS Psychotherapy and combined treatment Atypical depression History/development of the clinical concept The “atypical depression” concept arose from clinical observations that some depressed patients had better response to MAOs than TCA DSM-IV criteria arose from research at Columbia University Atypical features specifier (DSM-IV, APA, 1994) Greater than two symptoms with mood reactivity: Significant weight gain or increase in appetite* Hypersomnia* Leaden paralysis Long-standing interpersonal rejection* * appear to be very common in atypical depression Atypical depression—community data 2002—4.8% prevalence rate 2005—triadic concept (female, eating, sleeping) Females affected more than males Bipolar disorder type II Rates of atypical depression Features in 22% – 40% of MDD patients In community, private, tertiary settings, recommend thinking prevalence as 25% – 30% STAR-D reports that 18% of those with depression met criteria for atypical depression; features assessing for atypical depression symptoms is not fully found in standartized testings Primary Care Setting study Mean age 46 Men 1/3 Women 2/3 Mean HAMD scale 18 (does not include increased appetite, hypersomnia, and rejection sensitivity) 26% with atypical Difficulties in comparisons of various studies Criteria of atypical depression vary Sampling methods in studies vary
Thein_Chap04.indd 39
11/3/2010 2:52:01 PM
40
Psychiatry Bullets Operational criteria in ICD-10 are missing HAMD is most frequent scale used in studies and does not include atypical symptoms of hyperphagia or insomnia (alternative is IDS-C) Pharmacotherapy MAOI TCA Newer AD SGA Treatment with monoamine oxidase inhibitors (MAOIs) Monoamine oxidase isoforms MAO A Deaminates 5HT, E, NE (and melatonin) Found in the brain and gut MAO B Deaminates phenethylamine and benzylamine Platelet as a marker Both MAO A and B Deaminates tyramine and dopamine Early MAOIs Inhibits MOA irreversibly and nonselectively Forms unbreakable bond with enzyme (It takes 14 days to synthesize new MOA) Decreases breakdown of NE and 5-HT Increases synaptic concentrations of NE and 5-HT Receptor and signal transduction changes In current use Isocarboxazid (Marplan) Tranylcypromine (Parnate) Phenelzine (Nardil) l-Deprenyl (Selegiline) Limitations of isocarboxazid, tranylcypromine, and phenelzine Dietary restrictions Risk of serotonin syndrome via drug-drug interactions Hypertensive crisis (due to undergraded tyramine) leading to stroke/death High side effect burden Orthostatic hypotension Edema Weight gain Sexual dysfunction Selegiline FDA approved for Parkinson’s (at lower doses—MOA-Bi) FDA approved for depression(at higher doses MOA-Ai) STS—Transdermal delivery Bypasses first pass and intestinal absorption Nonselective inhibition in brain (MAO A and B) Dietary and drug interactions Doses <6 mg/24 hours not problematic MAOI diet at >6 mg/24 hours Caution when switching from SSRI/SNRI A meta-analysis of randomized controlled trials of atypical depression demonstrates a robust response to phenelzine (72%) compared to imipramine (44%) compared to placebo (26%) Pharmacological treatment of atypical depression Modern antidepressants SSRIs
Thein_Chap04.indd 40
11/3/2010 2:52:01 PM
Chapter 4 Depression
41
Varied response 65% response rate for fluoxetine Moclobemide (MAOI not approved for use in the US) superior to fluoxetine Phenelzine = Fluoxetine Fluoxetine compared to imipramine No difference (but fluoxetine was better tolerated) SNRIs 5-HT1a agonists Buspirone Gepirone (not approved for use in the US) Partial 5-HT1a agonist Response rate at 8 weeks—62% (placebo’s response rate—20%) Dosed at 30 – 120 mg/d Alternative Chromium picolinate Possible effectiveness Giving immediate release may improve mood Inconsistent findings Typical dose 600 mg/d Mechanism of action is not known Increases insulin sensitivity via enhancing central NE and 5H activity Downregulates postsynaptic 5-HT2a receptors and activation of these receptors contributes to differences with sleep and sexual function Phosphoinositol second messenger system used for insulin resistance (and carbohydrate craving found in atypical depression) St John’s wort A small study showed that it can be helpful with increased sleep and appetite A larger study is pending although promising a similar response TCA MAOIs are considered superior Imipramine is the best studied Special populations—elderly Best estimate incidence of atypical depression 28% SNRI study (Venlafaxine XR) in women especially Unmet needs in treatment of atypical depression Limited evidence of efficacy of newer classes of antidepressants Limited studies of efficacy Limited studies of nonpharmacological treatment
DIFFERENTIAL DIAGNOSES Medical Treatment side effects Comorbidity (hypothyroidism) Psychiatric disorders—Bipolar conditions Comorbid psychiatric conditions Anxiety (panic disorder, generalized anxiety disorder) Polysubstance use/abuse/dependence New-onset anxiety in the elderly is likely to be depression Bereavement/grief Normal bereavement Associated with sadness, insomnia, poor concentration in waves Usually lasts less than 2 months Not usually associated with
Thein_Chap04.indd 41
11/3/2010 2:52:01 PM
42
Psychiatry Bullets
Psychomotor retardation Worthlessness or guilty preoccupations Suicidal ideation Hallucinations Treat especially if there is a history of past depression Symptom manifestation in the chronically medically ill Negative thinking Poor concentration Depressed mood Lack of interest Impaired daily functioning likely to overlap with chronically ill conditions Impairment of appetite, sleep are also often unreliable
TREATMENT Historical observations Reserpine (antihypertensive) found to cause depression (amine depletion) Iproniazid (a drug for tuberculosis) has antidepressant effects due to its MAOI activities Imipramine (antihistamine—TCA) with antidepressant effects Doxepin (powerful antihistamine—TCA) with antidepressant effects Blunted TSH response to TRH challenge secondary to down-regulation when increased TRH reaches it Blunted GH response to clonidine (alpha 2 agonist) Substance P/neurokinin 1 A general approach Monotherapy does not help in 30% of conditions (but does help 70%) Improved adherence → improved outcomes (know patient’s preferences) “Do something”—“Start low, Go Slow, But GO” Antidepressant selection Individual’s response history Family members’ response histories Side effect profiles Cytochrome P45 Izoyme inhibition (2D6) SSRIs versus TCAs Discontinuation usually due to high doses and rapid cessation Sexual dysfunction side effects (30% – 40% chance if on SSRIs) Drug holiday/substitution—consider 24 – 30 hours t½ Augmenting with bupropion/buspirone Residual symptoms are high risk for recurrence (and early relapse) Other augmenting agents SGA (consider long-term side effects) Modafinil Recurrence (after recovery from MDD) Duration Coordinated care Team approach Case manager Support, self-help, patient visit groups Psychiatrist Remind individuals of upcoming appointments Education About illness and offer available therapies (CBT) Exercise moderately (relieve tension and improve sleep)
Thein_Chap04.indd 42
11/3/2010 2:52:01 PM
Chapter 4 Depression
43
Avoid caffeine Avoid alcohol and nicotine (excess) Sleep hygiene Support—providing HOPE Other ECT, TMS, VNS, therapy Electroconvulsive therapy (ECT) Mechanism of action (essentially not known) Bioaminergic Metabolic activation (mobilize cortical hypometabolism) Impact sleep architecture (soporific) Anticonvulsant Indications Mood disorders Depression Active symptoms No positive findings for maintenance Refractory Can be a first-choice treatment Mania Acute symptoms No positive findings for maintenance Refractory Can be a first-choice treatment If complicated by catatonia Psychotic disorders Acute symptoms If complicated by catatonia Can be a first-choice treatment Other Neurological disorders EPS Seizures Emergent states Contraindications (none absolute) Recent MI or cardiac instability Increased intracranial pressure Recent stroke (especially hemorrhagic) Cerebral aneurysm/AV malformations Severe pulmonary disease ASA score ³4 (American Society of Anesthesiologists six category physical status classification) Obtain informed consent Preparation Psychoeducation Medical CXR EKG Basic metabolic profile/CBC Other pertinent consultations (cardiac) When necessary Pseudocholinesterase levels Concerns for high prelevels Spinal films History of osteoporosis Neuroimaging
Thein_Chap04.indd 43
11/3/2010 2:52:02 PM
44
Psychiatry Bullets Concerning medication effects MAOI Hypertensive crises Lithium Delirium Depakote Even at a therapeutic range, ECT may reverse anticonvulsant effects Premedication NPO Anasthesia Methohexital 0.75–1 mg/kg Propofol 0.75–1.5 mg/kg Etomidate 0.15–0.30 mg/kg Muscle relaxant Succinylcholine 0.5–1 mg/kg (care as it is a pseudocholinesterase—cured with curare) Other Atropine (reduce mucus) Watch for rebound bradycardia Oxygen ?Lowers seizure threshold (increases pH) Beta-blockers to Lowers blood pressure Benzodiazepines Lowers anxiety Electrode placement Unilateral Nondominant lobe Usually first-line placement Bilateral Individuals present Psychiatrist Anesthesiologist or CRNA Monitor Vital signs Typically increases Observe for generalized seizures EEG Muscle twitch Prolactin levels Increases during seizures Duration of seizures Standard 30–60 seconds but <90 seconds No correlation between length of seizures and benefit If no seizure obtained Repeat process Identification for failed procedure Discontinue medications that raise seizure threshold Increase energy input But cognitive impairment is correlated with energy input Increase oxygenation Caffeine iv 120–140 mg Effectiveness Study comparing to sham ECT reveals effectiveness Remission rate >80% (time-limited)
Thein_Chap04.indd 44
11/3/2010 2:52:02 PM
Chapter 4 Depression
45
Relapse rates high (approximately 70%) Response rate unknown but comparable to adequate pharmacological treatment Less effective Mixed mood episodes Based upon case studies Schizophrenia—unless Acute symptoms Catatonia Past positive response to ECT Ideal candidate Neurovegetative symptoms Absence of personality disorder Minimal reactivity Psychotic symptoms Frequency Two to three times per week Gradually phase out over months Improves high relapse rates Integrated with other elements of treatment Adverse events Cognitive Postictal amnesia Retrograde and anterograde Impaired short-term memory No structural findings No changes in neuropsychological functioning Postictal delirium Headaches Oral complications prevented by bite blocks Tongue bites Loose teeth Status epilepticus (often when benzodiazepines unavailable) Grand mal seizure (succinylcholine not used or underdosed) Transcranial magnetic stimulation (TMS) Principles of mechanism of action Electricity in insulated coils induces magnetic fields Magnetic fields pass through the cranium for 2–3 cm and induce electric fields in the brain Nerve cells are stimulated to fire and release 5-HT NE DA Deep brain stimulation (DBS) Principles of mechanism of action Implantation of implanted pulse generator (IPG), a lead, and an extension The IPG is implanted in the clavicle or abdomen The lead is implanted in the brain The extension connects the lead to the IPG Cranial electrotherapy stimulation Principles of mechanism of action Suppression of thalamocortical activity (CES activates 5-HT in the raphe nuclei, which will then inhibit brainstem ACh and NE systems) Suppression of agitation/reduction of aggression Induces alpha EEG and decreases delta rhythm More alert More relaxed 5-HT itself Modulates pain sensation in the dorsal horn of the spinal cord Alters pain perception in the limbic forebrain
Thein_Chap04.indd 45
11/3/2010 2:52:02 PM
46
Psychiatry Bullets Cognitively Emotionally FDA-approved for Anxiety: Effect Size 0.58 Depression Insomnia: Effect Size 0.64 in Side effects Self-limiting Headache
0.1%
Skin irritation at electrode sites
0.07%
Enduring for hours or days (especially if history of vertigo) Headaches Vertigo Nausea Disorientation (if abruptly discontinued) Contraindications Pacemakers, defibrillators Pregnancy STAR*D The STAR*D Trial www.star-d.org Overall aim: Define preferred treatments for treatment-resistant depression Overview I Duration 7 years (10/99 – 9/06) NIMH funding National Coordinating Center, UT SWMC (Dallas) Data Coordinating Center (Pittsburgh) Overview II 14 Regional Centers 41 Clinical Sites 18 Primary Care Settings (and, not research based) 23 Psychiatric Care Settings (and, not research based) Level I Obtain consent Citalopram given (chosen as it was available generic, easy to use) Follow up (if satisfactory response) Level II (if not satisfactory or <50% change from baseline) Level II Randomize—trying to mimic clinical practice; thus, ask the patients what they were willing to do Augment Augment to psychotherapy Switch Switch to psychotherapy Choices Sertraline Switch Bupropion SR Venlafaxine XR Cognitive behavioral therapy (CBT) Augment Citalopram + Bupropion SR Citalopram + Buspirone – chose it “because we thought it would be a dog” Citalopram + CBT
Thein_Chap04.indd 46
11/3/2010 2:52:02 PM
Chapter 4 Depression
47
Study methods Independent, blind, treatment evaluators obtain research outcomes Multiple research outcome domains Treatment protocols provide consistent, adequate treatment before declaring resistance “It is useful to measure what you treat quickly” Participants MDD Nonpsychotic Representative primary and specialty care practices (nonacademic) Self-declared patients Inclusion criteria Clinician deems antidepressant medication indicated 18–75 years of age Baseline Hamilton rating scale for Depression17(HRSD17 ≥ 14) 17-item scale Scores ≥ 14 Most concurrent axis I, II, III allowed! This deviates from most other studies currently performed Multiple research outcomes Symptoms Function Side effect burdens Patient and clinician satisfaction Utilization and costs of health care services Why remission was the end point? Nonremission is common 35%–45% remission 10%–20% response with residual symptoms 15% partial response 25% nonresponse 7%–15% intolerant Consequences of nonremission Poor function (work, family) Poor prognosis (increased recurrence) Psychiatric or general medical complications Health service utilization Death from Medical comorbidities Suicide Treatment resistance—a strong predictor of relapse or recurrence Clinical procedures Open treatment with randomization Symptoms/side effects measured at each clinical visit Clinicians guided by algorithms/supervision Dose adjustments “mandatory” to achieve remission Education for all patients Quality control of treatment Clinical research coordinator support Clinician training Clinical manual Web-based monitoring system Routine measurement of symptoms (QIDS-C16)
Thein_Chap04.indd 47
11/3/2010 2:52:02 PM
48
Psychiatry Bullets
Findings Level I Clinical baseline Features N = 2,876 Recurrent depression
75%
Onset <18
37.8
Family history of depression
55.6
History of suicide attempt
25.3
Anxious depression
53.2
Majority had concurrent axis I at baseline 34.8% Treatment Pushed citalopram (41.8 mg, for 10 weeks) Categorical symptom outcomes Response (without remission 50% decrease) Similar outcomes in primary settings Of those that responded, 2/3 responded in 6 weeks; 1/3 will get there in time Of those that remitted ½ remitted by 6 weeks ½ even at 12 weeks Risk factors—medical conditions Conclusions weeks Studies of remission require longer duration of studies 30% remission rate (across all treatment) Follow-up—12 months If you remitted, a greater proportion stayed better over time (½ “lose it”—30% reach remission, but 50% don’t remain or 15% get better) Level II Medication switch Treatment outcomes 25% will get to remission ACROSS ALL Also the timing of remission was the SAME CBT––The same rate of remission as meds Days to remission similar Acceptable switch option Acceptable augmentation option Follow-up required Not as popular as expected Medication augmentation Treatment outcomes Buspirone worked as well as Venlafaxine XR Timing to response was also the same Serious side effects All Death GMC (medical) GMC (medical––hospitalized) All psychiatric side effects Psychiatric hospitalization Conclusions Cumulative remission rate is over 50% I and II Patient preference plays a big role in strategy selection Follow-up—12 months same as Level I Level III Randomize Switch Mirtazapine Nortriptyline
Thein_Chap04.indd 48
11/3/2010 2:52:02 PM
Chapter 4 Depression
49
Augment Lithium Thyroid (T3) Few people remitted with any method (20%) T3 augmentation was much better tolerated by patients Level IV Randomize Tranylcypromine (MAOI) Venlafaxine XR + Mirtazapine Very few people remitted, and tranylcypromine was not tolerated
Thein_Chap04.indd 49
11/3/2010 2:52:02 PM
Thein_Chap04.indd 50
11/3/2010 2:52:02 PM
Chapter
5
Bipolar Disorder
OVERVIEW Lifetime prevalence of bipolar I is 1.0% and bipolar spectrum is 4.4% Age of onset is adolescence Median age of onset 18 years (STEP BD 2000 data) New onset rare after 50 years 30% of cases are untreated for the first 10 years (median 6 years lapse in treatment) Fourth leading cause of neuropsychiatric disability worldwide High suicide rate—19% (lower if never hospitalized) Females = males incidence Strongly comorbid with Substance abuse 60% Anxiety disorders >50%
ETIOLOGY Genetic Twin studies 60%–93% variance in bipolar disorder Shared environmental factors account for 30%–40% variance Unique environmental factors account for 10%–21% variance Genome-wide association scans Family study—increased rates of affective disorder (depression), anxiety, and behavioral disorders (attention deficit hyperactivity disorder [ADHD]) in offspring Monoamine hypothesis 5-HT Roles in mood/sleep/appetite/circadian rhythm/cognitive Receptor subtypes 5-HT1A—(buspirone is an agonist) ANXIETY 5-HT2A Findings Lower 5-H1AA levels in brainstem and CSF Acute depletion of tryptophan associated with relapses from depression Fewer 5-HTT in prefrontal cortex Antidepressant effects NE activity elevation DA activity elevation GABA Cholinergic Inputs reduce REM latency 51
Thein_Chap05.indd 51
11/3/2010 2:55:38 PM
52
Psychiatry Bullets
Anticholinergic effects are antidepressant Lycine—an anticholinergic precursor that can cause depression Glutamate NMDA receptors Antidepressant effects of glutamate NMDA receptor antagonists Mitochondria Decreased mitochondrial functioning Leading to neuronal dysfunction and apoptosis Neuropeptides/hormones Cortical-hypothalamic-pituitary axis hyperactivity Hypersecretion of CRF leading to downregulation of hypothalamus Hypothalamic-pituitary-thyroid axis Blunting of TSH response to TRH challenge (downregulation of TRH receptors in the pituitary) Hypothalamic-GH axis Brain growth factors GH BDNF Substance P and neurokinin-1 receptors Alteration of neuronal circuits Frontal lobe dysfunction—“Brakes” Limbic cortex dysfunction—“Accelerator” Neuroimaging Prefrontal lobe dysfunction Reduced blood flow and glucose metabolism Orbital and medial PFL Limbic dysfunctions Other Abnormal G protein, protein kinase C, and second messenger activities (their potential roles in neuroplasticity) Neuronal death occurs with repeated mania Lithium promotes neuronal growth Smaller hippocampal sizes in bipolar patients Kindling––SENSITIZATION Repeated stressors lead to more exaggerated responses With regard to mood disorders Clinically (Robert Post) More mood episodes leads to even more mood episodes Cycle length decreases with time Psychosocial triggers decrease with time Physiologically, seizure-like focus in limbic areas Does not appear to be the same kindling as seen in seizures Treatment—anticonvulsants more effective than lithium for rapid-cycling patients Supportive observations for the kindling model Episodes more frequent with time Well periods shorten with time Psychosocial triggers decrease with time Rapid cycling increases with time Treatment responsiveness decreases with time Circadian rhythms––FAST PACEMAKERS Stress diathesis model (GENES and ENVIRONMENT) Underlying vulnerability plus stress leads to observed illness Medications reduce underlying vulnerability and therapy reduces stress A look at the genes—inquire about family history beyond first-degree relatives (i.e., cousins, aunts, uncles, etc.) A look at environment Ask not just concerning immediate shared family experiences Random events
Thein_Chap05.indd 52
11/3/2010 2:55:41 PM
Chapter 5 Bipolar Disorder
53
Intrauterine/prenatal Genotype/environmental interaction
COURSE Some statistics 1 /3 get completely better with monotherapy mood stabilizers 2 /3 need polypharmacy ½ have partial recovery ¼ do not recover Predictors of poor prognosis Polysubstance abuse/dependence Psychosis Early age of onset Predominant depression Mixed states Many episodes Good prognosis Euphoria Unipolar mania Late age of onset Few episodes Clinical course (13-year follow-up study) Approximately, 50% will start asymptomatic (50% with symptoms) and then 68% will be depressed 19% will have hypo/mania 16% will have mixed symptoms Comorbidity is the rule Migraines Pain disorder Diabetes Cardiovascular disease Obesity Substance use Eating disorder Anxiety disorder Impulse ADHD Personality disorder Phenomenological issues Mixed episodes Full episode criteria in both poles Contrast with dysphoric mania or agitated depression Spectrum model Pure depression
Agitated depression
Depressive mixed state
Dysphoric mania
X
X
X
Pure mania
Mixed states Gradations of “Mixedness” (and 60% of BP is mixed!!!) Rapid cycling
>4 episodes/year (not hour to hour)
Seasonality
Mania in summer, depression in winter
Remission
¾ remit (thus ¼ never remit)
Unipolar mania
Never had depression—most responsive to lithium
Thein_Chap05.indd 53
11/3/2010 2:55:41 PM
54
Psychiatry Bullets Childhood presentation Preadolescence (<12 years of age) 80% continuous rapid cycling 1 week of hypomania/mania identifiable Family history in first-degree relative Adolescence (≥13 years of age) 60% mixed Chronic Similarities with ADHD 90% of bipolar conditions diagnosable with ADHD Adults 33% diagnosable with childhood ADHD Different developmental presentations of the same underlying disease Stimulants and mania They are associated with an earlier age of manic onset (small studies do not conclude this) Modafinil may also be activating Effects of childhood use of amphetamines in adulthood (based upon animal studies) Decreased response to rewarding stimuli Increased depression and anxiety Decreased dopaminergic neuronal activity Increased corticosteroid response after stress Decreased long-term survival of new neurons in the hippocampus
MISDIAGNOSIS Clinician factors Lack of assessing family members—ask that family be involved Poor assessment of manic symptoms Overemphasis on symptoms rather than Course Family history Treatment response Disease factors Lack of insight (impaired insight is part of the illness) Frontal lobe involvement suggesting poor executive functioning Ask that family be involved in treatment Poor memory Unreliability of hypomania Overlapping features with borderline personality disorder/traits Rule out mood disorders prior to diagnosing personality disorders Findings more often associated with borderline personality Trauma Self-injury Chronicity—not state dependent Interpersonal characteristics Countertransferential effects Prodromal mood symptoms Overlapping symptoms with depressive disorders Findings more often associated with bipolar disorder Atypical symptoms (using DSM-IV-TR criteria) Psychotic symptoms Postpartum manifestation Earlier age of onset Bipolar at 19 years Unipolar at 30 years
Thein_Chap05.indd 54
11/3/2010 2:55:41 PM
Chapter 5 Bipolar Disorder
55
Brief episodes Bipolar 3–6 months Unipolar 6–12 months Poor antidepressant response Effectiveness “wears off” Three antidepressant trials ineffective Antidepressant-induced mania No prevalence of pervasive developmental disorder Recurrent major depressive episodes >3 in a lifetime Overlapping symptoms Depression—90% of bipolar disorders Psychosis 60% lifetime prevalence 15% point prevalence Anxiety—50%–90% of bipolar disorder (mostly during depressed phase) Long-term frequency of depressive symptoms Most people with bipolar disorder (even treated) live in depression Causes of treatment refractory depression quantitated by Sharma (2005) 50% misdiagnosis 50% other Other diagnoses Personality disorders Substance abuse Psychosocial stressors (neurotic depression) Treatment intolerance Side effects “Nocebo effect” (the patients who develop side effects to any medication intervention) Patient nonadherence Rapid metabolizers Inadequate dosing True treatment resistance
ASSESSMENT Scales MDQ study overall prevalence at 3.4% Sensitivity—0.81 Specificity—0.67 Predictive value 45% (right 45%, wrong 55%) Bipolar spectrum diagnostic scale Manic-depressive spectrum Clues in the history Antidepressant-induced mania or hypomania Family history in a first-degree relative Hyperthymic personality (baseline, nondepressed state) Recurrent major depressive episodes (>3) Early age of onset (<25 years old) Atypical depressive symptoms Brief major depressive episodes (<3 months) Psychotic major depression Postpartum depression
Thein_Chap05.indd 55
11/3/2010 2:55:41 PM
56
Psychiatry Bullets Antidepressant wear-off Acute but not prophylactic response Rapid onset of action No response to three or greater number of adequate antidepressant trials Validators of diagnosis (these are classically used in research—not in DSM-IV-TR) Phenomenology Cross-sectional symptoms DSM-IV criteria Family history Course Age of onset Number of episodes Outcome Treatment response Poor substitute for biological markers
DIAGNOSIS Types Subtypes 1. Type I—mania 2. Type II—hypomania + DD 3. NOS 4. Cyclothymia—hypomania + subthreshold depression a. Adults—2 years duration required b. Adolescents—1 year duration required Diagnosis Mood elevation Euphoria or irritability Dysphoria (mixed) Depressed mood +/– irritability DIGFAST Mnemonic Distractibility Insomnia Grandiosity Flight of ideas Activities Speech Thoughtlessness Mania Three symptoms plus euphoria Four symptoms plus irritability Hypomania—no dysfunction Duration 1 week mania 4 days hypomania Hospitalization with any duration Clinically, at least 2 days for hypomania Possible criteria of lasting less than one day proposed
Thein_Chap05.indd 56
11/3/2010 2:55:42 PM
Chapter 5 Bipolar Disorder
57
Cardinal symptoms Distractibility Insomnia: decreased need for sleep as opposed to inability to sleep Grandiosity Flight of ideas (ruminations/worries are of the same theme—flight of ideas is almost tangential) Activities (work, school, home, social, sexual) Pressured speech, increased talkativeness Thoughtlessness Sexual indiscretions Recklessness Sudden traveling Spending sprees If irritable, fights and arguments
SUGGESTED DEFINITIONS OF BIPOLAR DISORDER Bipolar spectrum disorder A. Criteria Antidepressant-induced hypo/mania Diagnosed or treated bipolar disorder in a first-degree relative B. Criteria Major depressive characteristics <3 months Recurrent >5 episodes Atypical Psychosis Postpartum Early age of onset <20 years Antidepressant tachyphylaxis (or acute but not preventative response) Nonresponsive to full trials of three antidepressants Hyperthymic personality at baseline Diagnosis of bipolar spectrum → 1A + 1B or 5B alone Hierarchy of diagnosis (e.g., once a mood disorder is diagnosed, lower diagnoses must not be diagnosed) Mood disorders Bipolar disorder Unipolar disorder Psychotic disorders Schizo-affective disorders Schizophrenia Anxiety disorders Other Personality disorders ADHD
DIFFERENTIAL DIAGNOSES Secondary to Clear psychosocial stress Other medical illness
Thein_Chap05.indd 57
11/3/2010 2:55:42 PM
58
Psychiatry Bullets
Substance use
Cocaine
Medications
Steroids
Neurological conditions
Multiple sclerosis Frontal lobe syndromes Temporal lobe epilepsy Stroke
Endocrinological conditions
Hyperthyroidism Cushing syndrome
Infections
HIV
Autoimmune disease
Lupus
Metabolic states
Hypoxia
Psychiatric conditions Depression Schizophrenia Schizo-affective disorder ADHD Borderline personality disorder Primary substance abuse PTSD Panic disorder
TREATMENT Symptomatically—as elaborated below Address comorbid issues Psychiatric conditions Medical conditions Address other issues Stress Tobacco use Weight Burden/side effect from medications prescribed Support Family Avocational Educational Financial issues Address overall functioning
NONPHARMACOLOGIC Diagnostic clarification Management Charting of entire life events relating to symptom presentation Treat substance use Treat side effects vigorously Psychotherapy (focus on adherence, education, and integrity of sleep cycle) Anticipate polypharmacy Patients live in depression 2/3 of time—but watch for induction/switching High suicide risk
Thein_Chap05.indd 58
11/3/2010 2:55:42 PM
Chapter 5 Bipolar Disorder
59
PHARMACOTHERAPY: MOOD STABILIZERS Lithium Lithium carbonate ER ½ 24 hours Dose once daily if decreased renal function observed Usage for Acute mania Maintenance Combination with paroxetine or imipramine If lithium levels are >0.8 mmol/L, then Li = Li + antidepressants But antidepressant addition may still be important (controversial) Sachs et al., NEJM (2007) Mood stabilizer with placebo is equivalent to mood stabilizer with bupropion (you may still capture those who will respond with the medication combination) Side effects Checking creatinine clearance is more sensitive than just Cr Check TSH—depressive episode predictor Specifics CNS—poor memory, slowed function Cardiovascular—arrhythmia, hypotension, bradycardia Gastrointestinal—anorexia, nausea, vomiting, diarrhea Genitourinary issues Issues Blood levels Gastrointestinal activation Tremor Fetal abnormalities Warnings Lithium toxicity if patients have cardiovascular or renal disease Nephrogenic diabetes insipidus Encephalopathic syndrome associated with lithium Carbamazepine Carbamazepine ER (Equetro) Only mood stabilizer that addresses mixed symptoms YMRS change for mixed symptoms Indications—mania and mixed Side effects Nausea, vomiting, dry mouth Blurred vision, speech disorder Dizziness, ataxia, somnolence Pruritus Issues Dizziness Gastrointestinal activation Drug-drug interactions Warnings Aplastic anemia Agranulocytosis Depakote Forms Divalproex Depakote ER Acute mania only Equivalent to lithium and both are superior to placebo Unstudied
Thein_Chap05.indd 59
11/3/2010 2:55:42 PM
60
Psychiatry Bullets
Lithium is better for euphoric mania Depakote is better for dysphoric mania PCOS (polycystic ovarian syndrome)—depakote forms usage increases risk 10 fold Did not separate from placebo during maintenance phase of bipolar Side effects Nausea, GI pain, vomiting, dyspepsia Somnolence, athenia, dizziness, headaches Rash Findings and issues—symptom relief by day 4 or 5 Lamotrigine Profile Metabolism Hepatic—glucuronidation Renal—94% excretion Absorption per oral—completely absorbed Protein binding <55% t½ 24–33 hours (longer if in the presence of carbamazepine or divalproex as much as twice) Dosing Rash if lamotrigine is effective, consult a dermatologist 10% have a rash 1/100 0.1% develop Stevens-Johnson syndrome 1/1,000 Concerns for Stevens-Johnson syndrome if The individual is a child Mouth/mucosal involvement Painful If eosinophil counts are elevated If creatine clearance is higher If there is truncal involvement of rash FDA approved for maintenance only Out of five trials for use in depression, only one was positive (maybe due to the time necessary to develop therapeutic doses) Mania—does not appear to address manic symptoms Lamotrigine and lithium individually more robust response compared to placebo (but lamotrigine better for addressing depressive symptoms and lithium better for manic symptoms)
PHARMACOTHERAPY: ATYPICAL ANTIPSYCHOTICS Olanzapine Indications Mania Clinical features CATIE trials suggest that this is the most efficacious agent Side effect Metabolic syndrome Aripiprazole Indications—all phases of bipolar disorder Clinical features Not anticholinergic, mildly antihistaminic Switching from a highly anticholinergic/antihistaminergic medication (olanzapine or clozapine) may cause increased cholinergic/histaminergic effects (treat with diphenhydramine and hydroxyzine)
Thein_Chap05.indd 60
11/3/2010 2:55:42 PM
Chapter 5 Bipolar Disorder
61
Partial D2 receptor agonist Aripiprazole reduces 30% of dopaminergic activity (haloperidol reduces 100% of dopaminergic activity) suggesting that drug-naïve patients are likely to respond to aripiprazole since previous exposure to D2 receptor has blockers already upregulated receptors Better to do a slow cross taper (perhaps over 2–3 months!!!) Used to counter side effects connected with DA antagonism (prolactinemia) Intramuscular treatment study This trial did not include concomitant use of lorazepam since lorazepam was one of the independent arms Aripiprazole 9.75 and 15 mg and lorazepam 2 mg intramuscularly significantly better compared to placebo (after a 1-hour time period) One of the studies leading to FDA approval in treatment of mania High initial dose of aripiprazole was used (30 mg)—a dose not typically used in clinical settings (both aripiprazole and placebo arms were used along with lorazepam) Side effects Nausea Akathisia Activation Onset of action by day 4 Quetiapine Indications—all phases of bipolar disorder (Seroquel XR) Issues Sedation Slower onset of action Clinical Higher doses (600 mg or greater) suggested for acute mania Bipolar depression—the only one with FDA approval for monotherapy Doses of 300 and 600 mg separated from placebo responses More robust for bipolar type I compared to bipolar type II Risperidone Indications Mania: monotherapy Mixed or bipolar depression: combined with lithium Side effects EPS (dose dependent) Prolactin Ziprasidone Indications Mania Mixed Maintenance Side effects Asthenia Abnormal vision Somnolence Issues Unpredictable initial response (dosing possibly related) Onset within hours
Thein_Chap05.indd 61
11/3/2010 2:55:42 PM
62
Psychiatry Bullets
Comparing Agents: FDA-Approved Medications Mania
Mixed
Maintenance
Depression
Ariprazole
×
×
×
−
Ziprasidone
×
×
−
−
Risperidone
×
×
−
−
Quetiapine
×
−
−
×
Chlorpromazine
×
−
−
−
Olanzapine
×
×
×
−
Valproate DR ER
×
−
−
−
Carbamazepine ER
×
×
−
−
Lamotrigine
−
−
×
−
Lithium
×
−
×
−
Symbyax
−
−
−
×
Antipsychotics
Anticonvulsants
Other
Comparing Agents: Side Effects Profiles O
R
Q
Z
A
Weight gain
+++
++
++
+/0
+/0
Dyslipidemia
+++
+
+
0
0
++
+
+
0
0
+++
++
+++
+
+
Metabolic
Hyperglycemia Neurological Sedation
+
++
0
+
+
CVS— Hypotension
EPS
++
+
−
±
±
Endo—Prolactin
+/0
++
0
0
0
Anticholinergic
±
+
±
±
±
Treatment from a symptomatic point of view BP depression Monotherapy Lithium FDA approved for bipolar depression (long-term use) Eight placebo-controlled studies, all before 1980 (out of nine studies) Small studies Response rate—overall 79%, unequivocal 36% Onset of action 6–8 weeks Valproate—two small studies (− and +) Lamotrigine Four negative studies, one positive study
Thein_Chap05.indd 62
11/3/2010 2:55:42 PM
Chapter 5 Bipolar Disorder
63
Suggest adding along to a mood stabilizer (lithium) Possible role in treatment-resistant bipolar depression Possible role in preventing an episode of depression Not found to be helpful in preventing an episode of mania FDA approved for prevention of relapse of bipolar depression SGA Quetiapine (300–600 mg)—FDA approved for bipolar depression Aripiprazole Two negative studies Modafinil Antidepressants Few studies, small studies, MAOI focused Significant concerns for switching Combination Adding antidepressants: STEP-BD reveals no benefit with antidepressants for bipolar depression with mania History of switching is a risk for future switching Olanzapine—fluoxetine: FDA approved for bipolar depression Psychotherapy An arm of treatment offered to test subjects STEP-BD reveals benefit Types CBT Family-focused therapy Psychoeducation Rehabilitation BP acute mania Anticonvulsants Lithium Prevention Valproate Carbamazepine extended release SGA Entire list FGA Haloperidol Role as augmenting agents BP maintenance Lithium “the gold standard” Role in preventing manic episode Prevents suicide Divalproex SGA Olanzapine—similar to response rates of lithium Quetiapine XR BP rapid cycling Valproate Equivalent to lithium Lithium Equivalent to valproate BP mixed—“don’t use antidepressants” Recurrence (overall psychotherapy may have critical role in treatment) Depression Lithium Lamotrigine Mania Lithium
Thein_Chap05.indd 63
11/3/2010 2:55:42 PM
Thein_Chap05.indd 64
11/3/2010 2:55:42 PM
Chapter
6
Anxiety
ANXIETY AND DEPRESSION (www.adaa.org, a web site for patients with anxiety disorders) OVERVIEW WHO findings Depression is the fourth greatest health problem Depression will be the second greatest problem by 2020 Depression is already the world’s greatest source of disability among adults DSM-IV classification Panic disorder with or without agoraphobia Social phobia Specific phobia Obsessive-compulsive disorder Acute stress reaction Posttraumatic stress disorder Prevalence 10% of the population Point
Lifetime
Social phobia
6.8%
12/1
OCD
1
1.6
PTSD
3.5
6.8
Agoraphobia
0.8
1.4
Panic disorder
2.7
5.7
GAD
3.1
4.7
Breaking down panic attacks, panic disorder, and agoraphobia Any panic attack
28%
Panic attack only
22%
Panic disorder only
4%
Panic disorder with
1.1% (females>males)
Agoraphobia
0.8%
65
Thein_Chap06.indd 65
11/3/2010 2:59:42 PM
66
Psychiatry Bullets
AGE OF ONSET COMORBIDITY WITH DEPRESSION Order of occurrence: Specific phobia>social phobia>agoraphobia>panic disorder*>GAD *depression occurs with panic disorder, others before Why? Affective spectrum disorder Inspired by neurosis construct Strong familial aggregation Challenges notion of individual heritability Neuroticism and internalizing disorder in twin studies There was a set of genes that explain increased suicide attempts STAR*D (NIMH funded) Profile Older, unemployed, less educated More severe depression More suicidal ideation More symptoms of panic, GAD, OCD, social anxiety disorder, PTSD, hypochondriasis, somatoform disorders Depression features associated with remission Anxious depression most likely not to remit Length of depression medium likely not to remit Recurrent depression least likely to remit Effect of comorbid depression on antidepressant Increases severity Increases chronicity Increases social impairment Increases vocational impairment Increases alcohol/substance use Increases risk of suicide Increases poor response to acute and long-term treatment Comorbidity with bipolar disorder—another NIMH-funded study Looking at bipolar and anxiety disorder (1/3 of bipolar patients have comorbid anxiety disorders and fewer days well, and the more anxiety disorders, the even fewer days well, and increased risk for relapse (especially social anxiety disorder [SAD] and PTSD)
HERITABILITY Behavioral disinhibition Behavioral disinhibition is associated with family history of anxiety disorder But only <30% of kids with behavioral disinhibition develop anxiety disorder Risk increases if the parent has an anxiety disorder, especially panic disorder Risk increases even more if parent has childhood onset of anxiety disorder Family study of anxious school refusal/phobia School refusal/phobia is related to anxiety disorder Two common reasons for school refusal/phobia Separation anxiety disorder—look for family history of panic and agoraphobia Phobia (especially social phobia)—look for family history of social phobia Family study of generalized social phobia—very familial Heritability of panic disorder Panic disorder runs in families Higher in monozygotic twins than dizygotic twins (concordance)
Thein_Chap06.indd 66
11/3/2010 2:59:43 PM
Chapter 6 Anxiety
67
High rates of 35% carbon dioxide sensitivity among first-degree relatives Remember giving patients 35% carbon dioxide can induce panic attacks What is inherited? “Phobia-proneness” genes for internalizing disorders like mood and anxiety disorders But does not adhere to our diagnostic criteria Agoraphobia—maybe this is more inherited—a study Relationship with chromosome 11p CCK BR locus CCK—cholecystokinin is associated with panic Alternate diagnostic conceptualizations: Panic—bladder/renal associated interstitial cystitis LOD3.57 at chromosome 13q (D13S793) Heritability of social anxiety-related concerns 48%
OVERALL TREATMENT APPROACHES Antidepressants Current FDA anxiety indications GAD Paroxetine Venlafaxine Escitalopram Duloxetine Panic disorder Fluoxetine Paroxetine and CR form Venlafaxine Sertraline SAD Paroxetine and CR form Venlafaxine Sertraline Posttraumatic stress disorder Paroxetine Sertraline Obsessive-compulsive disorder Fluoxetine Paroxetine Sertraline Fluvoxamine Clomipramine GAD PD
F
SAD PTSD OCD
F
P
V
Esc
D
P/cr
V
S
Pcr
V
S
P
S
P
S
L
Cl
F, fluoxetine; P, paroxetine; V, venlafaxine; Esc, escitalopram; S, sertraline; L, fluvoxamine; D, duloxetine; and Cl, clomipramine Specific studies on SSRIs Escitalopram and citalopram in panic disorder both effective Paroxetine—in social phobia is effective Predicting SSRI response 5-HTT promoter region polymorphism ss << sl ≤ ll social phobia responsiveness to SSRI This was not shown for MDD Anxiety disorders work more on 5-HT availability
Thein_Chap06.indd 67
11/3/2010 2:59:43 PM
68
Psychiatry Bullets
SNRI’s—Venlafaxine XR Demonstrating that NERI is not necessary as 75 mg just as good as 150 to 225 mg Benzodiazepines Examine risks Long-term use Dose escalation Not typically found with therapeutic doses Observe for individuals with Substance use disorder Personality disorder Dependence Commonly after 4 to 6 weeks of continuous use Risk Daily dose Prior dependence on sedative-hypnotics Withdrawal Shorter half-life agents result in greater rebound Speed of discontinuation effects symptoms Beware of discontinuation symptoms all Cognition Acute Decrease recent/immediate recall Dependent upon Dose Potency Chronic Reversible Decrease short-term recall Interaction with alcohol Examine benefits Rapid onset of action No sexual side effects Clonazepam in social phobia One study shows a superb response 50% of people with social phobia will not respond to SSRIs Combination with antidepressants Potential benefits: effectiveness SSRI + Clonazepam (specifically for panic disorder) Use these first before using a second-generation antipsychotic agent Gabapentin Mechanism of action Release of GABA (nonsynaptically) from the glia Binds to alpha-2-delta subunit (subunit of voltage gated calcium channel) NOT a benzodiazepine and does NOT work at that receptor Not FDA approved for any anxiety disorders Possible role in Social phobia (Pregabalin-tiagabine also effective) Agitation Rage Irritability Usual doses 750 to 1,200 mg daily (TID) Pregabalin Mechanism of action similar to that of gabapentin Possible role in GAD (pregabalin 300 mg equivalent to alprazolam)
Thein_Chap06.indd 68
11/3/2010 2:59:43 PM
Chapter 6 Anxiety
69
Buspirone Mechanism of action: 5-HT1A agonist Onset of action similar to that of SSRIs No FDA approval for any anxiety disorders Beta-blockers Helpful for Autonomic symptoms Objective symptoms SGA Low doses being used Same risk management approaches recommended Kava-kava Over-the-counter agent Withdrawn in Europe Hepatotoxicity Encephalopathy (due to hepatotoxicity) Liver failure Cognitive behavioral therapy (CBT) Useful alone or in combination with medication for Refractory symptoms Persistent dysfunctional cognitive, behavior, and anxiety sensitivity Comorbid conditions Facilitating medication discontinuance Panic disorder, social phobia, PTSD CGI response in panic disorder comparing medications, CBT, and combination Barlow et al. JAMA 2000 Both good acutely and maintenance You can use either treatment alone (60% will do well) NIMH web site www.adaa.org (Anxiety Disorder Association of America)
TREATMENT GUIDELINES APA Practice Guidelines (1998) for the Treatment of Panic Disorder Guideline Watch: Practice Guideline for the Treatment of Patients with Panic Disorder www. psych.org/psych_pract
RESIDUAL SYMPTOMS A complex concept in evolution Why do we care? Common Disabling Increased health care utilization Harbinger of recurrence … and MDD—a debate May be a variant of treatment resistance or partial response May represent residual symptoms present after supposed remission May have second comorbid condition responsible for the symptoms May be medication induced May have symptoms as a result of an underlying personality construct
Thein_Chap06.indd 69
11/3/2010 2:59:43 PM
70
Psychiatry Bullets
If due to Incomplete/partial response → treat core symptoms aggressively Untreated symptoms (not core) → develop symptom-focused approach Secondary to comorbid condition → treat comorbid condition Treatment emergent side effects → modify the treatment Personality → focus on personality (treat with CBT/DBT) 20% to 45% of patients who meet response criteria have persistent residual symptoms Common residual symptoms—not well studied 75% of partial responders had mild-to-moderate residual symptoms General somatic symptoms Fatigue Psychic anxiety Depressed mood Insomnia Guilt If residual symptoms are thought to reflect partial response Increase the initial antidepressant as tolerated Switch class of antidepressant Add augmenting agent Modafanil Bupropion Stimulants Bupropion Atypical antipsychotic Dopamine agonists Add evidence-based psychotherapy Add somatic treatment Manipulate the environment
SPECIAL CONSIDERATIONS Comorbidity Psychiatric disorders Depression Medical disorders Cancer COPD Infectious disease Chronic pain Autoimmune conditions Cardiovascular disease Irritable bowel syndrome Role of neurotransmitters in mood disorders NE
energy motivation anxiety/irritability mood/emotion/cognitive
5-HT
impulse anxiety/irritability mood/emotion/cognition/sex/appetite/ aggression
DA
drive motivation mood/emotion/cognition sex/appetite/aggression
CURRENT MEDICATIONS Current medications—are they optimized? Have common treatment interventions been explored? Other options—see augmenting agents above
Thein_Chap06.indd 70
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
71
Reboxetine augmentation very selective SSRI and NERI can be helpful MAO-I Indications Reverse gastrointestinal signs (more eating, sleeping, anergia) Nonendogenous Mood reactivity Rejection sensitivity MAOI > TCA > PBO DA, NE > 5-HT Selegiline transdermal system (STS) (FDA approved)
COMORBIDITY OF MDD AND ANXIETY DISORDERS General 60% with MDD have anxiety disorder Anxiety disorder occurred first (watch for depression in the future) What are they? (how do they manifest?) Worry Psychic anxiety (ask about trauma—PTSD) Somatic anxiety Panic attacks Phobic symptoms Obsessive-compulsive symptoms
ANXIETY AND FATIGUE Fatigue—too little data Agents Stimulants Bupropion Modafinil—good for fatigue and sleepiness during the day; does not necessarily treat the depression itself Desipramine (more noradrenergic compared to other tricyclic agents) Practical thoughts Ask patients for presence of residual symptoms Do the symptoms bother the patient? What is the intensity? How frequently (times/day or week)? How does it affect quality of life? Quantify the symptoms with the patient Care Engages patients with the process of their own healing It gives the patients power over their own symptoms Objective monitoring of treatment Evidence-based psychotherapies Options Light (fatigue, concentration) Exercise (anxiety, somatic, fatigue) 20 to 30 aerobic minimally 3× week Massage (anxiety, somatic, sleep, fatigue) Other—yoga, acupuncture Effective most of the time Remission (defined as >50% improvement) 80% of remitters had residual symptoms
Thein_Chap06.indd 71
11/3/2010 2:59:44 PM
72
Psychiatry Bullets
ANXIETY AND INSOMNIA Insomnia Prevalence and impact Prevalence in adults (chronic insomnia) 10% to 15% (2000, 2003) Varying degrees of severity 20% to 30% additionally have transient or occasional sleep problems (two nights in a month of poor quality sleep) Morbidity (1997, 2000, 2005) Absenteeism Accidents at work and driving Memory impairment Greater health care utilization Chronic insomnia Sleep hygiene Limit caffeine Alcohol intake (rebound insomnia and withdrawal symptoms) Illicit drugs Psychotropic management (behavioral, lifestyle approaches not discussed) Indications Impaired daytime functioning Behavioral approaches alone insufficient Insomnia compromising mental health outcomes Best use Initially—nightly therapy (4 to 6 weeks) Intermittent use—longer term—several days to a week in a row and then stop Couple with behavioral therapy and sleep hygiene FDA approved Trade name
Onset in minutes
t½
Restoril
45 to 60
Intermediate
Halcion
15 to 30
Short
Ambien
15 to 30
Short
Ambien CR
15 to 30
Intermediate
Sonata
15 to 30
Ultra short
Lunesta
15 to 30
Intermediate
Rozerem
30 to 45
Intermediate
ANXIETY AND PULMONARY DISEASE COPD or asthma with depression associated with: Poorer adherence to meds Poorer lifestyle choices (smoking, exercise) More severe symptoms Poorer disease outcomes (thus, COPD/asthma is a risk factor) Treatment of asthma and comorbid anxiety disorder Evidence-based therapies SSRIs and SNRIs Benzodiazepines are usually not contraindicated; but—avoid prn! Consider drug-drug interactions Use psychotherapy Lifestyle modifications Adjustment to chronic illness B agonists may make anxiety worse
Thein_Chap06.indd 72
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
73
PATHOPHYSIOLOGY OF ANXIETY DISORDERS Neurotransmitters GABA GABAa site—specifically delta and gamma subunits Glutamate Ionotropic—fast excitatory transmission AMPA Kainate NMDA Antagonists are anxiolytic Metabotropic—modulatory and couple with phospholipase C or AC Group II mGluR2 and MGluR3 agonists reduce glu transmission Serotonin Norepinephrine Brain regions Frontal cortex Lack of effective functioning Ineffective ability to utilize executive functioning effectively Limbic cortex: Increased activity Amygdala: Increased activity
SUBTYPES OF ANXIETY DISORDERS PTSD Historical overview Focus on adults (war: battle fatigue, shell shock, nervous breakdown) 1970s research on childhood trauma Chowchilla incident: 26 kids were kidnapped on a bus and held for 17 hours before escaping PTSD in 1980 DSM-III Lifetime prevalence 7.8% Neurobiology Structural changes—reduced hippocampal volume Cause versus effect Overlap with depression Functional changes Paralimbic area Prefrontal cortex (PFC) The anterior cingulate (AC) is a filtering device for external stimuli Thus, there is a reduced functioning of the AC Lack of filtering Contributes to startle response Neurophysiological changes—HPA axis CRF, cortisol, DHEA Sympathetic nervous system Neural correlates of traumatic memory in PTSD Increased activity in amygdala and thalamus Decreased activity in AC (using procaine) procaine is novocaine which can cause panic attacks Diagnostic criteria and clinical findings TR—Event leading to fear, helplessness, horror, disorganization, and agitation Reexperienced: recall/play, dreams, flashbacks/reenactment, and distress reactivity
Thein_Chap06.indd 73
11/3/2010 2:59:44 PM
74
Psychiatry Bullets
Persistent avoidance: thoughts, activities, recall, interest, detachment, restriction, sense of foreshortened future Persistent arousal: Difficulty falling asleep, irritability, decreased concentration, hypervigilance, startlement More than a month; impairment Acute (<3 months), chronic (>3 months), delayed (at least 6 months after the stressor) Exposure to a stressor Consider verbal exposure, trauma from a distance, displacement Children are prone to malleable memories; ask parents/adults Rape and exposure lead to more symptoms than disasters or accidents Reexperiencing Traumatic play Reenactment behavior (repetition compulsion like) Traumatic reminders (circumstances, precipitants, signs of danger, objects, situations) Avoidance of stimuli/numbing Increased state of arousal PTSD complexity (diagnose to population frequency) Risk factors Female gender (twice as common in women) Age (an inverse relationship) Education Intelligence Socioeconomic status Family history (of anxiety, alcoholism, depression, and attention deficit symptoms) Reported childhood abuse, combat, rape (30% of victims develop PTSD) Reports of other adverse childhood events Extent of trauma (the more combat exposure, the more PTSD symptoms) Poor social support/ quality of attachment Post trauma life stress Previous psychiatric disorder (conduct, mood, ADHD) Coping styles/strategies Developmental considerations Toddlers cannot articulate Loss of acquired/new skills (talk, enuresis) School behavior/mood, forgetting to do things Adolescence Comorbidity MDD
50%
Alcohol (M>F)
50/30% assoc with 5-HTT phenotype!
Drug (M>F)
30/25%
SAD
25%
Agoraphobia
12/25%
GAD
15%
Etiology Psychoanalytic—attacking the ego, rendering it helpless Social learning theory—fight/flight/freeze Neurobiology (neurotransmitters) NE, 5-HT, DA, GABA, corticosteroids, and endogenous opioids Assessment: Careful history Ask parents/loved ones Clarify the stressor
Thein_Chap06.indd 74
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
75
Trauma history—type, age, and duration PTSD symptoms (>1 month) Reexperiencing (Flashbacks, nightmares, psychological, and physical reactivity) This is usually considered a core symptom Avoidance/numbing (usually functionally impairing) Hyperarousal (usually needs separate medication) Difficulty concentrating Memory difficulties Insomnia Safety Suicidal ideation Homicidal ideation Personal characteristics Resilience Genetics regarding the 5-HTT promoter region Social support Fewer risk factors Coping skills Interpersonal relatedness Faith Psychosocial situation Home environment Social supports Stressors Acute Ongoing Treatment Nonpharmacological treatment Prolonged exposure Originally developed for rape-related PTSD Effective and sustained benefit over time Imaginal exposure (focus on feelings—not events) Patient imagines and describes trauma and associated symptoms Effective in reducing PTSD symptom severity In vivo exposure Uses systemic desensitization to trauma triggers Effective in decreasing symptom severity Benefits sustained over time Stress inoculation training (SIT) “Tool box” for managing trauma Contents Breathing exercises Components of relaxation Role play Covert modeling Thought stopping Self-dialogue Effective in reducing PTSD symptoms Imagery rehearsal therapy Brief Decreases chronic nightmare (a refractory symptom and SSRIs may worsen them) Improves sleep quality (avoid deep sleep, cannot sleep deeply) Cognitive processing therapy (CPT) Manualized treatment developed for treating PTSD Corrects maladaptive cognitions Emphasis on written dialogue
Thein_Chap06.indd 75
11/3/2010 2:59:44 PM
76
Psychiatry Bullets Exposure and education about issues of Safety Trust Esteem Intimacy Reduces severity of PTSD and depression symptoms Gains maintained over time Efficacy Eye-movement desensitization and reprocessing (EMDR) Exposure-based therapy using Eye movements Trauma Memory recall Verbalization Effective as other therapies (small studies) Eye movement component may be unnecessary Psychodynamic Focus Countering demoralization Understand meaning of trauma Integrate trauma into the patient’s life narrative Trust and boundaries Most helpful in improving numbing and avoidance One small randomized controlled study supports efficacy Debriefing Group and individual Staged Semistructured interview Addresses Facts Related emotions Not effective (individual) (group not studied) Role in acute stress disorder (thus, use early) New directions Imagery rehearsal therapy → nightmares and insomnia Guided imagery → PTSD Group treatments→ PTSD (early use) Secondary prevention (increase resilience) Critical incident debriefing (not helpful; more studies) Resources Effective treatment for PTSD Gender and PTSD PILOTS database Department of Veteran Affairs Web site PTSD treatment guidelines This is evidence-based APA treatment guidelines (www.apa.org) NIMH (www.nimh.org) Children Debriefing children in classrooms describing and clarifying Play (drawing/squiggle game) to repair Role play Family therapy Pharmacological Goals Reduce core symptoms
Thein_Chap06.indd 76
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
77
Reexperiencing Avoidance or numbness Hyperarousal symptoms Treat associated comorbidities (MDD especially) Improve quality of life and resilience to stress via reducing disability and stress vulnerability Facilitate nonpharmacologic therapies First-line SSRIs (FDA-approved sertraline and paroxetine). Long-term studies did not support gender preference Efficacy in long-term studies Latest combining therapy and medications better than either alone Antidepressants Sertraline Flexible dose After 12 weeks Augmenting with prolonged exposure (better) (resilient to reexperiencing symptoms) Paroxetine—fixed dose Fluoxetine—6 month study → protects against relapse Others studied Nefazodone
100 to 600 mg
open label/RCT
Mirtazapine
15 to 45 mg
“
Venlafaxine
75 to 300 mg
“
Bupropion
75 to 300 mg
Citalopram Escitalopram
“ less data
in combat veterans helpful
Benzodiazepines No controlled studies support efficacy in acute/chronic PTSD Controversial monotherapy use (increased risk of PTSD) Use to help reduce anxiety, improve sleep acutely Side effects and high substance abuse comorbidity Impairs cognition—thus, difficulties with memories Mood stabilizers Helps flashbacks? But, in general most studies are negative Medications studied Valproate
Open-label study
Carbemazepine
Open-label study
Lamotrigine
Small randomized control study
Topiramate
Open-label study
Tiagabine Lithium
Open-label study
Phenytoin Antipsychotics Helpful for Treatment of refractory patients Comorbid psychotic symptoms 40% of veterans may have comorbid psychotic features Larger controlled studies pending
Thein_Chap06.indd 77
11/3/2010 2:59:44 PM
78
Psychiatry Bullets
Second generation antipsychotics—some studies Olanzapine Augmentation if antidepressants insufficient One negative trial Quetiapine Helps in treatment of refractory veterans Risperidone Augmentation helps Aripiprazole Monotherapy (pending) Augmentation helps Adrenergic inhibitors Alpha 2 agonists mixed results Clonidine (role in startle and panic awakenings) Guanfacine Alpha 1 antagonist prazosin 5 to 10 mg or higher Role in startle and panic awakenings B blocker—propranolol 40 to 160 mg For peripheral autonomic arousal Other medications Topiramate Role in decreasing nightmares Sleep disturbances Common—polypharmacy often directed at sleep problems EEG findings (limited findings) Awakenings from REM phenomenon Movement suppression during sleep Epidemiological samples—“remarkably normal sleep” More brief arousals from REM sleep With perception of poor sleep Treatment Addressing nightmares and fear for safety Address security, make bedroom safe Install night lights and remove potential hazards “Dream-scripting” CBT technique Special treatment considerations for service members Goals of treatment Increase resilience Encouragers include providers, service leaders, and family Encourage calm responsivity Encourage overall positivity Encourage optimism during duress Encourage recovery Focus on reintegration Of service members and family Awareness especially 3 to 6 months after returning home Monitor Comorbidity PTSD Depression Substance use Family members At risk for operational stress Often moves with the service member (consider duration) Consider the unit in which the service member is involved Also viewed as “family”
Thein_Chap06.indd 78
11/3/2010 2:59:44 PM
79
Chapter 6 Anxiety Options for treatment Nonpharmacological CBT—Focusing on resilience, recovery, and reintegration Yoga Acupuncture Mindfulness training Relaxation therapy Exercise Spiritual support Pharmacological (as noted above)—consider side effects Resources www.realwarriors.net www.dcoe.health.mil www.ncptsd.gob Defense Centers of Excellence (DCoE) Outreach Center 1-866-966-1020 (available 24 hours/7 days)
GENERALIZED ANXIETY DISORDER (GAD) Symptoms Core Excessive anxiety and worry about a number of events for the majority of days over 6 months Difficulty in controlling the worry (obsessional quality) Associated with physical and psychological symptoms Significant distress or impairment Not due to substance or a general medical condition Associated symptoms ≥3 Psychic symptoms Irritability Difficulty in concentration or mind going blank Sleep disturbance Somatic symptoms Restlessness or feeling keyed up on or on edge Fatigue Muscle tension Common presenting somatic symptoms in GAD Muscle tension, trembling, twitching, aching, and soreness Cold, clammy hands Dry mouth Sweating Nausea or diarrhea Urinary frequency Epidemiology Prevalence 1 year: 3% Lifetime: 5% (chronic) Age of onset: adolescence—30 years 2:1 females:males Comorbidities—high rates Any disorder: 90% MDD: 60% (explains why antidepressants work) Alcohol use: 35% (generally secondary) SAD: 30% (generally secondary) Panic disorder: 25% (generally secondary)
Thein_Chap06.indd 79
11/3/2010 2:59:44 PM
80
Psychiatry Bullets
Impairment comparable to depression—CONSIDERABLE Impaired occupational functions: 15% Impairment in social functioning: 25% Risk Factors Childhood depression Mother with phobic anxiety Developmental problems Psychosocial stress Differential diagnoses Generalized anxiety disorder SAD Panic disorder Obsessive-compulsive disorder Adjustment disorder with anxiety—with the specific stressor within 3 months of stressor and asymptomatic after 6 months Remission THE GOAL (just like in depression) Anxiety remission
HAM-A ≤7 or ≥70% improvement in symptoms
Depression remission
HAMD17 ≤7
Disability remission
Sheehan disability scale ≤5
Prevent recurrence
HAM-A/D17 ≤7
Pharmacotherapy Benzodiazepines Risks and benefits Benefits Effective (data with diazepam and alprazolam) Rapid onset of action Syndromic benefits of higher sustained doses (max) Easy titration Can be used PRN Can be used for augmentation Risks Side effects Sedation Decreased reaction time Incoordination Memory impairment Dependence Cross-tolerance with ETOH/abuse potential No effective for comorbid depression Sexual side effects (especially diazepam) Withdrawal syndrome First several days → Anxiety, insomnia, and restlessness First 10 days → Confusion, tachycardia, hallucinations, depersonalization, and alteration in conscious 2 to 3 weeks → Tremor, anorexia, sweating, lethargy, nausea, anxiety, agitation, insomnia, myoclonus, tachycardia, and high blood pressure Earlier/3 weeks → Perceptual hyperacusis and photophobia GABA Generally The inhibitory neurotransmitter of the brain Three receptor types GABA-A GABA-B GABA-C
Thein_Chap06.indd 80
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
81
Roles in Sensitivity for neuronal firing (seizures) Emotion, cognition, pain, sleep, and motor function Buspirone Efficacy demonstrated in individual studies and meta-analysis Delayed onset of therapeutic benefits (5 weeks in 1 study) Excellent tolerability and low side effect burden No sedation, cross tolerance with alcohol, abuse potential Modest effect for depression (most commonly used as an augmenting agent with antidepressants) Tends to be underdosed (>30 mg required) (another use is agitation in dementia) 5-HT1A agonist Gabapentin Pregabalin Promising effects SSRIs/SNRIs Generally Efficacy determined in controlled studies Delayed onset of therapeutic benefits 2/3 of patients respond by 8 weeks Significant functional improvement Generally well tolerated Effective in other anxiety disorders and depression Flexible dose paroxetine (20 to 50) > placebo in patients with GAD Sertraline (25 to 50 mg) > placebo (kids) (better if highly depressed) Venlafaxine XR (75 to 150 mg) > pbo Increasing dose became increasingly effective This was a 6-month study (remission increases with time) Equivalent to benzodiazepine and > buspirone 30 mg Symptom improvement by week 1 Psychotherapy General Evidence in randomized controlled trials (CBT) Other types Psychoeducation/support Psychodynamic for those with a history of trauma CBT A study Many rating instruments Continuing efficacy Cognitive model for anxiety disorders Anxieties associated with patterns of thinking Increase in anxiety results in thoughts/images of social harm and/or physical harm Panic attacks → physical harm Social phobia → social failure GAD → loss of control/vigilance Prognosis Generally very good Risk factor for social phobia, MDD, GAD, and panic
SOCIAL ANXIETY DISORDER Symptoms for at least 4 weeks with an onset before 18 months ≥3/8 symptoms Clinical findings Procrastination in AM, somatic (GI, HA), difficulty attending school Decreases with age
Thein_Chap06.indd 81
11/3/2010 2:59:44 PM
82
Psychiatry Bullets
Comorbidity Specific phobia OCD ADHD Treatment SSRIs and SNRIs MAO inhibitors TCAs Benzodiazepine Role in Prevention of SAD relapse Adjunctive role Beta-blockers Performance anxiety CBT for SAD Efficacy studies Individual or group CBT is effective Comparable to pharmacotherapy as supported by RCTs Phenelzine v group CBT (1998, 1999) Fluoxetine v group CBT (2004) Integrating CBT into pharmacotherapy Information Elements of the anxiety experience Role of maladaptive thoughts in escalating the anxiety role Exposure—encouraging step-by-step exposure to fear and avoided situations and sensations
SEPARATION ANXIETY DISORDER Normal Beginning at 6 to 7 months Peaking at 18 months Decreasing after 30 months Abnormal Persistent, excessive, associated with significant distress or impairment
PANIC DISORDER Prevalence Comorbidity Affective conditions Substance use Other anxiety disorders Phobias Obsessive-compulsive traits Relapse can occur in 2 months to 2 years after medications have stopped Treatment Generalizing principles Focus on unexpected limited symptom attack (not panic attack) that would reinforce the panic attacks Dizziness Chest pain Choking spells Symptoms of GI discomfort
Thein_Chap06.indd 82
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
83
Chronic treatment will be required (acute, long-term, relapse) Patient education Treatment choices CBT treatment—80% to 90% panic free within 6 months Types Exposure therapy: In vivo, imaginal, interoceptive Systemic desensitization SSRIs Overall Better outcomes than with TCAs Benzodiazepines Recommend higher doses “Start low, go slow, but go” Suggesting titrating dose up till side effects FDA-approved agents Paroxetine/CR 40 mg needed (compared to 10 and 20 mg) Sertraline Fluoxetine Venlafaxine/XR Note: others are not necessarily ineffective Citalopram Escitalopram Fluvoxamine SNRIs TCA Effective Consider adverse events MAOIs Effective Consider adverse events Benzodiazepines Half-life is not a good predictor of treatment outcome Half-life does not correlate with duration of therapeutic action Other Divalproex (if effective, reconsider comorbidity with bipolar) Tiagabine Not appearing to be effective Gabapentin Pregabalin SGA Even when used with patients comorbid with bipolar disorder, effectiveness was not noted Bupropion Not effective for panic disorder Consider it as exacerbating anxiety 5-HT1A agonists—not appearing to be effective Buspirone Gepirone Combination SSRIs + Benzodiazepine Addresses possible activation seen in early stages of SSRI treatment Improved adherence to the SSRI Watch for any signs of withdrawal SSRIs + CBT
Thein_Chap06.indd 83
11/3/2010 2:59:44 PM
84
Psychiatry Bullets
Differential diagnoses Hyperthyroidism/hypothyroidism Mitral valve prolapsed Cardiac arrhythmias Coronary insufficiency Pheochromocytoma Hypoglycemia Vertigo Substance withdrawal
OBSESSIVE-COMPULSIVE DISORDER Diagnostic criteria (NB: children may not see symptoms as problematic) Clinical findings Age of onset for boys—9 years for girls—11 In children, boys to girls 3:2; adolescents 1:1 Early onset—male family history with OCD/tic disorders Excessive cleaning, repeating, checking, counting, ordering, hoarding Compulsions without obsessions common in young kids Subtypes can change over time (no particular pattern) Practice Parameter AACAP 1998; CYBOCS Subtypes Early onset: male, ADHD, family history, tic (familial variety) and obsessions are ego-syntonic PANDAS severe symptoms, then remit OCD/tic symptoms presents Often prepubertal GABHS infection Check throat culture antistreptolysin O antiDNAse B streptococcus ANA Differential diagnoses Depression Anxiety Autism Mental retardation Panic disorder Brain damage Anorexia nervosa Bulimia nervosa Tourette syndrome Epidemiology Prevalence 0.8% Lifetime 1.9% or 3% for adolescence Etiology Frontal-limbic-basal ganglia dysfunction Parkinson, Huntington Chorea, Sydenham (antibodies to the basal ganglia after a streptococcal infection) with increased OCD Decreased caudate nucleus activity Treatment Selection AACAP parameters
Thein_Chap06.indd 84
11/3/2010 2:59:44 PM
Chapter 6 Anxiety
85
Behavioral CBT (exposure with response) gold choice treatment Pharmacological Clomipramine Sertraline >6 years of age Fluvoxamine >7 years of age Fluvoxamine >8 years of age Citalopram—no studies Escitalopram—no studies Venlafaxine POTS (pediatric OCD treatment study): cognitive behavioral therapy (CBT), sertraline, and combination for children and adolescents with OCD Design Randomized controlled trial 3 U.S. centers Methods 12 weeks Individuals aged 7 to 17 years N = 112 Conclusion Combined treatment superior to CBT or sertraline alone Effect sizes Combined: 1.4 CBT alone: 0.97 Sertraline alone: 0.67 Augmentation strategies Clomipramine is highly serotonergic (and its metabolite is highly noradrenergic) Both vulnerable to first pass iv clomipramine bypasses liver Effective for treatment OCD resistant Adding low dose fluvoxamine taking advantage of 3A4 and 2C19 metabolism interference Neuroleptics Buspirone Additional SSRI Lithium Fenfluramine Stimulants Other Bupropion Valproate might be helpful for refractory (if in context of complex partial seizures) Adjunctive (will not work alone) Adding benzodiazepines does not work unless anxiety is an independent disorder Synergistically How long to treat? Never for the rest of life until they recognize that they are different When to stop springtime? Summer camp winter holiday How to stop? No breakthrough symptoms no seasonal slumps Slowly Watch closely—wait for 1 year Psychodynamic and psychosocial; self-esteem, life effects, compliance Family therapy (discord, roles/boundaries) Investigational
Thein_Chap06.indd 85
11/3/2010 2:59:44 PM
86
Psychiatry Bullets
Deep brain stimulation Current indications Parkinson tremor Dystonia PANDAS Pediatric autoimmune neuropsychiatric disorders associated with strep Not a validated disorder “Most treatments should be done as part of a research trial” Plasmapheresis results of small (N = 10) study—no benefit Penicillin prophylaxis results of a study in 1999 revealed that prophylaxis with penicillin and azithromycin was helpful in reducing the streptococcal infections and the neuropsychiatric symptoms exacerbations If there is a suspicion, perform a throat culture—If positive treat (consider for an extended period like 20 days instead of 10 days) Effectiveness of obtaining titers—for research only? Prognosis: most patients can expect improvement although a small number do experience chronic and debilitating symptoms
Thein_Chap06.indd 86
11/3/2010 2:59:44 PM
Chapter
7
Substance Use Disorders
GENERAL PATHOPHYSIOLOGY Brain areas Addiction Brain areas Mesolimbic dopamine pathway Nucleus accumbens Neurotransmitter Dopamine Mechanism Dopamine transmission does not decrease with repeated use of the substance Seeking and craving Brain areas Amygdala Frontal cortex Neurotransmitter Glutamate Circuits Motor memory Limbic priming Basolateral aspect of the amygdala associated with cue priming Extended aspect of the amygdala associated with stress priming Genetics Twin studies Family studies Adoption studies Gene expression Lowered acetaldehyde dehyrogenase in Asian ethnic groups (Alcohol’s rate-limiting step of metabolism; a less efficient enzyme leads to a buildup of toxic metabolites) Environment Social learning Family habits/issues Risk factors in teens and adolescents Family conflict Use of tobacco at an early age Peers’ usage Low scholastic priority Stressful/traumatic events Lack of supervision Delinquency 87
Thein_Chap07.indd 87
11/3/2010 3:20:44 PM
88
Psychiatry Bullets
Preventative measures for teens and adolescents Investment in scholastic activities Consistent family patterns, expectations, dynamics Anger management Emphasize prosocial behaviors in all realms of life Comorbidity with other psychiatric disorders Self-medication hypothesis Conduct disorder is the highest predictor for substance abuse in adolescents with ADHD
DEFINITION Substance abuse (does not apply to caffeine or nicotine) DSM-IV TR definition (One or more within the last 12 months) Maladaptive pattern of substance use leading to clinically significant impairment Failure to fulfill major-role obligations (work, school, home) Physically dangerous (MVA, machinery) Legal problems (OUI) Recurrent physically hazardous behavior Continued use despite social problems Does not meet criteria for substance dependence Substance dependence Maladaptive pattern of use, distress within 12 months—three or more: Tolerance Need for larger amounts Decreased effect with same amount Withdrawal Classic withdrawal syndrome associated with the agent The same substance is taken to relieve or avoid the withdrawal symptoms Larger amounts and longer periods than intended Persistent desire or unsuccessful effort to cut down or control the usage Great deal of time is spent on obtaining the substance Important (social/job/recreational) activities are given up or reduced because of usage Use continued despite knowing problems Specifiers With physiological dependence/without physiological dependence Early full remission/early partial remission/sustained full remission/sustained partial remission On agonist therapy in a controlled environment Substance intoxication (does not apply to nicotine)—reversible, substance-specific syndrome with maladaptive behavioral or psychological changes developing during or shortly after using the substance)
SUBSTANCE WITHDRAWAL ETIOLOGY AND PATHOPHYSIOLOGY Biological factors Genetics Dopamine receptor alleles Hyporesponsiveness to alcohol and sedative drugs Neurobiological substrates for positive and negative reinforcement Psychological High rates of depression High rates of sensation seeking (control of aggressive impulses)
Thein_Chap07.indd 88
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
89
Social factors Peer influences Family influences Gateway drugs (tobacco, alcohol, cannabis) use during early teens leads to substance dependence in early 20s; (ideal delay of 1–2 years during adolescence may be preventative) Life stressors Risk factors Male gender Alaskan-Inuit ethnicity Some college education (as opposed to none) Unemployment
SPECIAL ISSUES IN THE PSYCHIATRIC EXAM Source of information Better to ask individuals other than the patient Family Friends Work School Exact amounts difficult (naloxone challenge, barbiturate tolerance test) Underreporting likely (especially if the patient is not the referring party) Aberrant behavior Intoxication Violence Suicide (overdose) Elicit precipitant that led the patient to seek treatment now Keep evaluation focused on specific data needed to evaluate the substance use Stay away from affect since it is often a defense from the core issues Impaired cognitive functioning (driving can only occur after impairment is over) Uncontrolled affective displays
COURSE AND NATURAL HISTORY Most individuals who experiment with drugs do not develop dependence Gateway agents used during early teens (as noted previously) Risk factors Conduct disorder (especially if linked with substance dependence) Crime Dysfunction at home Poor education Studies suggest that different drugs are popular at different times National Institute on Drug Abuse (NIDA) High school senior surveys Drug abuse treatment outcome studies (DATOS)
ASSESSMENT Domains and stages to be assessed Consider health, aggression, family, school, peer, work, recreation Consider progression of substance
Thein_Chap07.indd 89
11/3/2010 3:20:47 PM
90
Psychiatry Bullets
Consider stages Experimental/social → misuse → abuse disorder → dependence Standardized assessment instruments Cut down/Annoyed/Guilt/Eye opener (CAGE) Car/Relax/Alone/Forget/Family-Friends/Trouble (CRAFFT) Drug Use Screening Inventory (DUSI)—149 yes/no questions Problem Oriented Screening Instrument for Teens (POSIT)—139 true/false questions (free on NIDA) Personal Experience Screening Questions (PESQ)—38 questions including lie scale Personal Experience Inventory (PEI)—300 questions including validity questions Adolescent Drug and Alcohol Assessment (ADAP) Addiction Severity Index/Teen Addiction Severity Index (ASI[T-ASI]) Urine toxicology
ALCOHOL Epidemiology Overall use per capita is decreasing, but majority are heavy drinkers Lifetime prevalence Males 15%–20% Females 5%–7% Prevalence in the United States amongst adults Alcohol abuse/dependence: 18.6 million (8 million are dependent) Diagnosed: 2.5 million Treated: 1.5 million Treated with pharmacologic agents: 140,000 Gender Females More drink at a later age Progression to abuse more rapid–“Telescoping” More likely to abstain More associated with depressive symptoms Higher blood alcohol levels Lower amounts of alcohol dehydrogenase in gastric mucosa More body fat relative to body water (greater intoxication) Look for signs of physical, sexual, and emotional abuse Developmental issues Adolescence Binge drinking (Motor vehicle accidents) (Suicide) National patterns of adolescent substance use—the “MTF” “Monitoring the Future” is a study sponsored by the NIDA tracking substance abuse by US adolescents since 1975. Surveys 50,000 8th, 10th, and 12th graders in 400 schools—www. monitoringthefuture.org Findings The rates of both alcohol and tobacco use increase with age Lifetime and daily rates of alcohol use are higher than that of tobacco Alcohol used by 47% of high school seniors compared to 23% for tobacco Alcohol is most commonly used agent By 18 years, 92% boys and 73% girls have tried 6% of adolescents binge drink 4% of adolescents drink daily (Cannabis is the most commonly used illicit agent) Illicit drug use in 20% of 8th graders and 30%–40% of 12th grades Prescription pain meds and sedative/barbiturate use rates are increasing College students 46% have used tobacco
Thein_Chap07.indd 90
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
91
43% have alcohol (with 20% reporting frequent high-risk use) 32% have used cannabis 4%–8% have used “club drugs” and other hallucinogens Elderly—1/3 late-onset alcoholism Ethnic patterns of drinking and types of alcohol problems in the United States White males > Hispanics > Blacks > Asians The toll of alcohol dependence >8.1 million in the United States meet DSM-IV-TR criteria for alcohol dependence $185 billion/year Premature death Lost work days Fetal alcohol syndrome (leading cause of preventable cause of mental retardation)— 120,000 deaths/year in the United States Definitions DSM-IV TR definitions Alcohol dependence ≥3 symptoms in 12 months Tolerance more alcohol is needed for intoxication less effective Withdrawal ≥2 signs and symptoms of withdrawal Larger number over longer time Great deal of time drinking or recovering from drinking Social/work/fun given up More drinking despite knowledge of having the problem Qualifiers Early remission Partial remission Full remission Sustained remission in a controlled environment Alcohol intoxication—metabolism is 1 oz/hour or 7–10 g/hour Alcohol withdrawal 10%, delirium tremens in 5%, and generalized seizures in 3%–5% Alcohol-induced persisting amnestic disorder Wernicke’s—confusion, ataxia, nystagmus, gaze palsy Korsakoff’s impaired memory anterograde amnesia ± confabulation Acute: 100% reversible—treatment is thiamine 100 mg TID Chronic: 20% reversible—treatment is thiamine 100 mg TID Blackouts—not technically in DSM-IV-TR Alcohol-induced mood disorder Alcohol-induced persisting dementia—repeated Wernicke’s leads to frontal lobe atrophy and increased ventricle Controversial as others can cause this (Liver/pancreatic/kidney dysfunction) Alcohol-induced anxiety disorder Alcohol-induced psychotic disorder—usually within a month of intoxication or withdrawal (and fully alert and oriented) Alcohol-induced sleep disorder—can occur after 1 month of abstinence Alcohol intoxication—increase NREM, decrease REM, restless/vivid dreamsnightmares/REM rebound Alcohol withdrawal—fragmented sleep and REM increase Alcohol-induced sexual dysfunction Theoretical subtypes Cloninger’s Type I: Late onset, rapid tolerance, guilt/anxiety about drinking, high reward dependence/avoids harm Type II: Early onset, family history, no guilt, low reward dependence, low harm avoidance, high new stimulation seeker: male → male transmission DA and NE triggered
Thein_Chap07.indd 91
11/3/2010 3:20:47 PM
92
Psychiatry Bullets
Type A and B definition Type A: late onset, tends towards decreasing dependence and problems, treatment focused on interactional treatment Type B: early onset, tends toward increasing dependence and problems, treatment focused on coping skills Gamma and Beta definition Gamma: Americans—out of control Beta: Europeans—in control, but must drink daily Miscellaneous definitions Antisocial: male poor prognosis Develop cumulative: increased use with precipitants Negative affect: female—mood regulator Develop limited: decreased use with better circumstances Comorbidity Prevalence 61% mood disorder 54% conduct disorder 43% anxiety 16% severe functional impairment Major diagnostic categories Depressive disorders Bipolar disorder Anxiety and PTSD Organic mental disorders Schizophrenia ADHD Conduct disorder and Asperger’s disorder Eating disorders Genetic predisposition Affective dysregulation Pharmacological vulnerability Personality disorder Asians with alcohol dehydrogenase insufficiencies and polymorphisms 12 month odds of ETOH dependence and mood and anxiety Any mood disorder: 4.1 (patients with a mood disorder have 4.1× greater risk of alcohol dependence) MDD: 3.7 Dysthymia: 2.8 Mania: 5.7 Any anxiety disorder: 2.6 Panic: 3.6 Social phobia: 2.5 Specific phobia: 2.2 GAD: 3.1 Antidepressants exert modest beneficial effect for major depression and alcoholism; thus, treatment should include therapy targeting the addiction Pathophysiology Converging actions of drugs of abuse on the VTA to the NA (limbic) (dopaminergic reward pathway) Opioid: euphoria GABA: release of tension DA: energy NE: final common pathway Glutamate alcohol artificially stimulates the reward system
Thein_Chap07.indd 92
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
93
the brain has an overexpressed stress system (glutamate) and when alcohol is removed, the stress system (glutamate) can be overactive even after 1 year of not drinking (clinical symptoms: insomnia, irritability, inattention) Brain changes Frontal lobe—making judgments and controlling impulses Limbic system—impulses Extended amygdala—amygdale, stria terminalis, nucleus accumbens “artificial stimulus of the reward system” Relapse prevention is the central concern of alcoholism treatment “Any alcoholic can stop at any time—it is the relapse that’s difficult” Opportunities for treatment Acute withdrawal—Protracted withdrawal (glutamate) Clinical status 1 year posttreatment 20%–30% resume dependence level of drinking (minority) Chronic medical disorders Diabetes mellitus: 30%–50% Hypertension: 50%–70% Asthma: 50%–70% Assessment Screening tools Michigan Alcoholism Screening Test (MAST) 25-item question CAGE AUDIT Alcohol Use Disorders Identification Test 10-item questions Psychiatric history and examination Sleep Impaired Decreased REM (resulting in later dreams) and stage 4 sleep Comorbidities with depression, anxiety, etc. Motivational stage of change Physical exam Look for end-organ damage and evidence of polysubstance abuse conditions Laboratory Immediate detection—Breathalyzer Blood alcohol levels (possible clinical findings based upon the individual’s history of exposure) 0.05—Loose disrupted 0.1—Clumsy 0.1–0.15—Intoxicated (0.08) 0.2—Depressed brain 0.3—Stuporous 0.4—Coma (1 drink = 12 oz beer = 4 oz wine = 1–1.5 oz liquor) Heavy use (none of the following are sufficiently sensitive or specific for routine screening of alcohol abuse) Glutamyl peptidase (GGT) Elevated in 75% of patients with alcohol dependence before liver problems manifest Increased in 30% of problem drinkers Normalizes after 4–8 weeks of abstinence Nonspecific reasons of GGT elevation (added under the section of GGT) Fatty liver Anticonvulsant medications and others SGPT/SGOT >2 Erythrocyte mean cell volume (MCV) Elevated in those who also smoke tobacco Found in 60% of those who use alcohol Females > males
Thein_Chap07.indd 93
11/3/2010 3:20:47 PM
94
Psychiatry Bullets
Nonspecific causes of elevated MCV Chronic liver disease Hypothyroidism Folate deficiency Normalizes after 3 months of abstinence Carbohydrate deficient transferrin (CDT) Suggests heavy use over 7–10 days; obtaining a baseline is recommended Mechanism of action—impairment of glycosylation of transferrin More helpful in monitoring abstinence or increased alcohol consumption MCV increase in 60% (women > men) Triglyceride increase Aspartate amino transferase (AST) Less sensitive than GGT More elevated relative to ALT for patients with alcohol-related conditions Alcohol metabolism Alcohol is converted to acetaldehyde via alcohol dehydrogenase Acetaldehyde is converted to acetic acid via aldehyde dehyrdrogenase (The site of action for disulfiram) Alcohol is metabolized in the liver 90%, kidneys and lungs 10% at 15 mg/hour (different factors affect metabolism) Treatment Examining neurotransmitters Relapse pathways Exposure to drug (reward/extinction) Exposure to conditioned cues (people/places/things) (craving/dysphoria) The basis for the 12-step program Exposure to nonspecific stress (anything that raises cortisol) Neurotransmitters Cortisol releasing factor (CRF) CRF role Hypothalamus controls pituitary-adrenal response to stress Brain stem CRF controls CNS response Alcohol Alcohol acutely activates HPA response to stress via CRF Chronic alcohol use produces tolerance to HPA response and sensitizes brain’s CRF responses CRF antagonists decrease excessive drinking associated in animal studies GABA: “The brain’s braking system” General information Primary inhibitory neurotransmitter in CNS GABAa most prevalent Many medications associated with GABA Alcohol and GABAa receptors Alcohol affects GABA and GABAa: incoordination, sedation, anesthesia and withdrawal are symptoms Decreased sensitivity to GABAa inhibition Creates imbalance in absence of alcohol “can’t put on the brakes” May contribute to excitatory aspects of withdrawal Glutamate: “The accelerator” General information Major excitatory NMDA most sensitive to alcohol Activated NMDA receptor allows positive ion influx NMDA receptors adapt to chronic alcohol exposure Up-regulates the number of receptors During withdrawal—hallucinations, hyperactivity, seizures
Thein_Chap07.indd 94
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
95
Contributes to Tolerance Sensitization—increase in withdrawal symptoms after alcohol exposure and withdrawal Clinically → increased craving and risk of relapse NMDA receptors and alcohol withdrawal Excessive glutamate excitation “foot stuck on the accelerator” Increases risk of excitotoxic cell death (cognitive) 5-HT: modulates consummatory behavior DA: reward system (nucleus accumbens) Endo-cannabinoid: CB1 receptor (future antiobesity drugs may target this receptor) Endogenous opioid: hedonic tone (pain/temp) Endogenous opioids and their receptors Therapeutic targets B endorphins: mu receptor enkephalins: delta dymorphins: kappa Withdrawal treatment CIWA (Clinical Instrument Withdrawal Assessment) scale Autonomic hyperactivity Tremor Anxiety Hallucinations Agitation Nausea/vomiting Headache Seizure with an onset between 2 and 4 days Delirium tremens (onset typically 3–7 days following cessation) General guidelines Thiamine 100 mg iv with dextrose for 3 days and continue with 100 mg thiamine po daily Magnesium 240 mg (po) Benzodiazepine individually tailored usage while following CIWA Chlordiazepoxide recommended for its long-acting quality Caution necessary in the context of severe hepatic function Oxazepam often used in these situations Tapering of doses over time Phenobarbital or pentobarbital challenge Offer until no intoxication within a 12–16 hour time period Dose up to 60–100 mg (for pentobarbital 200 mg) If patient becomes severely intoxicated or is asleep, no treatment is required after that dose challenge If moderate symptoms (dysarthria, nystagmus, ataxia, not sedated), offer another 200–300 mg of phenobarbital or 60–90 mg of pentobarbital If no symptoms, offer 600–1,000 mg of phenobarbital or 180–300 mg of pentobarbital Then, reduce dose by 10% daily or every other day Pharmacological approaches following the treatment of withdrawal Overall goal for medication targets Reduce intensity of binges Assist in abstinence Decrease urge to drink Normalize dysregulated brain systems Reduce symptoms associated with relapse (negative effect, insomnia) Persistence and patience are required as it typically takes time (Individuals average seven attempts before “quitting” tobacco)
Thein_Chap07.indd 95
11/3/2010 3:20:47 PM
96
Psychiatry Bullets FDA-approved medications Naltrexone (Revia) Campral (Acamprosate) Naltrexone IM Disulfiram Combinations Specific agents Disulfiram (Antabuse) Mechanism of action: alcohol dehydrogenase inhibition—Alcohol → acetaldehyde (toxic) → acetate Adherence and abstinence Adherence leads to abstinence Safety and tolerability Side effects (“desired effects”) usually within 15 minutes Facial flushing Palpitations Increased heart rate and blood pressure Nausea and vomiting Hepatotoxicity Contraindications for use Ischemic heart disease Pregnancy Drug interactions Anticoagulants Phenytoin Isoniazid Food/over-the-counter agents Summary Appears to decrease drinking days in alcohol Minimal evidence that it increases abstinence Limited data on implants Adherence is critical Naltrexone (Revia) Pharmacology Endogenous opioid system—pure opioid antagonist with rapid onset of action (within 2 hours of ingestion), but leaves quickly too; inhibits opioid effects at the mu receptor Antagonist—reduces rewarding effects of drinking “any organism that has a mu receptor will drink less—you do not have to have alcohol dependence” No tolerance or abuse potential Reversibly blocks the subjective effects of iv opioids Will precipitate withdrawal symptoms in opioid addicts Blocks self-administration of alcohol in animal models Blunts rewarding effects of alcohol in humans Clinical trials—allowed up to 200 mg/day (start low, go slow, but go) 50 mg/day—rate of total abstinence 50 mg/day—relapse to heavy drinking: significantly Side effects (nausea and headaches are brief and transitory) Nausea most common reason for discontinuation Headaches Dose-dependent hepatotoxicity Check LFTs initially and then at follow-up Black box warning (usually problematic at higher doses of 300 mg/day)
Thein_Chap07.indd 96
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
97
Induction of opiate withdrawal Increased depression in depressed patients Interactions with NSAIDS Adherence (monitor GGT, which is sensitive to changes in drinking) Encourage adherence to promote effectiveness Side effects Nausea Headaches Dizziness Fatigue Insomnia Anxiety/nervousness Sleepiness Contraindications Current opioid use Pregnancy/breast-feeding Conditions requiring analgesic effects of opioids Summary Reduced heavy drinking for active drinkers Also good for abstinent patients Side effects (nausea, fever, decreased appetite, injection site pain) Liver transaminase elevation not usually problematic Naltrexone IM (Vivitro) Efficacy and tolerability Abstinence through 3 months Pharmacokinetics Sustained over 1 month im 380 mg versus po 1,400 mg Reduced fluctuations in plasma concentrations Reduces heavy drinking at 380 mg (>190 mg) Side effects Nausea: 33% (the GI tract is lined with opiate receptors) Fatigue: 20% Decreased appetite: 13% Dizziness: 13% Injection site pain: 12% Discontinuation due to side effects: 14% (identical to po form) Pearls Helpful for heavy users Helpful for treatment resistant illness Long-acting formulations (encourages adherence) can be helpful Good safety profile Good for short-term benefits (especially if patients are adherent) Acamprosate (Campral): 2 g/day Pharmacology General information Not active at GABAa Weak inhibitor of GABAb in nucleus accumbens Generally inhibits glutamatergic system in mammals Inhibits glutamate transmission presynaptically Negative reinforcing effects of alcohol, conditioned “pseudowithdrawal” may be cue-induced Glutamate (NMDA) receptor modulator Taurine analog—normalizes alcohol-induced hyperexcitability
Thein_Chap07.indd 97
11/3/2010 3:20:47 PM
98
Psychiatry Bullets Normalizes glutamate neurotransmission related to alcoholism (the patient should have alcohol dependence since you need this abnormal neuroadaptive response present for this medication to work) Not metabolized by the liver Absorbed drug is excreted unchanged by kidneys If renal insufficiency exists, halve the dose Hepatic impairment does not affect the medication No known drug interaction Steady state in 5 days—unlike naltrexone Clinical trials findings Total abstinence—even a year after treatment Days to first drink: length of abstinence 5 months Reduction of drinking: fewer drinks/week for a year Reverses problems with sleep architecture Side effects Asthenia/depression Nausea Pruritus Flatulence Diarrhea (most problematic) but not significant Bloating Rash Contraindications Severe renal impairment History of hypersensitivity to acamprosate Benefits Long-term abstinence Excellent safety profile No serious side effects Encourage adherence even after relapse as improvement will occur anyway Risks No observed health risks in >1.5 million patients since 1989 Motivate patients to have abstinence as a goal Acamprosate + Naltrexone combination Rationale Safe and effective Different mechanisms of action Different effects on drinking Naltrexone—reduces heavy drinking Acamprosate—helps with abstinence Studies Pharmacokinetics and pharmacodynamic drug interactions studies Naltrexone increases the bioavailability of Acamprosate But, the combination did not affect Naltrexone Rate of relapse to heavy drinking was best addressed with combination Project COMBINE results Design: Naltrexone at 100 mg/day Acamprosate at 3,000 g/day Combined Naltrexone + Acamprosate Neither Half received psychotherapy One cohort received psychotherapy alone Conclusions % days abstinent
Thein_Chap07.indd 98
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
99
All arms did well 75% at 4 months Worst outcome—CBT only arm Best outcome—combination arm % relapse to heavy drinking All did well BEST combo The rate of nausea, vomiting, diarrhea all high even placebo group (“recovery hurts”) Side effects Nausea/vomiting Diarrhea Decreased appetite Somnolence AST/ALT five times upper limit Discontinuation due to side effects Treatment algorithm Monotherapy with Acamprosate or Naltrexone after 3 months approx Alternative monotherapy (allow 2 days abstinence for Acamprosate) after 3 months Combination of Acamprosate and Naltrexone Disulfiram monotherapy Disulfiram + Acamprosate (Never disulfiram combined with naltrexone as they both have black box warnings for hepatotoxicity) Serotonergic agents Alcohol dependence Animals: it does reduce use in animal studies Humans: no difference, overall Type A later onset fair better with SSRI (sertraline study) Type B <18 month, family history, father with antisocial personality disorder, individual psychiatric history (SSRIs not as helpful) Abstinence Ondansetron (5-HT3 antagonist) Study: failure but Type B individuals performed better Conclusions 5-HT dysregulation in alcohol is complex, affective disorder comorbidity may benefit 5-HT3 for Type B Anticonvulsants Topiramate Fewer heavy drinking days Greater likelihood of days abstinent Dopaminergic Haloperidol reduces euphorigenic effects and craving But, outcomes are inconsistent and individuals develop dysphoria Other neurotransmitter sites (not approved by the FDA) Other agents Selective 5-HT3 antagonist (ondansetron) Anticonvulsants CB1 antagonists Baclofen (GABAb agonist) Nonpharmacological approaches Treatment strategies for experimental or social use Education Counseling Treatment strategies for substance misuse Individual and group
Thein_Chap07.indd 99
11/3/2010 3:20:47 PM
100
Psychiatry Bullets Family: parent management training and contingency contracting Abstinence contract Motivational learning Treatment strategies for substance abuse and dependence Family: coherent with clear rules but not hierarchal Multisystemic Alcoholics Anonymous 12-step approach Therapeutic communities: move through stages of individual/community development CBT Motivational Prochaska motivational interview Use through Abstinence Maintenance Prevention of relapse Community-reinforcement approach Level of care Alcoholics anonymous Consideration of special groups Psychiatric comorbidity Adolescents Geriatric Gender Ethnic Counseling Day-to-day life Lifestyle without alcohol Identify risk factors to prevent relapse Web sites www.alcoholfree.info: Patient education and self-help www.asam.org: Patient assessment and levels of care criteria www.niaaa.nih.gov: Provider guide to treatment (including CBT guide) www.alcoholics-anonymous.org: AA guide to medications www.aaap.org: Specialists’ reference
CAFFEINE Caffeine use disorders Caffeine intoxication Caffeine-induced anxiety disorder Caffeine-induced sleep disorder (No disorder named for caffeine withdrawal) Introduction Most widely used psychoactive substance in the world >80% of adults and kids consume regularly Methyxanthines Caffeine Theobromine (chocolate) Theophylline (treatment for asthma) Caffeine intoxication (also caffeine tolerance) Definition Set of symptoms developing during or shortly after caffeine use ACUTE versus CHRONIC Symptoms
Thein_Chap07.indd 100
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
101
Nervousness Restlessness Insomnia Periods of inexhaustibility Diuresis Excitement GI disturbance Muscle twitching Psychomotor agitation Flushed face Tachycardia or cardiac arrhythmia Rambling flow of thought and speech Acquired tolerance Inadvertent overdosing—IV theophylline, NODOZ, caffeinated water Pathophysiology Adenosine receptor antagonist Effects of adenosine antagonism Increased synaptic activity in the brain Neurotransmitter release Vasoconstriction Tachycardia Bronchodilation Assessment Caffeine intoxication Caffeine-induced anxiety disorder Caffeine-induced sleep disorder Flow diagram for diagnostics Heavy use of caffeine or acutely greater than normal use No—no disorder Yes Symptoms for caffeine-induced disorder Anxiety Panic disorder Obsessive-compulsive symptoms Sleep disorder → caffeine-induced sleep disorder Differential diagnosis better understood Epidemiology—not well-known, caffeine intoxication in 7% of the population Course short t½ of 3–6 hours Treatment Careful history of beverages and medications Rule out chronic use of high doses of caffeine Caffeine withdrawal (not a disorder in the DSM-IV TR) Definition Headache—most common symptom Fatigue, lethargy, sluggishness Sleepiness, drowsiness Dysphoric mood Difficulty concentrating Work difficulty, unmotivated Depression Anxiety Irritability Nausea Vomiting Muscle aches or stiffness
Thein_Chap07.indd 101
11/3/2010 3:20:47 PM
102
Psychiatry Bullets Assessment Awareness and incorporation into psychiatric review of systems Presurgical or “non per oral” states Inpatient psychiatric hospitalizations Differential diagnosis Viral illness Sinus conditions Headaches (migraine, tension, postanasthesia) Other drug withdrawal (stimulants or cocaine) Idiopathic drug reactions Course 12–24 hours after discontinuation; especially peaks 24–48 hours, can last 2 days to 1 week Treatment—taper Caffeine dependence not a disorder in the DSM-IV TR Definition See DSM-IV-TR for substance dependence Strain et al. 1994 found caffeine dependence associated with psychiatric and physical symptoms Etiology Caffeine’s subjective effects Low doses (20–200 mg) well-being, alert, energy, concentration, and motivation High doses (800 mg) anxiety, nervousness Caffeine reinforcement due to the positive effects noted above Genetics and caffeine use Monozygotic and dizygotic rates of heavy use found with Caffeine tolerance Caffeine withdrawal Caffeine use and alcoholism possibly linked (alcohol use and nicotine use are often coexistent) Caffeine use and nicotine/cigarette Greater caffeine use among tobacco users Caffeine in psychiatric patients Schizophrenia Substance use disorder Anorexia nervosa Assessment Incorporate in psychiatric review of systems Differential diagnosis Caffeine intoxication Caffeine withdrawal Caffeine dependence Epidemiology US average daily consumption is 280 mg Course—no studies Treatment 75% of primary care providers recommend to their patients to stop/taper usage Caffeine-induced anxiety disorder is a DSM-IV TR condition Etiology and pathophysiology—Individuals with anxiety disorders should avoid caffeine Assessment and differential diagnoses Associated with caffeine Presence of caffeine tolerance, withdrawal, and dependence But the anxiety should be excessive compared to caffeine intolerance or withdrawal Epidemiology and comorbidity—no studies Course—nothing is known Treatment—benzodiazepines during taper
Thein_Chap07.indd 102
11/3/2010 3:20:47 PM
Chapter 7 Substance Use Disorders
103
Caffeine-induced sleep disorder Definition In the context of caffeine withdrawal or intoxication Sleep disorders Insomnia Hypersomnia Parasomnia Mixed Etiology and pathophysiology Based upon time of caffeine, person’s caffeine tolerance, other substance use Delays sleep onset, REM, total sleep time Alters normal stages of sleep Decreases quality of sleep Assessment and differential diagnoses Amount used less than 100 mg/day: no disorder greater than 100 mg/day and: (consider caffeine use disorder) Individual wants to quit Difficulties related to caffeine usage Withdrawal symptoms Tolerance symptoms Compulsive usage Greater than 100 mg/day, after 24 hours and: (consider caffeine withdrawal) Headache Drowsiness Dysphoria Nausea and/or vomiting Problems related to caffeine Sleep disorders may be exacerbated by caffeine Epidemiology, comorbidity, course and treatment no data ICD-10 places caffeine disorders and amphetamines under “other stimulants” Flow diagram during review of systems
CANNABIS Cannabis related disorders Cannabis abuse Cannabis dependence Cannabis intoxication Cannabis-induced psychosis Cannabis-induced anxiety disorder Cannabis related disorder NOS Most common illicit substance Adolescent use lower than compared to 2001 (adolescent opioid use has increased since 2001) Use patterns Male, white > 26 years Female = male 12–17 years Botany and pharmacology Cannabis: female sativa plant has high Delta-9-THC the primary psychoactive ingredient Marijuana is created from this plant’s dried leaves Hashish is more potent (prepared by extracting and drying the resin with or without flowers)
Thein_Chap07.indd 103
11/3/2010 3:20:48 PM
104
Psychiatry Bullets
Hashish oil is distilled hashish and is more potent than its nondistilled form Potency has increased over the last 30 years Effects can last minutes to hours after smoking (and faster), 8–24 hours if eating Highly lipophilic: crosses placenta and breast milk Liver hydroxylation into 20 metabolites Excreted in urine Resorbed in Bile, urine, sweat, hair, fat (released slowly here) G-protein coupled cannabinoid receptors CB1 (brain) and CB2 (immune) Found in Basal ganglia, hippocampus, cerebellum, not cortex Inhibits adenyl cyclase, decreasing cAMP, inhibits calcium and potassium transport Mediates the excitatory effects of mitogen-activated protein kinase Modulatory role in Mood Motor control, perception (including pain), appetite, sleep, memory, cognition, reproductive, immune Can potentiate alcohol, barbiturates, caffeine, amphetamines Etiology and pathophysiology Cannabis use disorder Frequent use is an important predictor of developing the disorder Mesolimbic dopaminergic pathway (VTA → NA) Naloxone—an opioid antagonist at the µ1 receptor in VTA blocks this increase in DA Regular use (short as 1–3 weeks) can produce tolerance Discontinuation of cannabis increases CRF in amygdala and decreases DA in limbic structures Withdrawal symptoms Irritability, anxiety, physical tension, decreases mood/appetite, restlessness, tremor, sweating, insomnia, increased aggression, vivid dreams (milder but longer than opioid withdrawal) Starts days after discontinuation, peaks at 3rd day, complete after 1 week (does vary with individuals) Cannabis-induced disorders Euphoria due to mesolimbic dopaminergic reward pathway Physiological signs and symptoms Noradrenergic, cholinergic, serotonergic, opioid Anxiety and psychosis may occur in those who have a predisposition Assessment and differential diagnosis Cannabis-related disorder A positive toxicology screen merely suggests that the following could be possible Cannabis dependence (Usually comorbid with other Axis I or legal issues, ask about family history, performance at work/health/home, attempt to stop, tolerance) With physiological dependence Without physiological dependence Early full remission Early partial remission Sustained full remission Sustained total remission In a controlled environment Cannabis abuse—large continuum Cannabis intoxication ± perceptual disturbances
Thein_Chap07.indd 104
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
105
Establish recent cannabis use (positive toxicology screen not really always helpful) Production of clinically significant maladaptive behavior or psychiatric changes Some physical signs of cannabis abuse Tachycardia, high blood pressure, thirst, increased appetite, constipation, decreased intraocular pressure, mydriasis, mild bronchoconstriction followed by brochodilation, increased reaction time, impaired coordination, distorted time and perception, decreased libido, mild analgesia, mild antiemetic effects Ataxia, ptosis, miosis, drowsiness, bradycardia, low blood pressure, hypothermia, peripheral vasoconstriction Some psychological signs Common and quick Euphoria, distortions (also with time), enhanced sensations Uncommon and quick Dysphoria, anxiety, panic disorders, restlessness, depression, derealization, paranoia Some neuropsychiatric deficits Short term memory difficulties, sustained/divided attention, complex decision-making Symptoms are not due to any other mental disorder Cannabis-induced delirium should resolve in 1–2 days Cannabis-induced psychotic disorder With delusions with onset during intoxications With hallucinations with onset during intoxications (consider underlying Axis I condition) Cannabis-induced anxiety disorder With onset during intoxication With generalized anxiety With panic attacks With obsessive compulsive symptoms With phobic symptoms Epidemiology and comorbidity Cannabis use disorder Adolescents’ (as cannabis is one of the gateway agents) usage typically ceases by 30 years of age (90%) Look for polysubstance use Look for Axis I—bipolar, anxiety, antisocial personality traits Cannabis-induced delirium—see above; REASSURANCE is the best as it is self-limiting Course Cannabis use disorder Self-limiting “Amotivational syndrome” (controversial) Lack of direction, motivation, ambition Cannabis-induced delirium—self-limiting—see above Treatment Cannabis use disorder Standard approaches to treatment Longest retention in a facility—best prognosis Prochaska’s motivational interviewing Abstinence is the goal Treat other addictions as well (hospitalize, if necessary) Special features influencing treatment Replace cannabis with better coping skills
Thein_Chap07.indd 105
11/3/2010 3:20:48 PM
106
Psychiatry Bullets Treat Axis I conditions Refractory patients and nonresponse to initial treatment Anticipate relapse—get friends/families/work involved Treat underlying conditions Cannabis-induced delirium No particular treatment other than the condition itself ICD-10: SAME
COCAINE Pathophysiology: Blocks dopamine reuptake Cocaine use disorders Cocaine dependence Cocaine is psychologically addictive Maybe not physiologically addictive Cocaine abuse Maladaptive pattern of substance use Recurrent and significant adverse consequences related to repeated use Cocaine initiation may herald psychosocial difficulties Cocaine intoxication Intense euphoria Powerful reinforcer Anxiogenic Route (iv/smoked) leads to greater tolerance (not necessarily euphoria) Cocaine-induced delirium Cocaine-induced psychosis Cocaine-induced mood Cocaine-induced sexual disorder Cocaine-induced sleep disorder Forms: Erythrooxylon coca Cocaine HCl—powder (in), mixed with water (iv) Freebasing—cocaine HCl heated in ammonia/baking soda plus water—smoked Crack—precooked form of cocaine alkaloid Cocaine intoxication Cocaine abuse Cocaine dependence—pervasive pattern of frequent use and psychosocial effects/ medical Binge use can lead to a mild withdrawal syndrome char by depression (dysphoria and anhedonia) Epidemiology MTF study—overall use is a downward trend Rising use in crack-cocaine and “Crystal Meth” (“Ice”) specifically in the west coast “Pharm parties” use of prescription drugs intranasally and po increasing But 0.5% of the population over the age of 12 are using it Gender differences Males were studied more Females closing the gap Pregnancy Vascular injury to CNS Placental abruption Preterm labor Low birth weight Abuse and neglect But children exposed to cocaine in utero do not have permanent sequelae
Thein_Chap07.indd 106
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
107
Psychiatric disorders Comorbidity with mood, schizophrenia, PTSD, ADHD Mood → cocaine use Cocaine use → ADHD Treat both conditions simultaneously Course and natural history Energy, self-esteem, decreased anxiety and social inhibition, emot enhancement, pleasurable experiences are heightened but not distorted (hallus are absent) Euphoria Highly reinforcing Cocaine complications Cocaine intoxication Paranoia Grandiose delusions Hallucinations (auditory, visual, tactile) Pressured speech Cocaine withdrawal >2 weeks dysphoria; ≥2: Fever Nightmares Sleep change (typically increased) Increased appetite Psychomotor change Suicidality Medical complications of cocaine abuse Nasal/mucosal problems; infectious embolisms; acute dystonias, tics; migraine-like headaches; cardiovascular strokes Cardiac arrhythmias; death (seizure, respiratory depression, cardiovascular disease, myocardial infarction) Treatment Psychotherapy Address craving and behaviors attached to craving Consider patient provider relationship Pharmacotherapy No specific agent effective for chronic use Treat/address ADHD symptoms Treat psychotic symptoms with antipsychotics
STIMULANTS Amphetamine General: Cannabis 1st; Amphetamine 2nd (most widely used illicit drug) History Preparations: prescription source; over the counter (banned 2006); “street” source Amphetamine dependence Amphetamine-induced intoxication Heart rate changes Dilated pupils Blood pressures changes Chills Perspiration Nausea/vomiting Decreased weight Weakness Chest pain
Thein_Chap07.indd 107
11/3/2010 3:20:48 PM
108
Psychiatry Bullets
Arrhythmia Confusion Seizures Coma Dyskinesias Amphetamine withdrawal Change in affect in the evening Increased appetite Sleep changes Nightmares Fatigue Amphetamine-induced intoxication Amphetamine-induced psychosis Amphetamine-induced mood disorder Amphetamine-induced anxiety Amphetamine-induced sexual disorder Amphetamine-induced sleep disorder Acidic urine decreases the half-life, thus increasing elimination Metabolized by the liver and excreted in the urine Increased prescription drug misuse/abuse/diversion “Pharm parties”
ANABOLIC STEROIDS Anabolic steroid disorders: (DSM-IV TR other substance-induced) Anabolic steroid withdrawal Anabolic steroid-induced mood disorders Anabolic steroid-induced psychosis Anabolic steroid related disorder NOS Used in treatment Testosterone decrease Hypogonadal hereditary angioedema Anemia secondary to Fanconi’s (bone marrow anemia) Renal failure AIDS (wasting syndrome) Metastatic breast cancer Osteoporosis Endometriosis Premenstrual symptoms Side effects/toxicity Acne Hyperlipidemia Blood pressure Myocardial infarction/cardiomyopathy/strokes Hepatic: jaundice/increased liver transaminase Muscle hypertrophy Sterility Gynecomastia Testicular atrophy Hirsutism Mood lability/aggression (“Roid Rage”)/psychosis Withdrawal symptoms Fatigue Depression
Thein_Chap07.indd 108
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
109
Need for more steroids 1988: 6.6% lifetime use in hs seniors Typical cycle of use: 4–18 weeks on steroids 1 month–1 year off
HALLUCINOGENS Hallucinogen and MDMA-related disorders Introduction Hallucinogen intoxication Hallucinogen persisting perception disorder Hallucinogen-induced delirium (NO withdrawal delirium) Hallucinogen-induced psychosis Hallucinogen-induced mood disorder Hallucinogen anxiety disorder Hallucinogen dependence Hallucinogen abuse Epidemiology 10% high school seniors have used hallucinogens LSD is the most common (synthetic) Shrooms (psilocybin) peyote cacti Increase in accidental deaths from MDMA (Ecstasy, E, XTC) natural forms (psilocybin, DMT) Other hallucinogens LSD is most commonly used (but lower use compared to 20–30 years ago) Ketamine (K, Special K) is gaining greater use General findings No physiological dependence but incredible tolerance, no physical addiction No withdrawal or death from overdoses of LSD MDMA or E or XTC, natural psilocybin, DMT Neurotoxic and serotonergic or 5-HT ± ? Etiology and pathophysiology: somatic first → mood → psychological 0–30 minutes Dizzyness, nausea, weakness, anxiety 30–60 minutes Blurred vision, visual hallucinations, pseudohallucinations, after-imagery decreased concentration, dissociation, depression, out of body sensation, synesthesia 60–240 minutes Intensified after-imagery, false perceptions of movement, flood of emotions 4–12 hours Return to previous state but with arousal, headache, fatigue, sense of profundity Drug response variability Experience, environment, personality, previous psychiatric disorders, genetics No dependence, but rapid tolerance (4–7 days for LSD) LSD binds to 5-HT2 receptors LC Decreases spontaneous activity and activates NMDA receptors (enhances sensory responses) Cortex Induce glutamine and inhibits GABA SSRIs Blunt hallucinogenic effects via 5HT1 receptor agonists GABA An antianxiety agent (like benzodiazepines), stops the “high” (inhibits the LC)
Thein_Chap07.indd 109
11/3/2010 3:20:48 PM
110
Psychiatry Bullets Opiates Reduce glutamatergic action in the cortex, stops the “high” (thus, heroin addicts do not use LSD) Diagnosis for acute intoxication Have a high index of suspicion because gas chromatography is costly Autonomic arousal (hyperreflexia, tachycardia, dilated pupils) Hypersensitivity to visual and auditory stimuli Reduced motor functioning (individuals are not usually aggressive) LSD-related psychosis can be prolonged Differential diagnosis Other agents PCP, cocaine, amphetamines, anticholinergics, inhalants Schizoaffective/schizophrenia/pyschotic disorders Head injury Withdrawal states Sedative/hypnotic Anxiolytic Alcohol Hypoglycemia/hyperthermia/seizures/vascular events/CNS Treatment for acute intoxication Benzodiazepines (PCP acute symptoms are treated with antipsychotics) or “talk them down” PALM TEST—draw a line—what colors—if bright then LSD, if aggressive PCP Hallucinogen persisting perception disorder and hallucination intoxication Imperative to rule out other possible conditions Treatment Benzodiazepines Palliative (Olanzapine, Sertraline, Naltrexone, Clonidine) Not as desirable (risperidone, THC) Reduce the difference between internal and external environments with sunglasses (darkness is not desired)
MDMA Epidemiology Increasing use (increasing perceived harmlessness) 1990 “Raves”—much higher doses, other drugs (ETOH, THC, opiates) Most need 1 day to recover Pharmacology—toxic to serotonergic neurons (reduced 5HT, 5HIAA), damage but reversible Suspect if College student Tobacco use Binge alcohol use Acute positive psychological effects—“feels good” about others Physical consequences Nausea, vomiting, anorexia, high blood pressure, palpitations, diaphoresis, headaches, ataxia, muscle aches, hot/cold flashes, urinary urgency, nystagmus, blurred vision, dry mouth, bruxism (5HT1B receptor agonist of trigeminal nerve), increased body temperature Clinical manifestation of long-term MDMA toxicity Depression OCD Anxiety No libido
Thein_Chap07.indd 110
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
111
MDMA somatic toxicity Strokes Myocardial infarctions Arrhythmias Death Due to electrolyte abnormalities (“Raves” are very warm and the individuals are diaphoretic) Treatment—SSRIs? ICD-10 almost the same
PCP Forms Phenycyclidine Animal tranquilizer Anesthetic hallucinogen Angel dust Ketamine/K/Special K Phencyclidine use disorders (aka angel dust ketamine) Phencyclidine abuse Dependence Induced anxiety disorder Induced mood disorder Psychotic disorder with delusions Psychotic disorder with hallucinations Intoxication Intoxication delirium Introduction Originally created as an anesthetic; but, psychosis lasted hours to days One hit can last several hours in an individual, and weeks in those with schizophrenia Symptoms CNS effects Sympathomimetic Neuromuscular effects Kidney effect Act on NMDA glutamate via receptor noncompetitive blockade (prevents calcium influx) Epidemiology Overall, declining use—highest amongst 18–20 year olds—2% of population Greater prevalence in males (two times) Greater prevalence in ethnic minorities Greater prevalence in age range of 20–40 years Death NOT secondary to overdose or drug interaction, but accidents/homicide Etiology and pathophysiology Withdrawal, negativism, catatonia, concrete/bizarre thought process Problems with symbolic thinking process and attention like issues found in individuals with schizophrenia (not the case for LSD or amphetamine intoxication) Phenomenology and variations in presentation Cardiovascular High blood pressure—most common finding—usually self limiting 4% developed severe symptoms) Tachycardia in 30%
Thein_Chap07.indd 111
11/3/2010 3:20:48 PM
112
Psychiatry Bullets Neurological Nystagmus, hyperreflexia, motor abnormalities/ataxia, nystagmus vertical or horizontal, seizures, coma, dysarthria, facial grimacing, generalized rigidity, localized dystonia, athetosis Cholinergic or anticholinergic signs Hypothermia or hyperthermia Myoglobinuria Psychological Can last 4–6 hours Hallucinations Delusions Paranoia Thought disorder Catatonia (with intact consciousness) Impulsive Violent (Ketamine intoxication is much shorter duration than PCP) Assessment Special issues in psychiatric exam and history—overly sensitized—minimize stimulation Physical exam and labs Vital signs (temperature, blood pressure, respiratory rate) q2–4h, consider its analgesic effects (minimizes presentation) Alkaline urine hides PCP Venlafaxine and its metabolite, DMX can cause false +tox Check urine for heme (myoglobinuria) Differential diagnoses Nystagmus and high blood pressure (and increased body temperature—think PCP) Rule out Schizophrenia spectrum disorder (especially if beyond 4–6 weeks) LSD (synesthesia) Others: (postictal state, primary metabolic issues) NMS Course and natural history Usually receding 5–21 days; possible to have flashbacks (stored in lipid cells) Physical signs and symptoms clear, then psychosis clears (1 day to 6 weeks) Overall goals of treatment Treat medical concerns Treat violent/impulsive behavior Avoid anticholinergic agents (chlorpromazine) if using antipsychotic agents Physician-patient relationship LSD—talk them down; REASSURANCE PCP—avoid talking them down; REDUCE STIMULI Pharmacotherapy and somatic treatments: none really—symptomatically ICD-10 – PCP included in the hallucinogen class
OTHER HALLUCINOGENS Other agents: MDMA (see following pages) Khat Club drugs (LSD, GHB, MDMA) GHB Nitrite inhalants: poppers/sex Nitrous oxide: laughing gas
Thein_Chap07.indd 112
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
113
Nutmeg: LSD Catnip: LSD Betel nuts: mild euphoria Kava: sedation incoordination hepatitis lung issues decreased weight Ephedra: arrhythmias Chocolate: Anandomide (THC receptors)—5-HT phenylalanine Ecstasy, XTC, X, E 3,4-methylenedioxy-n-methylamphetamine Effects in 30–60 minutes lasts 3–6 hours: euphoria, comfort, empathy, sense of connection, high heart rate and blood pressure, cognitive impairment GHB gamma-hydroxy butyrate Powder, clear liquid, tablet, capsule mixed with alcohol Alcohol like effects and growth hormone–like muscle-building Effects in 20 minutes lasts 3–4 hours Higher risk for seizures, unconsciousness, coma Websites www.theantidrug.com; www.dancesafe.org
INHALANTS Introduction Types Industrial/household Propellant gases (butane, fluorocarbons) Household aerosolized Medical gases (anesthesia) Aliphatic nitrites (whipped cream) Used as an inhalant for sexual enhancement Volatile hydrocarbons Toluene n-hexane methylbutyl ketone trichloro/ethylene, ethane, dichloromethane, gasoline, butane—not anesthesia or amyl nitrates Inhalant use disorders Dependence: Mostly psychological, some weak physiological General disorientation Sleep disturbances Headaches Muscle spasms Irritability Nausea Fleeting illusions Abuse: accidents Problems with family and school Inhalant intoxication (death) Disinhibition Slurred speech within 5 minutes and can last 30 years Excitedness Light-headedness Visual disturbances Incoordination Dysarthria Unsteady gait Euphoria Watch for decreased reflexes, stupor, coma, death—(due to arrhythmia) Mechanism of action
Thein_Chap07.indd 113
11/3/2010 3:20:48 PM
114
Psychiatry Bullets
CNS depressant GABA? Membrane fluidization (ETOH) Chronic use Peripheral neuropathy Headaches Parasthesias Tubular acidosis (kidney effects) Parkinson symptoms Decreased concentration/memory/IQ Irritant to liver; chest pain, bronchospasm (also seen in copper, zinc, and heavy metals) Epidemiology—worldwide, 8th graders Toxicology—death can happen quickly and on the first try (due to metabolic acidosis and renal failure) Treatment—most drugs are not helpful Different DSM-IV TR diagnoses Inhalant-inducedpsychotic disorder, with delusions Inhalant-inducedpsychotic disorder, with hallucinations Inhalant intoxication delirium Inhalant-inducedpersisting dementia Inhalant-induced psychosis Inhalant-induced mood Inhalant-induced anxiety Inhalant-induced intoxication Inhalant-related disorder NOS
NICOTINE Conditions Nicotine dependence Nicotine withdrawal Nicotine-related disorder NOS Introduction 20% of US population smoke tobacco Causes 440,000 deaths/year in the United States Six FDA-approved medications (Zyban and nicotine replacements: patch/gum/spray/ lozenge/inhaler) Behavioral psychotherapies Medications and behavioral intervention can assist 45% of attempters to quit Under 44% of smokers receive mental health care Definition of nicotine withdrawal Symptoms that develop after abrupt discontinuation/reduction of nicotine after at least several weeks of daily use Four or more Dysphoria or depression, insomnia, irritability-frustration-anger, anxiety, difficulty with concentration, restlessness, impatience, increased heart rate, decreased weight Other nicotine withdrawal symptoms Craving, craving for sweets, impaired vigilance tasks, degree is based upon severity of habit Typical profile Lower socioeconomic status Males (more successful at cessation) Increasing rate with adolescent girls (typically starts 14–18 years) More dependent personality traits Co-occurring psychiatric or substance use disorders
Thein_Chap07.indd 114
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
115
Receives mental health care (two to three times more than general population) Schizophrenia (70%–90%) Affective disorders (70%) Alcohol issues (60%–90%) Other substance (70%–95%) Cause of death usually smoking related injuries when polysubstance abuse is present Etiology and pathophysiology t½ 2 hours Early starters (90% by 18 years of age) Gateway drug—powerfully addictive (1/3–1/2 of all kids become habitual users) Multiple effects Mesolimbic DA pathway (reward/euphoria) Locus Coeruleus (mediator of stress reaction/vigilance and relation to higher mental/ cognitive functions) Specific nicitonic cholinergic receptors Hypothalamus, hippocampus, thalamus, midbrain, brainstem, cortex Endocrine-neuroendocrine system Catecholamine, serotonin, corticosteroid and pituitary hormones Release of ACh, NE, 5-HT, DA, vasopressing, growth hormone, corticotrophin, cortisol, prolactin endorphins Mediated by hypothalamic-pituitary axis Stimulant and depressive effects centrally and peripherally Cardiovascular, gastrointestinal, musculoskeletal Cholinergic (sympathetic/parasympathetic) and learning Improves mood and decreases anxiety Decreases distress in anxiety provoking situations Decreases aggression Improves cognitive functioning and performance Increases memory Helps disregard irrelevant stimuli Decreases appetite for carbohydrate Tolerance can take effect Withdrawal symptoms Anxiety, depression, bradycardia, decreased concentration, increased appetite and weight gain, insomnia, irritability/anger, restlessness Course and natural history 70% want to quit at sometime in lifetime 33% try to quit every year Median success rate for quitting 7% 3% quitting on own are successful 15%–45% 1 year abstinent rates High relapse rates (similar curve to opiates) Depression now and history is a predictor of relapse Individual factors Addiction Social and environmental circumstances Nicotine withdrawal Severe 1–3 days after Continuing 3–4 weeks maybe 6 months or more Nicotine dependence Chronic relapsing illness with intermittent episodes of remission (65%) Less than 25% quit with first attempt Average five to six attempts before success Predictor of success—previous success Relapse can occur after long cessation Evaluation and assessment
Thein_Chap07.indd 115
11/3/2010 3:20:48 PM
116
Psychiatry Bullets
Current and past tobacco use (consider multiple sources of nicotine) Current motivation to quit Objective measures Carbon monoxide levels of the breath Cotinine levels (saliva, blood, urine) Assess prior quit attempt (amount and what happened) Why quit? How long abstinent? Why relapsed? What treatment was used (how used? how long?)? Assess withdrawal symptoms and dependence criteria Psychiatric conditions and use of other substances/alcohol Medical conditions Seizures Eating disorders Pulmonary status Common triggers (car, people, mood, home, phone calls, meals, etc.) Perceived barriers and supports Preference for treatment strategy Overall approach to treatment Medications and therapy combined are best (consider health insurance limitations) Six FDA-approved medications Nicotine gum, inhaler, spray, patch Bupropion SR (Zyban) Clonidine Varenicline (Chantix) Good psychosocial treatment Phases of treatment Engagement American Cancer Society American Lung Association American Heart Association Local hospitals Quitting Quit date Preventing relapse Especially in the first few days (time of likely relapse) Nicotine replacement plus Zyban becoming more vogue Nicotine anonymous Self-help 50% are able to quit (>90% without professional help) COLD TURKEY is most common way—tapering leads to inconsistent loyalties Professional help may be inconvenient and time consuming Brief face-to-face with primary care provider can increase cessation by 2–10 fold especially if a serious medical condition exists Specific medications Nicotine replacement (prevents withdrawal, little abuse liability) Gum—first Releases nicotine and absorbed through buccal mucous membrane 2–4 mg doses and 9–16 pieces/day Better with conjunction with behavioral therapy Definitive schedule better than PRN dosing Tapering after 4–6 months of use Not great for individuals with TMJ, dental problems, dentures Highly motivated individual and understands complex instructions Crunched a few times and then park it in gum/cheek Not intended to be used like chewing gum
Thein_Chap07.indd 116
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
117
Avoid acidic (coffee, soda, orange juice) as it interferes with absorption/ release Patch Sustained release through the skin Higher doses related to higher cessation rates Eliminates conditioning of repeated nicotine use Easier to be adherent 7 mg and 14 mg and 21 mg dose forms Delivery 0.9 mg/hour of nicotine (steady state 13–25 ng/mL) Usually 6–12 weeks or longer No titration dose Safe to use with poor dentition Well tolerated (skin irritation, erythema, serious) Combination with gum replacement form Nasal spray 0.5 mg to ear nostril 1–3×/hour for 15–20 sprays day (8–10 mg) Higher blood level than gum per patch Nicotine inhaler 8–10 ng/mL Allows mimicking of upper airway stimulation when smoking Absorbed via oropharyngeal mucosa Effective Side effects Local irritation Cough Headache Nausea Dyspepsia Multiple dosing Not discreet Zyban—DA/NE reuptake inhibitor Varenicline (Chantix) Psychosocial treatment underused, understudied, effective Motivational enhanced therapy (MET) CBT 12 step Medication and psychosocial treatments Nicotine replacement doubles quit rate (versus placebo) Face-to-face behavioral treatment doubles quit rate (versus minimal psychosocial intervention) Also increases adherence by 50% Triples outcome rate ICD-10 for nicotine dependence includes craving, malaise, increased cough, mouth ulceration NOT decreased heart rate
OPIATES Opioid use disorders Opiate dependence Opiate abuse Opiate intoxication Opiate withdrawal sleep disorder Opiate sexual disorder Opiate delirium Opiate psychosis
Thein_Chap07.indd 117
11/3/2010 3:20:48 PM
118
Psychiatry Bullets
Opiate mood disorder Opiate anxiety disorder Introduction Receptors Gamma: analgesia Mu Morphine is the prototypical agonist Effects—analgesia and euphoria, respiratory depression, constipation Kappa: analgesia, sedation, diuresis Agents Natural—morphine Semisynthetic—heroin (more potent and lipid-soluble than morphine) Synthetic—meperidine, codeine, hydromorphone, methadone, oxycodone, fentanyl Buprenorphine—a partial agonist MPTP-induced Parkinson’s MPTP + opioid → irreversible Parkinson’s MPTP → (MO) → MPP+ → SN(DA neurons) kills cells Use Analgesia Anesthesia Antidiarrheal Cough suppressants Epidemiology of opioid abuse and dependence Heroin most commonly abused drug of this class 1.3% of US population has used it once 12%–15% of adolescents use it for nonmedical uses Increasingly pure and available Increase in prescription abuse Number of methadone related deaths due to overdose is increasing Often unintentional Often in context of drug-drug interactions Oxycontin can contain as much as 80 mg/tablet Chewing/biting on oxycontin eliminates the slow release effects Etiology and pathophysiology of opioid-related disorders Risk factors Social/peer group Availability History of childhood conduct disorder or adult Asperger’s disorder Family of origin psychopathology (alcoholism and antisocial personality disorder) Heroin—IV/in; tar heroin-smoked; morphine, meperidine(Demerol) IV; fentanyl IV; codeine/perc po Clinical picture of opioid-related disorders Intoxication (minutes to a few hours) Initial euphoria Then dysphoria Evening psychomotor retardation or agitation Impaired judgment/impaired social or occupational function Papillary constriction Anoxia and pupils are dilated in severe overdose coma/obtunded Respiratory depression Slurred speech Inattention Dry secretions (mouth and nose) Slow gastrointestinal activity or constipation Withdrawal
Thein_Chap07.indd 118
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
119
Anxiety Restlessness Ache Craving Irritability Increased sensitivity to pain Triad Dysphoria/depression Nausea/vomiting/diarrhea Muscle aches/lacrimation/rhinorrhia Also Diaphoresis Yawning Fever Insomnia Pupillary dilatation Piloerection NB: Fever and piloerection are signs of severe drug use Timing Heroin: occur 6–24 hour; peak 1–3 days; subsides 5–7 days LAAM/methadone: 2–4 days (anxiety, dysphoria, anhedonia, insomnia, craving) Subsides weeks to months Increases QTc duration: thus, caution should be taken when used in treatment Dependence Inappropriate use Exceeds use Tolerance Abuse Less use than dependence No signs of tolerance or wd Assessment and clinical picture Physical exam Tracks, skin popping (individual injects in subcutaneous tissue) Cellulitis tetanus Bacterial endocarditis Hepatitis B/C, HIV Irritation of nasal mucosa Difficulties in sexual functioning Premature ejaculation (opiate withdrawal) Impotence (opiate intoxication/use) Reproductive difficulties and irregular menses Laboratory values Detection Most forms in 12–36 hours LAAM methadone days Fentanyl not in standard urine test (needs specialized procedures) Oxycodone, hydrocodone, hydromorphone on gas chromatography Toxicology screen may be positive for other conditions Hepatitis B/C Liver transaminases Low platelets, anemia, neutropenia HIV Differential diagnoses Opiates withdrawal
Thein_Chap07.indd 119
11/3/2010 3:20:48 PM
120
Psychiatry Bullets
Pupillary constriction (not dilation like with alcohol, hypnotics, or sedatives) Watch with naloxone treatment Psychiatric signs and symptoms—depression and anxiety Course and natural history of opioid dependence Long history of abuse/dependence, etc. “Burn out” in 40s and older Treatment Opioid agonists Methadone mu receptor agonist and NMDA glutamate receptor agonist Suppresses opioid withdrawal for 24–36 hours after a single dose Higher doses recommended for treatment (80–120 mg/day) Best results if combined with psychosocial therapy LAAM Approved by the FDA in 1993 Longer acting than methadone 48–72 hours after a single dose Partial agonists Buprenorphine FDA-approved buprenorphine forms Buprenex—buprenorphine only FDA-approved since 1981 as an analgesic But illegal to use for opioid detoxification or maintenance treatment in United States 0.3 mg im/iv q4–6h Subutex—buprenorphine po (SL) only FDA-approved for opioid dependence (2 or 8 mg only) Not FDA-approved for pain Target dose is 8–16 mg/day (receptor saturation at 16 mg/d) Suboxone = buprenorphine + naloxone (2 mg/0.5 mg or 8 mg/2 mg) FDA-approved for opioid dependence Not FDA-approved for pain Target dose is 4–16 mg/day (available in 2 mg/0.5 mg or 8 mg/2 mg) Opioid partial agonist made inactive—if not parenteral Likelihood of death due to overdose significantly decreased Overdose (all forms SL SC IM IV) Risk minimal Low risk High doses do not cause respiratory depression But beware when ingested in large amounts with other CNS depressants Death from respiratory depression (France) (crushed with IV high potency benzodiazepines) Warning should be given if combined use (but no absolute contraindication from any/all benzodiazepines) Antagonists Naloxone Opioid antagonist Short acting High mu affinity Reverses opioids (especially respiratory depression) and can precipitate withdrawal No intrinsic agonist activity Opioid antagonist short acting with high mu affinity Naltrexone: Partial opioid antagonist Nonopioid alternatives Alpha 2 adrenergics
Thein_Chap07.indd 120
11/3/2010 3:20:48 PM
Chapter 7 Substance Use Disorders
121
clonidine Suppresses autonomic signs/symptoms of withdrawal Side effects Sedation Hypotension Lofexidine (originally antihypertensive) Less sedation and hypotensive Peaks and flattens earlier than methadone Guanfacine—more studies needed Benzodiazepines NSAIDS Psychosocial/behavioral therapies Helping with life issues Helps with cessation of all addictions 1993 study demonstrated that enhanced behavioral therapy Self-help groups Contingency management Adherence to appointments appear to be most difficult Individual drug counseling Therapeutic communities Residential settings 6–18 months Rare use of agonists/antagonists Psychotropic use Addressing comorbidity Psychiatric Depression Mood Insomnia Sexual functions Not often bipolar or schizophrenia PTSD Medical HIV HepB C Methadone increase plasma levels of zidovudine (looking like methadone withdrawal) Nevirapine lowers methadone levels Death due to overdose/accidents/injuries/medical complications Fetus Prematurity Low birth weight Found in breast milk (but 180 mg no adverse effects) HIV in 1/3 of infants (but 1/10 if moms are given zidovudine) HIV in breast milk, too Integrated treatment: helpful Harm reduction Needle exchange Education of hygienic measures ICD-10—craving, gastrointestinal cramps, tachycardia (not fever or dysphoria like in DSMIV-TR)
SEDATIVES, HYPNOTICS, AND ANXIOLYTICS Introduction Etiology GABA receptors
Thein_Chap07.indd 121
11/3/2010 3:20:49 PM
122
Psychiatry Bullets GABA a receptor on the GABA cell Over time the GABA a receptor may uncouple (thus less effective) Epidemiology—essentially not known Patterns of abuse (high, intensify other drugs, self-medicating the withdrawal of others substances, reduce side effects of other drugs) Barbiturates IV (infectious sites) irritating to tissue vasoconstriction (gangrene) Methaqualone Quaaludes removed from US market in 1984 Benzodiazepines (BNZP) Flunitrazepam (Rohypnal, Narcozep) “date rape drug” from mid-1990s Combined with other BNZP → synergistic respiratory depression GHB—has sedative/hypnotic properties Zolpidem (Ambien) Rapidly absorbed Short t½ (2.2 hours) Binds to subunit of GABA-bnzp complex Zaleplon (Sonata) Binds to subunit of GABA-bnzp complex on the omega 1 receptor Short t½ (1 hour) Acute intoxication with sedative hypnotics Slurred speech Incoordination Ataxia Sustained nystagmus Impaired judgment Mood lability Progressive respiratory depression/coma (quicker for barbiturates and other SH) Dependence Withdrawal typically within 1 day for short acting and 1 week for long acting Anxiety Tremors Nightmares Insomnia Anorexia Nausea and vomiting Postural hypotension Seizures Delirium—usually following insomnia Hyperpyrexia Death Iatrogenic dependence Assessment Drug use history Consider possibility in polysubstance abusers In the context of the conditions needed for treatment Ask family/friends Street sources are not “controlled” Physical exam Intoxication: sustained horizontal nystagmus (reliable) Withdrawal: abnormal diaphoresis, increase in pulse and blood pressure Labs Valium (Diazepam) and Librium (Chlordiazepoxide) weeks Xanax (Alprazolam) and Clonazepam may not show up on urine toxicology screens
Thein_Chap07.indd 122
11/3/2010 3:20:49 PM
Chapter 7 Substance Use Disorders
123
Treatment Detoxification Decreasing doses of the agent of dependence Substitute phenobarbital (or other long-acting barbiturate) Good for individuals with polydrug dependence Phenobarbital Safer than short-acting barbs Lethal doses much higher than toxic doses Toxicity—sustained nystagmus, ataxia, slurred speech Maximum daily dose is 500 mg/day Calculate daily equivalent dose Watch for toxicity especially sustained nystagmus If 1 symptom holds one dose, if all three hold two doses for 2 days If intoxication occurs 1–2 hours after im dose—intoxication is not severe Decrease phenobarbital 30 mg/day unless withdrawal is noted (increase by 50%) Replace with long-acting benzodiazepine Stabilization phase—see above Withdrawal phase—see above Psychotherapy Watch for physical symptoms, emergence of psychiatric symptoms, family/ occupational functioning Not insight oriented but supportive 12-step recovery Additional Treat psychiatric morobidity Abuse potential of benzidiazpines → not really, think more for self-medicating withdrawal from opiates Treatment of high-dose benzdiazepine dependence→ use Phenobarbital equivalents Low-dose benzodiazepine withdrawal syndromes Discontinuation (increasingly symptomatic usually at 10%–20% of peak dose) Symptom rebound (especially insomnia) lasting a few days to a few weeks (transient) Symptom reemergence (recrudescence) anxiety returns to what it was and should be treated Severe protracted withdrawal Risk factors Family history of alcohol or other sedative use Alprazolam use Treat (e.g. 20 mg valium (diazepam) needs 200 mg phenobarbital) Give clonidine or beta-blockers to address side effects ICD-10—Sedative/hypnotics intoxication includes erythematous skin lesions or blisters Sedative/hypnotic withdrawal has craving, postural hypotension, headaches, malaise/ weakness, paranoia (not on DSM-IV TR)
Thein_Chap07.indd 123
11/3/2010 3:20:49 PM
Thein_Chap07.indd 124
11/3/2010 3:20:49 PM
Chapter
8
Personality Disorders
ASSESSMENT Multiple resources Interviewing of the individual over time Multiple historians other than the individual Medical records Other providers Family members Friends/associates Psychological testing “Rule-out” Axis I, III, and IV Assess for other psychiatric conditions Assess for medical conditions Assess for psychosocial stressors
DEFINITION TR: unusual situation <18, features >1 year maladaptive (Antisocial personality disorder: severe chronic CD and pattern of irresponsibility and as behavior <15 years) Rutter: institutionalized children have problems until late 20s
PERSONALITY DEVELOPMENT Family history OCD and compulsive traits Antisocial personality disorder ADHD and traits Character as a consistent pattern: Projection → paranoia Action/proneness → acting out Reaction formation → obsessive Repression → hysterical
LONGITITUDINAL STUDIES 3 months to 2 years stable: Mood Adaptability Approach
Thein_Chap08.indd 125
125
11/3/2010 3:27:15 PM
126
Psychiatry Bullets
Intensity (not: activity, distraction) Temperament Sense of identity established at 6 to 12 years Have a sense of “me-ness” Lower level defenses: splitting, denial, projection, good/bad, omnipotent But, will develop higher level defense mechanisms with time
TYPES (REFER TO DSM-IV TR) Paranoid personality disorder Assessment approach Individual may not likely seek treatment Therapeutic alliance strengthened if clinician can be Straightforward Factual Not overly warm style (avoids exacerbating paranoia) Treatment Group therapy addressing social skills CBT addressing anxiety management Psychopharmacological Antipsychotic agents to address potential psychotic decompensation Schizoid personality disorder Assessment approach Individual may not likely seek treatment Therapeutic alliance strengthened if clinician can be Interested Caring Nonconfrontational Treatment Supportive therapy Treatment if Axis I condition also present Group therapy addressing social skills Schizotypal personality disorder Assessment approach Individuals may not likely seek treatment Therapeutic alliance strengthened if clinician can be Straightforward Factual Treatment CBT addressing cognitive distortions and social skills Psychopharmacological treatment Antipsychotic agents to address potential psychotic decompensation Histrionic Treatment Frequent therapy Parental counseling (especially in female patients) Borderline Assessment approach Individual often found in treatment settings Therapeutic alliance strengthened if the clinician can be Consistent Expectant of the patient to be angry and disruptive
Thein_Chap08.indd 126
11/3/2010 3:27:17 PM
Chapter 8 Personality Disorders
127
Anticipatory of defenses Splitting Devaluing Idealization Denial Projection Treatment Supportive therapy providing “corrective emotional experience” Psychodynamic therapy with same intent Supportive group therapy with same intent CBT to address social skills DBT (dialectical behavior therapy) Developed by Marsha Linehan Cognitive behavioral techniques and mindful awareness Skills taught Core mindfulness Interpersonal Emotion regulation Distress tolerance Psychopharmacological agents to address Mood lability Cognitive distortions Aggression Narcissistic Assessment approach often requiring time (years) Treatment “Cornerstone” treatment: individual psychodynamic psychotherapy Empathy toward patient’s sensitivities and disappointments Insight directed toward maladaptive grandiosity Antisocial personality disorder Assessment approach Awareness of the possibility of this condition Monitoring of dynamics in the individual’s setting Inpatient hospital setting amongst other patients Treatment team dynamics of observations of the patient Family, social, occupational, etc. dynamics Treatment Treatment if Axis I condition present Supportive therapy to enhance awareness of behaviors Avoidant personality disorder Assessment approach Differentiate from Schizoid personality disorder—avoidant individuals avoid secondary to fearing rejection and/or criticism Social phobia—social phobia individuals have more specific fears Therapeutic alliance can be strengthened if the clinician can be Supportive of patient’s sensitivity Nonconfrontational Aware of potential for countertransference Overprotectiveness Too little or too much expectation for change Treatment Social skills training focusing on assertiveness CBT to address distortions of patient’s abilities Group therapy addressing social skills
Thein_Chap08.indd 127
11/3/2010 3:27:17 PM
128
Psychiatry Bullets
Dependent personality disorder Assessment approach Individuals often seek help for depression or anxiety Therapeutic alliance strengthened if the clinician is not overly directive or protective Treatment Group therapy addressing social skills CBT addressing increased independent functioning Couples therapy to strengthen more adaptive independence Family therapy to strengthen more adaptive independence
Thein_Chap08.indd 128
11/3/2010 3:27:17 PM
Chapter
9
Somatoform Disorders
SOMATIZATION DISORDER Assessment Critical assessment for other conditions necessary: Medical conditions Axis I conditions Schizophrenia Anxiety disorders Mood disorders Medical records Family members Multiple providers Treatment Empathy toward individual’s sense of suffering Information Reassurance
UNDIFFERENTIATED SOMATOFORM DISORDER Assessment Symptoms are not consistent with somatization disorder Assess for Major depression Anxiety disorders Treatment Supportive therapy Time
CONVERSION DISORDER Assessment Nonintentional production of symptoms Specific symptoms Motor Impaired coordination/imbalanced Paralysis/localized weakness Difficulty swallowing/ “lump in the throat” Aphonia Urinary retention
Thein_Chap09.indd 129
129
11/3/2010 3:28:42 PM
130
Psychiatry Bullets
Sensory Hallucinations Loss of touch or pain sensation Double vision Blindness Deafness Seizures/convulsions with voluntary motor/sensory components Look for history of conversion symptoms Treatment Treat symptoms Reassurance Relaxation technique education Hypnosis
HYPOCHONDRIASIS Assessment Address physical disease (if present) Monitor for Mood symptoms Anxiety symptoms Other obsessive or compulsive inclinations Treatment Mood, anxiety symptoms, and obsessive/compulsive symptoms Team approach with other medical providers
BODY DYSMORPHIC DISORDER Assessment Monitor for Anorexia nervosa Gender identity issues Peaks during adolescence and early adulthood 2% of those who seek corrective cosmetic surgery have this condition Treatment Recognition Behavioral therapy addressing interpersonal relationship improvement Psychodynamic therapy addressing self-esteem Pharmacological therapy to address Distortions Depression
SOMATOFORM DISORDER NOS
Thein_Chap09.indd 130
11/3/2010 3:28:46 PM
Chapter
10
Dissociative Disorders
DISSOCIATIVE AMNESIA Assessment Peaks at age 30 and 40 Comorbidity Conversion disorder Bulimia nervosa Alcohol abuse Depression Histrionic, dependent, borderline personality disorders Treatment Time (most spontaneously revert) Hypnosis “screen technique” Relive a traumatic event as if watching it on TV or as a movie Mastery over event Observer—not a participant of the “reliving”
DISSOCIATIVE FUGUE Treatment—integrating dissociated memories/behaviors
DISSOCIATIVE IDENTITY DISORDER (FORMERLY KNOWN AS MULTIPLE PERSONALITY DISORDER) Assessment Emerges typically between adolescence and in the 30s (rarely in the 40s) Patient’s lack of awareness History of sexual and physical abuse Projective psychological testing Monitor for Depression Substance issues Borderline personality disorder Seizure disorders Treatment Maldonado’s “Rules of engagement” Free access to all pertinent records Review of all available and pertinent records Freedom to discuss all past and current pertinent information with previous therapists 131
Thein_Chap10.indd 131
11/8/2010 1:00:47 PM
132
Psychiatry Bullets
Complete organic/neurological workup Contract for safety Increased communication and cooperation amongst alters “No secrets” policy Establishment of hierarchical pattern of communication Establishment of hierarchical pattern of responsibility Limited exploration followed by therapeutic condensation of memories “All details are not needed” policy Rules regarding contact during hospitalization and continued therapy after discharge Videotaping Ultimate goal: “full integration” “One day you will make me obsolete” principle Psychotherapy to mastering past traumatic events Hypnosis Eliciting different personality states Eliminate regression and encourage cohesion of personalities CBT to address integration of personalities Pharmacological agents addressing Depression Seizure disorders
DEPERSONALIZATION DISORDER Rule out PTSD Treatment Hypnosis “Imaginary screen” to picture problems
DISSOCIATIVE TRANCE DISORDER Differentiate from Dissociative trance disorder Do not involve distinct identities Acitivities are simple Memory is not affected; amnesia is fragmented Possession trance Distinct alternate identity Deity Ancestor Spirit Activities are complex Amnesia may be lengthy Treatment Rule out physical conditions Treatment of any comorbid psychiatric conditions Education Cultural sensitivity
DEREALIZATION
Thein_Chap10.indd 132
11/8/2010 1:00:50 PM
Chapter
11
Factitious Disorders and Malingering
FACTITIOUS DISORDERS Assessment Intentional production or feigning of symptoms—psychological or physical Unconscious production of these symptoms Types Factitious disorder Munchausen Wanderers Multisystem complaints Multiple hospitalizations Non-Munchausen Often passive, immature, young adult female patients Often trained/employed in health care–related fields Conforming lifestyle Family support and involvement Single-system complaint Factitious disorder by proxy (diagnosis given to the victim of the proxy) Treatment Establishing safety of the patient (factitious disorder by proxy) Multiprovider interventions Awareness of potential countertransference Anger Aversion Violation of confidentiality Overidentification with patient Activation of rescue fantasies
MALINGERING Assessment Motivation is clear Monitor for frequent and/or unusual inconsistencies Treatment Confrontation Expectation of refusal of assessment/diagnosis Awareness of potential countertransference Anger Aversion Violation of confidentiality 133
Thein_Chap11.indd 133
11/3/2010 3:33:04 PM
Thein_Chap11.indd 134
11/3/2010 3:33:07 PM
Chapter
12
Eating Disorders
OVERVIEW Continuum of eating disorders Anorexia Restricting type Purge type Bulimia Binge/purge Binge eating disorder Obesity Types Anorexia nervosa Bulimia nervosa Binge eating episode Genetics and environment Genetics Heritability: 0.5 to 0.8 COMT s/s variant? What is inherited? Perfectionistic/obsessive compulsive disorder symptomatology Height (BMI) Actual eating disorder Environment Coping strategies of family members Environment stressors
ANOREXIA NERVOSA OVERVIEW Diagnostic criteria Subtypes Binge-purge: drugs (laxatives, diuretics), depression, impulse, and suicide Restricting: food restriction and compulsive exercising for weight loss Epidemiology 0.2% to 1.5% lifetime prevalence 90% to 95% female Age of onset typically in adolescence but ranges from 8 to mid 30s Associated with highest mortality rates of any mental disorder
135
Thein_Chap12.indd 135
11/3/2010 3:34:45 PM
136
Psychiatry Bullets
Course Remitting Recurrent Chronic Clinical features Physical symptoms Cold intolerance, dizziness, constipation, gastrointestinal discomfort, and hyperactivity Exam Cachexia, breast atrophy, dry/yellow skin, Russell’s sign, bradycardia, lanugo, and alopecia Medical complications Cardiovascular complications Signs and symptoms Low voltage, bradycardia, T-wave inversions, ST depression, supraventricular premature beats, or ventricular tachycardia Watch in purging or diuretic abusers Also watch in cases of hypokalemia and hypochloremia Hypercholesterolemia Hematological changes: mild anemia or leucopenia and low platelets Gastrointestinal complications Decreased GI motility and gastric emptying time (GET) Pancreatitis (sometimes) Elevated LFTs and amylase if fatty degeneration of the liver exists Low fasting blood sugar Elevated serum salivary amylase Acute gastric dilation/rupture + acute vascular compression of duodenum Renal complications High BUN levels, polyuria, and peripheral edema during refeeding Neurological abnormalities—rarely (large ventricles and sulci), smaller gray matter Endocrine complications Amenorrhea precedes weight loss (20% to 30%) Thyroid Diabetes mellitus (careful use of insulin necessary) Skeletal complications Reduced bone density—osteoporosis (90% of bone mass in adolescents) Hypercortisolism and hypoestrogenisms → osteopenia Psychological assessment Severe body-image distortion Obsessive tendencies Interpersonal insecurity Minimal emotional expressivity Perfectionism Identity confusion Excessive conformity and guild Rigid control over impulses Competitiveness Envy Ambivalence of sexual and emotional maturation Psychiatric conditions: mood disorder, kleptomania, polysubstance abuse, and OCD Personality disorders Starvation effects Psychological Constant preoccupation with food and weight Heightened craving for food Heightened anxiety/obsessiveness Poor concentration Depressed and labile mood
Thein_Chap12.indd 136
11/3/2010 3:34:49 PM
Chapter 12 Eating Disorders
137
Feelings of inadequacy and irritability Social withdrawal Physical Electrolyte imbalance leading to cardiac arrhythmias Delayed gastric emptying time—bloating after meals Lowered metabolism, fatigue, and edema Ovarian abnormalities, fatigue, and edema Osteoporosis, dry skin, hair loss, and lanugo Insomnia, hypersensitivity to noise and temperature DIFFERENTIAL DIAGNOSIS Diabetes mellitus Crohn disease Colitis Thyroid conditions IBS Acid peptic disease Addison’s Motility disorder Brain cancer Conversion Schizophrenia ETIOLOGY High-risk populations Models Ballet dancers Athletes Chronically ill Diabetes Cystic fibrosis History of sexual abuse PATHOGENESIS Genetics COMT s/s variant Family history Mood disorders Eating disorders Environment Parental roles Family perspectives: individual with anorexia nervosa as the identified patient Sociocultural factors TREATMENT Practice guidelines American Psychiatric Association (APA) Practice Guidelines National Institute of Clinical Excellence (NICE) Guidelines Address multiple possible comorbidities Depression Substance use issues Anxiety disorders/PTSD/obsessive tendencies Setting of treatment Outpatient psychiatric treatment involving a specialist First episode—no previous treatment or relapse after resuming weight Continuing treatment following inpatient/partial hospitalization Weight loss is gradual over 3 months Weight loss within 75% to 80% of BMI Normal serum electrolytes Must consider inpatient care if: >20% original body weight loss in <3 months
Thein_Chap12.indd 137
11/3/2010 3:34:49 PM
138
Psychiatry Bullets
Weight <75% BMI Abnormal electrolytes (decreased K/Cl; metabolic alkalosis) Evidence of dehydration Abnormal EKG Depression with psychosis or suicidal tendency Incapacitating obsessions not related to the eating disorder Nonfunctioning otherwise Essential features Cognitive behavioral therapy Two core assumptions about anorexia nervosa Food avoidance activated by distorted thoughts of food and weight Anorexia nervosa serves a positive function Creation of life events chart Patient and therapist work together; homework given Visual account of relationships between interpersonal functioning, self-esteem, life events, and development/maintenance of eating problems Tasks Involve patient in short-term and long-term goals to reduce fear of treatment Establish regular weekly weighing Educate patient about negative effects of Dietary restriction Low weight Binge-eating/purging Introduce regular eating pattern and strategies to cope with anxiety Education Cognitive view of maintenance of the illness Psychological and physical effects of starvation—cost/benefit analysis Monitoring Weekly weighing Food records Cognitive restructuring and problem solving For interpersonal problems and eating behavior Family therapy (if patient is <18 years of age) Therapist with medical backup Medication—SSRI for depression/OCD behaviors Family Maudsley (to be implemented after weight restoration) Three phases of treatment of 20 sessions over 6 to 12 months Parents are in charge of weight restoration Assumes parent Available and willing participants Has a partner Assumes patient Available and willing participants Not with severe illness (weight > 70% to 75% ABW) Systems family therapy Focuses on patterns of behaviors and beliefs Studies family member’s roles and relationships Examines how patient’s developmental stage is accommodated by the family Pharmacology Only used adjunctly after weight restoration SGA ?Olanzapine Addresses overwhelming anxiety and obsessionality Study involving outpatient use with efficacy
Thein_Chap12.indd 138
11/3/2010 3:34:49 PM
Chapter 12 Eating Disorders
139
SSRIs are ineffective 5-HT levels are depleted l-Tryptophan availability is low (from food) Cyproheptadine Weight gain Antidepressant effect Tranquilizers—reduce anxiety Resistance to treatment adherence in anorexia nervosa Illness provides a useful function in life Escape from developmental issues Escape from life stresses Highly reinforcing—terrifying to relinquish Egosyntonic nature—patient denial Reinforcing factors that interfere with treatment Coping styles Developmental transitions Fears of maturity and autonomy Distressing life events Feelings of ineffectiveness Helplessness Poor self-esteem Disturbed relations with others Elevation of self-esteem and control PROGNOSIS Outcome 5% includes suicide Risk factors for poor outcome Low weight Social functioning Polysubstance abuse Binge-purge Mood disorder COURSE as above
BULIMIA NERVOSA Prevalence and epidemiology 2% to 3% lifetime prevalence for females (0.1% to 0.3% for males) Female:male ratio 10:1 Peaks during adolescence and young adulthood Course Remitting Recurrent Chronic Risk factors Familial Family member/relative with anorexia nervosa, bulimia nervosa, or obesity Family member/relative with depression/ alcohol-drug abuse/dependence Individual biological factors Mildly overweight Early menarche
Thein_Chap12.indd 139
11/3/2010 3:34:49 PM
140
Psychiatry Bullets
Individual psychological factors Perfectionistic Low self-esteem Affective disorders, alcohol/drug use Individual behaviors Dieting Activities that emphasize weight control Early feeding problems Cultural Industrial country “Thin is beautiful” United States has had a general significant weight increase Stressors Death of close friend/relative Sexual abuse or history of trauma Developmental features Lack of experiences to foster personal independence Sense of personal ineffectiveness Social ineffectiveness Poor self-esteem Warning signs Low weight or large fluctuations in weight Purging to lose weight Persistent concerns with weight loss Persistent attempt to lose weight despite normal or low weight Social withdrawal and isolated eating Unexplained amenorrhea Definition and diagnostic criteria DSM-IV TR criteria—eating within 2 hours large amounts, sense of a lack of control; compensatory behavior (diet pills, laxatives/enemas, exercise) two times a week for 3 months; influenced by body shape and weight and not during AN Types Purging Nonpurging Etiology Biological Family history (twin studies) Neurotransmitters (5-HT, DA, NE) Neuropeptides (CCK, opioids, neuropeptide Y, peptide YY, hypocretin/orexin) Leptin (plasma levels are higher) IDDM Psychological and family Attachment quality to mothers Cluster B personality disorder characteristics Image issues History of sexual abuse Risk factors: Cultural effects Dissatisfied with body Depression Signs and symptoms Chipmunk face (parotitis), fluid retention, irregular menses, bradykinesia, and shortness of breath
Thein_Chap12.indd 140
11/3/2010 3:34:50 PM
Chapter 12 Eating Disorders
141
Fatigue, hypotension, cold intolerance, muscle pain, gastrointestinal dysfunction, and epigastric symptoms Fullness, polyuria, dry cold skin, dental erosions, and Russell’s signs (back of hand erosions due to personally inflicted vomiting) Ruptured esophagus/stomach, cardiomyopathy (ipecac use), and cardiac arrhythmias Cardiomyopathy especially if ipecac use is present Subconjunctival hemorrhages, kidney failure, and low T3 levels Reduced insulin and glucose, increased lipolysis Sleep, libido, sex, dysphoria, irritability, social withdrawal, obsessional Psychological symptoms Preoccupied with weight, food, and body size Anxiety Depression, guilt, and impulse control issues Perfectionism Families focused on perfectionism, history of sexual abuse Labs Fasting (decreased volume and kidney function increase aldosterone release Potassium is excreted leading to hypokalemia and retention of Carbon dioxide—or if in metabolic acidosis, loss of carbon dioxide) Anemia Low potassium and chloride, high sodium Low protein (bloating) Low magnesium (cardiac and vascular, bone, kidney, thyroid) and zinc Osteopenia (if prolonged, restrictive type or Ipecac usage) Cardiomyopathy, congestive heart failure (perform ECHO) Chest pain, shortness of breath Generalized muscle weakness Hypotension, tachycardia, and EKG changes Increased liver function Increased sedimentation rate Irrational beliefs regarding “thinness” Differential Diagnosis Upper gastrointestinal disorder Neurological (Kleine-Levin, Kluver-Bucy) Hormonal (hyperparathyroidism) MDD Personality disorder Other eating disorders Comorbidity Treatment CBT (studies demonstrate efficacy) Interpersonal therapy Dialectical behavioral therapy Psychodynamic (should be used in conjunction with other treatments) Psychoeducation Family therapy (Maudsley version) Pharmacological agents Antidepressants SSRIs Fluoxetine is the only FDA-approved medication Fluoxetine doses should be high (60 mg/day) as the serotonergic system is blunted Bupropion is contraindicated TCAs (desipramine and imipramine) MAOIs (phenelzine)
Thein_Chap12.indd 141
11/3/2010 3:34:51 PM
142
Psychiatry Bullets
Antiepileptics (topiramate) Opiate antagonists (naltrexone) Antiemetics (ondansetron) Other Topiramate Sibutramine Zonisamide Binge eating agents Topiramate Sibutramine Zonisamide SSRIs (fluoxetine, etc.)
Thein_Chap12.indd 142
11/3/2010 3:34:51 PM
Chapter
13
Sleep
NEUROLOGICAL UNDERSTANDINGS Neurotransmitters Acetylcholine (ACh)
Cortical activation
Norepinephrine (NE)
Heightens arousal from external stimuli
Serotonin(5-HT)
Affect and mood modulation
Histamine
Fired on only when awake
Hypocretin
Stabilizes arousal circuits when awake
Dopamine
Behavior modulation
Sleep neurotransmitters Wake Dopamine Norepinephrine Serotonin Histamine (antihistamine increases drowsiness) Acetylcholine Glutamate Hypocretin Orexin NREM Serotonin Adenosine GABA Theophylline and caffeine decrease sleep Benzodiazepines promote sleep REM Cholinergic nicotinic muscarinic receptors Nicotine promotes REM sleep TCA (anticholinergic properties) depresses REM sleep Brain areas Wakefulness is maintained by the coordination of two centers: Hypothalamus and the reticular activating system The hypothalamus integrates information Metabolic state Memory Mood Drives Environment 143
Thein_Chap13.indd 143
11/3/2010 4:37:19 PM
144
Psychiatry Bullets
The ascending reticular activating system Receives information from somatic and visceral sources Sends projections to subcortex and cortex The suprachiasmatic nucleus (SCN) is the sleep center of the brain. Major “afferents” into the SCN are Glutamate (via light) Serotonin and norepinephrine Melatonin (via the pineal gland) If the SCN is in the WAKE/ON mode activating neurons in the TMN or tuberomammillary nucleus: One is in a state of “external vigilance”(anxiety and fear) “calm alertness” (cognition/executive functioning) Histamine and hypocretin/orexin have been secreted from the TMN TMN cells almost solely produce histamine Projections of histaminic neurons go to the basal forebrain and cortex No histamine is “fired” during sleep Hypocretin/orexin theorized to stabilize wakefulness by suppressing REM and lowering the threshold for arousal Loss of this signaling causes “inappropriate transitions into REM” If the SCN is in the SLEEP/OFF mode activating neurons in the VLPO Or ventrolateral preoptic nucleus to inhibit the TMN Normally, ACh is present during wake stages GABA and ACh are released into the cortex A subpopulation of these cholinergic cells continue to fire during REM Brain structures Pons and midbrain (caudal) generate basic features of REM In general, REM sleep Anterior paralimbic cortex Error detection Motivation to action Ventral striatum/basal forebrain/basal ganglia Premotor
NREM
Motor cortex
Central pattern generation
Primary sensorimotor cortex
Sensorimotor
Cerebellum
Cognitive planning
Insular cortex
Interface w/ internal stimuli
Mesial temporal cortex (hippo/amy/uncus)
Emotion/memory
Brainstem reticular formation
arousal/approach
Brainstem → limbic/VM PFC → PFC Areas of decreased metabolism (relative to waking)––thalamus
Depression REM Depressed patients have increased REM sleep REM is a limbic activator NREM—changes in waking and NREM cerebral blood flow Insomnia Increased metabolism of the brain Arousal systems do not deactivate
Thein_Chap13.indd 144
11/3/2010 4:37:24 PM
145
Chapter 13 Sleep Physiology of sleep states REM Peripheral muscle tone paralysis Neuronal firing/neurotransmitter release and uptake/metabolic rates like the active state Vigorous mental activity (dreams) NREM (during the first 6 months of life, the NREM stages emerge) Peripheral muscle tone stops Slower respiratory (RR) and heart rate (HR) Stages 1 Looks like REM But, respiratory rate, heart rate, and eye movements patterns are inhibited 2 K complexes Sleep spindles 3 and 4 Slow, high voltage synchronized delta waves Sleep requirements In general: Birth
2 years
16 years
Diurnal
50%
10%
0%
Nocturnal
50%
90%
100%
Sleep Time
18 hours 13 hours
7 hours
Development of sleep-wake organization Newborns
Adults
REM/NREM
50%/50% No Stage 4NREM
20%/80% Stages 3&4 comprise of 20NREM
Length of cycles
Every 50 minutes
Every 90 minutes
Wake-Sleep state
Sleep begins with REM
Sleep begins with 4NREM
Even REM/NREM through-out sleep
First 1/3 of sleep is 4NREM Later part of sleep is REM Diurnal influences more notable
Aging Waking metabolic declines associated with aging But, areas where metabolism declines from wake→ sleep are less in aging
SLEEP DISORDERS—ADULTS Adult population Epidemiology
Thein_Chap13.indd 145
Difficulty falling asleep
4% to 17%
Difficulty remaining asleep
12% to 32%
Early morning awakening
5% to 16%
Nonrestorative sleep
3% to 15%
Pain during sleep
4% to 14%
11/3/2010 4:37:24 PM
146
Psychiatry Bullets
Insomnia Concerns Prevalence in adults over 10% (30% with disturbed sleep) Risk factor for psychiatric disorders Predictor of relapse from mood disorders Risk factor associated with a first myocardial infarction Predicted falls in the elderly (compared to hypnotic medications) Differential diagnoses Primary psychiatric disorder Major depression Bipolar disorder GAD PTSD Schizophrenia Panic disorder OCD Borderline personality disorder Dementia ADHD Substance abuse/dependence Medical conditions Cardiac Angina Paroxysmal nocturnal dyspnea Pulmonary COPD GI GERD Endocrine Hypothyroidism/hyperthyroidism Diabetes Menopause Neurologic Dementia Parkinson’s disease Strokes Migraines Urinary Renal issues Nocturia Substances Caffeine Alcohol (rebound insomnia) Medication—induced Antidepressants Stimulants Steroids/bronchodilators Decongestants Dopamine agonists (akathisia) Restless legs (RLS) and periodic limb movement disorder (PLMD) RLS Clinical features Urge to move Worsens at night/rest/inactivity Relieved with movement
Thein_Chap13.indd 146
11/3/2010 4:37:24 PM
Chapter 13 Sleep
147
Family history Monitor for Iron deficiency Renal insufficiency/failure Pregnancy Medication induced Treatment via dopamine agonists Periodic limb movement disorder Clinical features Repetitive stereotyped movements of the foot/leg “Kicking” at night Sleep disorder Circadian disorder Elderly (secondary to medical conditions) Management of insomnia Aims of treatment Reduce nocturnal arousal Sleep onset Sleep maintenance Multiple mechanisms Maintain daytime alertness Long-term therapy indicated Hierarchical levels of arousal Sleep hygiene → DLPFC Psychotropics → limbic/VMPFC Sedative/hypnotics → brainstem reticular formation → basal forebrain → hypothalamus Nonpharmacological approaches for insomnia Sleep hygiene → promote habits to help sleep → provide rationale for subsequent instructions Stimulus control → strengthen bed and bedroom sleep as sleep stimuli Sleep restriction → improve sleep continuity (by limiting time in bed) Relaxation → reduce arousal (and decrease anxiety) via meditation, muscle relaxation, yoga, and biofeedback CBT → challenge dysfunctional beliefs and misperceptions Circadian → reset/reinforce biological rhythm Rhythm Entrainment Pharmacological approaches for insomnia Nonhypnotic Types Diphenhydramine Sedating antidepressants (TCAs, trazodone, mirtazapine) Second generation antipsychotics (quetiapine) Anticovulsants (gabapentin) Risks and benefits Benefits Low abuse potential Addresses anxiety Inexpensive Nonscheduled Risks Efficacy unproven, priapism Residual sedation, anticholinergic side effects, weight gain, toxicity
Thein_Chap13.indd 147
11/3/2010 4:37:24 PM
148
Psychiatry Bullets Possible glucose and lipid abnormality (second generation antipsychotics) Cognitive impairment (anticonvulsants) Hypnotics FDA Approved
Medication
Active
Dose (mg)
Onset
t½
Metabolite Duration
Flurazepam (Dalmane)
15 30
Rapid
47 to 100
Y
Estazolam (Doral)
7.5 (15)
Rapid
39 to 100
Ya
Benzodiazepine
Prosom
0.5 (12)
Rapid
10 to 24
N
Temazopam (Restoril)
7.5 15
Interim
3.5 to 18.4
N
Triazolam (Halcion)
0.125 (0.25)
Rapid
1.5 to 5.5
N
Eszoplicone (Lunesta)
123
Rapid
6
N
6w/6m
Ambien CR
6.25 (12.5)
Rapid
2.8
N
3w
Zolpidem (Ambien)
5 (10)
Rapid
2.6
N
35d/3m/6m
Zaleplon (Sonata)
5 10 20
Rapid
1
N
2w/4w
Nonbenzodiazepine
Indiplon
2w
Melatonin receptor agonists Ramelteon (Rozerem)
8
Rapid
1 to 5
Y
12m
Benzodiazepine receptor agonists Mechanism of action Hypnotic Anxiolytic Myorelaxant Anticonvulsant Side effects Sedation Anterograde amnesia Ataxia/falls Respiratory depression Tolerance/dependence/abuse Triazolam issues Discontinuation rebound Dose escalation Nonbenzodiazepine receptor agonists No evidence of Tolerance Rebound Melatonin receptor agonist (ramelteon) Mechanism of action MT1 and MT2 receptors agonists (in hypothalamus) to maintain normal sleep-wake cycle t½ dose is the same no matter what the dose Efficacy Sleep onset Chronic insomnia Transient insomnia
Thein_Chap13.indd 148
11/3/2010 4:37:24 PM
Chapter 13 Sleep
149
Excessive daytime sleepiness Differential diagnoses Inadequate sleep Voluntary restriction Shift work Delayed sleep phase disorder Poor quality sleep Sleep apnea Obstructive—due to blockage of the airway Clinical features Risk factors Obesity Age (increasing) Large neck Acromegaly Micrognathia Oropharynx Excessive daytime sleepiness Restless sleep Night time diaphoresis Dry mouth/sore throat Intellectual impairment Impotence AM headaches Bed partner unable to sleep Treatment CPAP—continuous positive airway pressure Weight loss Surgery to upper airways Tracheostomy Sleep consult Central—due to brainstem or systemic illness PLMD Medication-induced Environmental factors Excessive sleep drive Narcolepsy Idiopathic hypersomnia Medication-induced
SLEEP DISORDERS—PEDIATRIC POPULATION Pediatric insomnia Definitions DSM-IVR Primary insomnia Insomnia related to another mental health disorder Associated with general med condition or substance abuse ICSD II Behavioral insomnia of childhood Sleep onset association Falling asleep extended process with special conditions Sleep onset associations highly problematic or demanding Sleep onset significantly delayed or disrupted Nightline awakenings require parent to help the patient limit setting Difficulty initiating or maintaining steep
Thein_Chap13.indd 149
11/3/2010 4:37:25 PM
150
Psychiatry Bullets
Child stalls or refuses to go or return to bed Parent cannot set limits Psychophysiologic Associated with mental or medical disorders In general, “an age-appropriate, short-lived disturbance is less serious and requires less intervention than a disorder that appears earlier or persists beyond the usual age limits” Studies point out that kids do not necessarily “outgrow” developmental sleep problems Classification of sleep disorders ICSD-DCM Dyssomnia Night waking, DFA Limit-setting sleep disorder, sleep-onset association disorder, and food-allergy insomnia Parasomnia Sleep disorders associated with medical or psychiatric conditions DSM-IV TR Dyssomnia (insomnia, hypersonic, circadian rhythm sleep disorders) Protodysomnia (the child focused criteria for infants and toddlers) Parasomnia (REM and NREM persona) DC 0-3 Sleep behavior disorder Prevalence 20% to 25% of kids have some kind of sleep disturbance More 20% of 0 to 2 year olds have night waking 25% to 50% preschoolers have DFA night awakening 15% 4 to 10 year olds have bedtime resistance 10% of adolescents have primary insomnia High risk populations General numbers Developmental delays
70% to 80%
Autism PDD
70% to 80%
Psychiatric (depression anxiety)
75%
Disruptive (ADHD/ODD)
50%
Medical
50% to 60%
Specific populations Autism Especially younger kids Severe chronic intermittent Asperger syndrome differences Most common symptoms Irregular sleep-wake cycles Delayed sleep onset Prolonged night wakening Short sleep duration ?need Early morning wake times more common parasomnias Early onset depression 10% experience insomnia after treatment of depression Like adults, this may be predictive of treatment resistance 88% of depressed kids have insomnia Specifically find Delayed onset
Thein_Chap13.indd 150
11/3/2010 4:37:25 PM
Chapter 13 Sleep
151
Decreased sleep efficiency Predicted prognosis Bipolar little data? decreased need for sleep certainly seen ADHD Measured objective findings show little difference with kids with or without ADHD Polysomnography (sleep lab) Actigraphy (more activity) But subjective findings (parents etc.) show bigger difference Delayed sleep onset Poor sleep quality Frequent night awakenings Daytime sleepiness Factors of Insomnia Environmental Circadian Medication and substances Psychiatric disorders Developmental factors (age) Primary sleep disorders Medical and neurological disorders Behavioral and conditioning factors This could explain the difference between the objective and subjective factors Impact Mood and affect Behavioral internalizing externalizing Neurocognitive especially executive function Performance––academic family social occupation driving Family disruption Health—more accidental injuries Differential diagnoses of sleep disorder Primary sleep disorders Dyssomnias Primary insomnia Primary hypersomnia Narcolepsy Circadian Breathing-related sleep disorder Circadian rhythm sleep disorder Parasomnia (Deep non-REM—stages III and IV) Nightmare disorder
Arousal disorder
Sleep terror disorder
Sleep-wake transition
Sleepwalking disorder
REM parasomnia
Sleep disorders related to a mental disorder Sleep disorders due to a general medical condition Substance-induced sleep disorders Differential diagnoses of sleep disorders according to developmental stage Infants Sleep disordered breathing SIDS Sleep-onset association disorder Children Failure to thrive Seizures
Thein_Chap13.indd 151
11/3/2010 4:37:26 PM
152
Psychiatry Bullets
Consider Visible tonic-clonic movements during sleep Enuresis beyond 16 years Night terrors from the ages of 5 to 9 years Treatments are not working Parasomnias Sleep disordered breathing Adolescents Circadian rhythm disorders Insomnia Sleep disordered breathing Excessive sleeping Evaluating the sleep disturbance in the pediatric population Taking a sleep history Age of onset of the problem Frequency (events/week) Course (stable, worsening, improving) Time of the night/day (clock time and time since falling asleep) Parasomnia related to sleep onset (90 to 120′) Phase delay related to clock time Nightmares occur later in the night when REM sleep predominates Recollection of dreams occurs Night terrors occur during the first 1/3 of the sleep period (4NREM) Dreams are not recalled Usual bedtime/rise time Regularity of sleep habits What are the sleeping arrangements? Room/bed mate? Do the symptoms disturb others? Bedtime rituals Common dreams and nightmares Common night waking and bedwetting Breathing during sleep/colds/labored breathing/pauses/snoring/mouth breathing Effects on daytime functioning (lethargic/bright) Sleep disorders in infants and toddlers (birth to 2 years old) Night waking problems → falling asleep problems → problems going to bed Falling asleep problems 15% to 20% of 6 months to 3 years old (rocking or holding at bedtime required) Night waking problems (assess what happens at the beginning of the night or naps) i.e. ask for symptoms of anxiety, specific phobias (dark, being alone) Treatment: night lights Signalers versus Self-soothers By 6 months, “all awaken once or twice during the night after 5-6 hours of sleep” Signalers Placed into the crib when already asleep No use of a sleep aid (pacifier) Awakens and begins to cry Self-soothers Placed into the crib and allowed to fall asleep using a sleep aid Awakens for 3 to 5 minutes, but falls asleep on own Separation issues (beyond 2years): battles, routines for transition Letting the infant cry five to seven nights Withdraw parental presence gradually by waiting for a longer time before intervening Shaping bedtime behaviors (getting ready for bed and sleep)
Thein_Chap13.indd 152
11/3/2010 4:37:26 PM
Chapter 13 Sleep
153
Sleep disorders in preschool-aged children (3 to 5 years): usually limit-setting issues Enjoying daytime activities (?over stimulation, TV, working parents) Watch for longer bedtime routines Nightmares—after 2 a.m. (REM phenomenon) Sleep apnea syndromes (see lecture) CNS (voluntary cortical mechanisms versus involuntary subcortical systems) Voluntary: wakefulness and synchronizes breathing vocalization Involuntary: maintains oxygen saturation during sleep Mechanical/physical Enlarged tonsils/adenoids Structural narrowing of the airways Neurological/medical conditions Presentation may not be excessive, daytime sleepiness or fatigue/ Rather consider hyperactivity, inattention, or failure to thrive Growth hormone is secreted during 4NREM Awakenings can interfere with this stage Sleep disorders in school-aged children (6 to 13 years) Parasomnia episodes of nonwaking activity, interrupted sleep suddenly and intermittently) Occurring from 4NREM into REM—so they wake up during NREM Confused, disoriented, and cannot remember Occurs within 90 to 120 minutes of sleep onset Risk factors: males, family history , retrograde amnesia for the event the next day Treatment: sleep hygiene, after school nap, BNZP EEG, if this occurs in adolescence or if extends into adolescence Night terrors (not to be confused with nightmares where children can remember, are oriented, and occur later at night) Sleep talking (usually garbled and meaningless) Sleep walking (complex behaviors are not likely to occur) REM sleep behavior disorder (RARE) no inhibition of peripheral muscle tone during REM Sleep disorders in adolescents (puberty—18 years) Excessive somnolence Narcolepsy REM sleep hypersonic secondary to sleep-wake regulation dysfunction Prevalence 0.04% to 0.07% (4 to 7/10,000) Adolescents normally nap for 20 to 40 minutes, wake up refreshed then repeat Q2-3 hours (this is a treatment—regular naps) “Full blown” (the tetrad) Irresistible attacks of REM sleep during wakefulness Treatment: stimulants Cataplexy—sudden loss of muscle tone following strong effect Treatment: TCA, MAOIs Hypnagogic hallucinations—VH during sleep onset Treatment: MAOIs Sleep paralysis—limb immobility during sleep onset Phase delay syndromes Disordered sleep in medical and psychiatric conditions Consider in residences, mental retardation, autism ?Psychiatric conditions Adults: short initial REM latency Fragmented ultradian regulations with multiple arousals and EMA Blunting of early morning cortical levels ?Substances Decreased REM sleep Fragmented sleep Periods of prolonged “drugged states”
Thein_Chap13.indd 153
11/3/2010 4:37:26 PM
154
Psychiatry Bullets
SPECIFIC SLEEP DISORDERS Sleep disordered breathing (AKA obstructive sleep apnea) Signs and Symptoms Apnea/snoring Failure to thrive in toddlers Pulmonary hypertension Mood changes Depression/aggression/impulsivity/hyperactivity/decreased attention Memory /vocabulary/executive function––more so in adults (language and IQ same) Etiology: partial or complete air flow obstruction Large tonsils/adenoids Obesity Anatomical Micrognathia Macroglossa ?Reversibility in children Parasomnia Definition: A disorder of arousal Onset in the sleep cycle: typically within the first 3 hours of sleep Examine EEG: Symptoms of sleeping while awake and finding of 4NREM sleep Signs and symptoms Not sleeping during the day Does not remember (or if there is a memory, believes it was a nightmare) Confusion at the time of waking Types Sleep walking Sleep talking Night terrors Risk factors Male Family history Poor sleep hygiene Narcolepsy Features: Severe daytime sleepiness Episodes of cataplexy (found in over 2/3 of patients) Sleep paralysis Hypnagogic and hypnopompic solutions (especially during sleep attacks) Mechanism of action Loss of a function of HYPOCRETIN (Orexin) Found in patients with HLA DQB1*0602 and DQA1*0102 An autoimmune process suspected of causing degeneration of the hypothalamic neurons that produce hypocretin Circadian rhythm sleep disorder Etiology: “a different internal clock” The SCN in the hypothalamus is our “internal clock” Light is the most important stimulus to this brain region, although, the environment plays a role as well (activities, exercise) Examples Jet lag Shift work “Night owls” Delayed sleep phase (e.g., teenagers) “late to bed, late to rise” Worse in the summer
Thein_Chap13.indd 154
11/3/2010 4:37:26 PM
155
Chapter 13 Sleep Signs: Sleepy Photophobic Depressed Family history Described as “willful or lazy” Advanced sleep phase (e.g. elderly) Early morning awakening Treatment Light
GENERAL TREATMENT OF SLEEP DISORDERS Steps: One: Rule out other conditions (depression) Two: Rule out other conditions’ contributory roles (obesity, medical illnesses, etc.) Three: Behavioral interventions Four: Pharmaceutical agents Treating sleep problems Insomnia TCAs
Histamine blockers anticholinergic
Benzodiazepines
GABA a/alpha (all subunits)
Zolpidem
GABA a/alpha1 subunit
Lunesta
GABA a/alpha1 subunit
Sonata
GABA a/alpha3 subunit
Trazodone
5-HT2 blocker/alpha1 blocker
Mirtazepine
5-HT2 blocker/histamine blocker
Diphenhydramine/hydroxyzine
Histamine blockers
Clonidine
Central alpha2 presynaptic agonist
Melatonin
Naturally secreted at night
Sleepiness Stimulants Mechanism of action Blocks DARI/NERI Enhances release of DA/NE ?release of histamine Caffeine Mechanism of action Blocks adenosine (during sleep, adenosine levels decrease) Increases ACh in the cortex Inhibits the VLPO, thus discouraging sleep Increases dopamine Modafanil Mechanism of action Releases histamine in the TMN Pharmacology No FDA-approved medications for children Behavioral intervention is the treatment of choice 80% get better Examples extinction, graduated extinction, preventative, scheduled awakenings Treatment studies Melatonin most studied in kids
Thein_Chap13.indd 155
11/3/2010 4:37:26 PM
156
Psychiatry Bullets
Findings Variable effects Well tolerated Some improvement daytime function No long-term data on efficacy safety Shortening of sleep onset Two essential roles Chronobiotic—circadian effects and to be given 5 to 6 hours before sleep Mild hypnotic effect—like diphenhydramine could its effects be more attributable to this? Premise—kids with circadian phase delay have later onset of melatonin secretion Darkness triggers melatonin secretion Lightness turns off melatonin secretion Diphenhydramine TIRED study (Mercer Stein et al. 2006) stopped due to lack of efficacy Clonidine Little empirical data No double-blind placebo controlled trials Comment of sudden death with stimulant high doses, structural heart defects Toxicity of rebound hypertension Adults benzodiazepine receptor agonists Less sleep onset delay Wake after sleep onset Total sleep time increase Better sleep quality with good safety profile Adults ramelteon Sleep onset latency and total sleep time effects Less side effect Medication and caffeine effects Psychotropic medications and sleep mechanisms Effects Effects on sleep architecture Stage 1 sleep, slow-wave sleep, REM sleep Effects on sleep onset latency Effects on sleep continuity arousals awakening Effects on subjective sleep quality freshness Effects on nocturnal sleep tenors nightmares Excessive daytime sleepiness Direct versus withdrawal effect Exacerbation of primary sleep disorder Some specific medication effects: TCA Anticholinergics decrease REM and increase REM latency Especially, clomipramine and amitriptyline CMI Histaminergic sedation (amitriptyline, doxepin, trazodone) Increase slow-wave sleep (doxepin) Rapid withdrawal leads to NM parasomnias (REM rebound), can exacerbate Restless leg syndrome SSRIs in general worsen periodic limb movement disorder Fluoxetine Paroxetine Sertraline Buproprion Venlafaxine Nefazodone/mirtazipine
Thein_Chap13.indd 156
None SWS None SWS None SWS Reduces DFA less Daytime steepness
REM Less REM Less REM REM REM More REM
Wakeful Wakeful? no sedation Latency increases REM EDS
11/3/2010 4:37:27 PM
Chapter 13 Sleep
157
Stimulants Wake Delayed steep onset Shorter sleep duration REM decrease Alcohol Faster sleep onset More disruption (REM rebound biphasic SWS) worse RLS SDB Nicotine Slower sleep onset—worse SDBRLS Caffeine Less total sleep SWS—REM Later sleep onset Fragmented sleep If intake is >300 mg, awake 3 hours after sleep Overall guidelines when using medications Optimize sleep hygiene Medications are rarely first choice or used alone Combine medications with b